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ABSTRACT OF THE DISSERTATION

Effects of Liposome-Encapsulated TNF-Alpha and
Radiation against Colon Cancer

by

Dong Won Kim

Doctor of Philosophy, Graduate Program in Microbiology and Molecular Genetics
Loma Linda University, August 2001
Dr. Daila S. Gridley, Chairperson

Previous studies have shown that tumor necrosis factor-a (TNF-a) can augment
the antitumor effects of radiation, inhibiting tumor progression to a greater extent than
either modality alone.

However, nonspecific toxicities associated with TNF-a have

limited its use as an adjuvant.

This limitation is potentially resolved with the

encapsulation of TNF-a in sterically stabilized, PEGylated liposomes (STEALTH®).
Thus, the overall hypothesis of the research was that the combination of radiation with
STEALTH® liposome encapsulated TNF-a (SL-TNF-a) will have greater efficacy and
fewer dose-limiting side effects in the LS174T human colorectal tumor xenograft model
compared to the combination of free TNF-a and radiation, as well as to each modality

xvi

alone. Furthermore, the increased antitumor efficacy of SL-TNF-a plus radiation will be
associated with greater and more prolonged augmentation of innate immune mechanisms.
Nude mice were subcutaneously injected with LS174T adenocarcinoma cells into
the right hind leg and treated with different regimens of intravenously injected free TNFoc or SL-TNF-a and/or radiation.

Tumor volume and mouse weight were measured

throughout the treatment. Furthermore, various immunological assays were performed
on the blood and the spleen, and immunohistological analyses were completed on the
tumor excised from the mice.
Collectively, the data of this research demonstrated for the first time that the
addition of SL-TNF-a to radiation results in more than additive tumor growth inhibition
using the LS174T xenograft model. Furthermore, the increased antitumor effect was
achieved without any observable toxicity.

The measurements of innate immunity

performed in this research showed that SL-TNF-a produced a spatially and temporally
different modulation of these immune parameters compared to free TNF-a when
measured in the spleen, blood, and tumor, which correlated with the greater decrease in
tumor growth after SL-TNF-a plus radiation treatment and thus, could account, at least
partly, for its greater efficacy. Overall, the research demonstrated that combination of
SL-TNF-a plus radiation is effective in inhibiting tumor growth without causing
unwanted toxicities and that the potential usefulness of this combination warrants further
study and consideration.

xvn

CHAPTER ONE

I.

Introduction

Although the death rate of all cancers has decreased each year since its peak in
1991, an estimated 553,400 Americans will die of cancer in 2001 according to the
American Cancer Society, which will be more than 1,500 deaths per day (Table 1)
(Greenlee et al., 2001). After heart disease, cancer is the second leading cause of death
among all age groups in both genders, accounting for 23.2% of all deaths in 1998.
Among men, cancers of the lung/bronchus, prostate, and colon/rectum will account for
52% of male cancer deaths in 2001, and among women, cancers of the lung/bronchus,
breast, and colon/rectum will account for 52% of the female cancer deaths in 2001.
Therefore, the fight to combat the incidence of and mortality from cancer continues
strong in the new millennium to find new methods of prevention, early detection,
treatment, and research (Bal, 2001).

In fact, an estimated 1,268,000 new cases of

invasive cancer will be diagnosed in 2001 in the US.
Of all sites, cancer of the colon and rectum ranks third among the leading causes
of cancer incidence and third as a cause of cancer death in the US (Figures 1-2).
Although incidence and death has been declining since the early 1990s, colorectal cancer
will still account for 138,900 of the new cancer cases and 57,100 of cancer deaths in 2001
(Greenlee et al., 2001). Without preventive interventions, approximately 5.6% of the
population will develop colorectal cancer at some point in their lifetime (Smith et al..
2001). Although the five-year survival is 90% if diagnosed early, only 37% is diagnosed
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Table 1. Leading causes of death in the United States in 1998.
Fifteen Leading Causes of Death, US, 1998
Rank Cause of Death
Number Death Rate
of
per 100,000
Deaths
Population*
All Causes
1
2
3
4
5
6
7
8

9
10
11
12
13
14
15

Heart Diseases
Cancer
Cerebrovascular Diseases
Chronic Obstructive
Pulmonary Disease
Accidents
Pneumonia & Influenza
Diabetes Mellitus
Suicide
Nephritis
Cirrhosis of Liver
Septicemia
Alzheimer’s Disease
Homicide
Atherosclerosis
HIV Infection
Other & Ill-defined

Percent (%)
of Total
Deaths’-

2,337,256

645.5

100.00

724,859
541,532
158,448

189.0
161.5
39.4

31.0
23.2
6.8

112,584

31.0
31.5
21.9
18.5
10.0
6.7
8.1
6.3
5.0
6.6
3.5
4.0

4.8
4.2

97,835
91,871
64,751
30,575
26,182
25,192
23,731
22,725
18,272
15,279
13,426

369,994

3.9
2.8
1.3
1.1
1.1
1.0
1.0
0.8
0.7
0.6
15.8

*Age-adjusted to the 1970 US standard population.
* Percentages may not total 100% due to rounding.
Data Source: US Mortality Public Use Data Tape 1998, National Center for
Health Statistics, Centers for Disease Control and Prevention, 2000.

Adapted from (Greenlee et al., 2001).
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Figure 1. Ten most common sites of estimated new cancer cases in 2001 by gender.
Colorectal cancer ranks third among the leading sites of estimated new cancer cases that
will be diagnosed by the end of 2001. Adapted from (Greenlee et al., 2001).

Estimated New Cancer Cases* 10 Leading Sites by Gender, US, 2001

Prostates 1%

31% Breast

Lung & Bronchus14%

13%Lung & Bronchus

Coton & Rectum 10%

11%Colon & Rectum

Urinary Biadder6%

6%Uterine Corpus

Non-Hodgkins Lymphoma5%

4%Non-Hodgkin's Lymphoma

Melanoma of the Skin 5%

4%Ovary

Oral Cavrty3%

4%Metanoma of the Skin

Kidney 3%

2%Unnary Bladder

Ledkemia3%

2%Panereas

Pancreas2%

2%Thyroid

All Other Sites18%

21%AM Other Sites

'Excludes basal and squamous cell skin cancers and in situ carcinomas except
urinary bladder.
Percentages may not total 100% due to rounding.
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Figure 2. Ten most common sites as the cause of the estimated cancer deaths in 2001.
Colorectal cancer ranks third among the leading sites of estimated cancer deaths in 2001.
Adapted from (Greenlee et al., 2001).
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Estimated Cancer Deaths* 10 Leading Sites by Gender, US, 2001

Lung & Bronchus 31%

25%Lung & Bronchus

Prostate11%

15% Breast

Colon & Rectum 10%

T1%Colon & Rectum

Pancreas 5%

6%Pancreas

Non-Hodgkin's Lymphoma 5%

5%Ovary

Leukemia 4%

5%Non-HocJgkin,s Lymphoma

Esophagus 3%

4%Leukemia

Liver 3%

2%Utenne Corpus

Urinary Bladder 3%
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Kidney 3%

2%Stomaeh

All Other Sites 22%

23%AI! Other Sites

‘Excludes m situ carcinomas except urinary bladder.
Percentages may not total 100% due to rounding.
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when the cancer is still localized. Of those with colorectal cancer, more than 50,000
patients each year will present with liver metastases (Fong, 1999). The liver is the most
common and often the only site of metastasis, and if left untreated, hepatic colorectal
metastases are fatal within a few months.
Surgical excision is usually considered the optimal treatment modality for the
primary tumor and liver metastases. However, after surgical resection alone, patients
with locally advanced cancer (Dukes Stage B2 or higher or TNM stage II or higher) have
a significantly increased risk of recurrence at the primary site, metastases, or recurrence
at the metastatic site (Macdonald, 1999).

Chemotherapy, namely fluorouracil and/or

leucovorin, is used for unresectable disease, for some liver metastases, or as an adjuvant.
Radiation therapy is also commonly used as an adjunct to surgery or for symptomatic
relief of localized metastases and is a major part of any adjuvant therapy in rectal cancer.
Although radiation treatment is generally not considered the primary treatment.
radiotherapy remains an important modality for the treatment of colorectal cancer and for
other cancer types such as prostate cancer (Horwitz and Hanks, 2000). Overall, however,
adjuvant therapies for colon cancer have had relatively limited success, possibly due to
dose limitations of the chemotherapeutic agents used, drug resistant tumor cell
subpopulations, and/or location of metastases outside of the irradiated field. Therefore,
the search for new primary and adjuvant therapies that would prevent recurrences or
metastatic disease has attracted increasing interest. Agents that can enhance the efficacy
of existing modalities (such as radiation), as well as upregulate the individual’s own
immune defenses, are prime candidates for evaluation.

7

A. Radiotherapy
1. Mechanism of Action
Energy from radiation is absorbed in biological material by transferring that
energy to electrons. Depending upon the amount, the energy either simply raises the
electron to a higher energy state (excitation) or ejects the electron completely
(ionization). Each ionizing event releases a large amount of localized energy of about 33
eV; this amount of energy is sufficient to break many strong chemical bonds. Ionizing
radiation is generally classified as either electromagnetic or particulate. Biologically
relevant forms of electromagnetic radiation are further subdivided into x-rays and y-rays.
Electromagnetic radiation is indirectly ionizing as the energy from each photon is
transferred to electrons via the photoelectric effect, the Compton effect, or pair
production to produce fast-moving charged particles, which in turn could produce
chemical and biological changes. Particulate radiation includes electrons, protons, aparticles, neutrons, and heavy-charged ions. Particulate radiation is directly ionizing as
the individual particles directly interact with atoms and molecules to produce chemical
and biological changes (Hall, 2000).
Genomic DNA is generally considered the most important subcellular target of
radiation. Either by direct action on the DNA molecule by a secondary electron or by
indirect action on the DNA by free radicals produced from secondary electrons
interacting with water or other molecules, radiation produces many genomic lesions
including single strand breaks, double strand breaks, and base modifications (Figure 3).
The majority of these lesions are repaired rapidly and with great fidelity. However, if
misrepaired or even unrepaired lesions persist or cause gross chromosomal aberrations,

8

they could lead to the generation of mutations, malignant transformation, or cell death
after a variable number of cell cycles, also referred to as mitotic or clonogenic cell death.
Radiation can also induce an apoptotic cell death (“programmed cell death” or “cell
suicide”) via a variety of pathways. Figure 4 diagrams one possible pathway leading to
apoptosis. Radiation can cause general cellular damage to various organelles and cellular
components including to the mitochondria, from which cytochrome c is released and thus
can initiate a caspase-9 dependent cascade leading to apoptosis (Kuwana et al., 1998;
Slee et al., 1999). Another major pathway for radiation-induced apoptosis involves the
damage of DNA and the subsequent activation of various genes involved in apoptosis by
p53, a transcription factor/phosphoprotein (Figure 5). If damage to the DNA is present,
p53 is involved in delaying the progression of the cell cycle until the damage is repaired;
however, if the damage cannot be repaired, p53 is integral in inducing apoptosis in the
damaged cell (Khanna and Jackson, 2001). Another pathway leading to apoptosis, which
is not directly triggered by DNA damage, involves the radiation-induced activation of
sphingomyelinase, which catalyzes the hydrolysis of sphingomyelin to ceramide (Santana
et al., 1996).

Ceramide then acts as a second messenger to stimulate a cascade of

kinases, phosphatases, and transcription factors to induce apoptosis (Lin et al., 2000;
Radford, 1999).

B. Combination Treatments
Although radiation therapy is considered the most important non-surgical
treatment for cancer, the use of radiation alone or even any other single modality to
achieve a cure is difficult (Siemann et al., 2000; Tobias, 1992).

11

With radiotherapy,

Figure 3. Schematic view of the actions of radiation on DNA. Radiation can induce
damage to the DNA by the direct action of secondary electrons or by indirect action of
the secondary electrons interacting with waters molecule to produce free radicals which
in turn damage the DNA. Adapted from (Hall, 2000).
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Figure 4. Schematic view of a pathway leading to apoptosis induced by radiation.
Radiation can induce programmed cell death by several different mechanisms. The
diagram shows one possible pathway leading to apoptosis induced by radiation.
Radiation induced changes in the mitochondria, causing the release of cytochrome c.
Through its interaction with Apaf-1, caspase-9 is activated to engage and activate
downstream caspases, eventually leading to apoptosis. Adapted from Schaefer, E.,
www.biocarta.com, BioCarta (San Diego, CA).
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Figure 5. Schematic view of the p53 signaling pathway. In response to DNA damage,
p53 is integrally involved in the upregulation of various genes, cell cycle arrest, and/or
apoptosis depending on the amount of DNA damage, cell type, and other physiological
factors. Adapted from Monell, C., www.biocarta.com, BioCarta (San Diego, CA).
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significant numbers of patients still continue to have recurrence of the tumor at the
original site or have metastatic spread of the tumor. This resistance to therapeutic doses
of radiation is not only due to the intrinsic genetic resistance of the individual tumors, but
also due to the variable microenvironment of the tumor. The expanding tumor mass
requires a proportionate increase in its vascular network to supply its growing metabolic
needs (i.e., oxygen and nutrients); any tumor beyond approximately 1 mm requires a
blood supply (Hahnfeldt et al., 1999). Thus, neovascularization is requisite in all solid
tumors growing beyond this critical size. As a major angiogenesis inducer, vascular
endothelial growth factor (VEGF) stimulates the growth of new vessels, although the
newly formed vessels are functionally and morphological abnormal compared to the
vessels in normal tissue (Siemeister et al., 1998). Nevertheless, each new tumor capillary
is able to supply the metabolic needs of up to 106 tumor cells.

However,

neovascularization, abnormal in nature, does not necessarily keep up with the growth of
the tumor resulting in heterogeneous regions of unfulfilled metabolic needs (Tannock,
1970; Vaupel et al., 1989). Varying degrees of hypoxia, acidosis, nutrient depletion, and
waste accumulation develop in different regions of the tumor mass, which may have a
profound effect on the treatment efficacy.

For example, variations in intra-tumoral

oxygen concentrations have been linked to variations in the success of radiation treatment
(Brizel et al., 1999; Knocke et al., 1999; Nordsmark et al., 1996; Overgaard and
Horsman, 1996).

Therefore, in addition to the aberrant morphology and spatial

distribution of the vessels, the differing metabolic regions of the tumor can negatively
affect the overall efficacy of radiation.
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As a result of these limitations of radiotherapy as a single modality, the
combination of several antitumor modalities is required to increase the therapeutic index.
The ideal combination regimen should increase the antitumor efficacy, have non
overlapping toxicities, and have different cellular targets or mechanisms of action, so that
at least additive, if not synergistic, effects can be achieved (Siemann et al., 2000; Steel
and Peckham, 1979). Due to the abnormal morphology and function of tumor vessels
and the formation of new vessels being very infrequent in normal tissues, tumor vessels
and neovascularization may be additional targets for adjuvant therapies. Because each
tumor vessel supplies so many tumor cells, even limited success in damaging some of
these vessels could produce extensive ischemic cell death, especially to hypoxic cell
populations within tumor that are refractory to radiation (Denekamp, 1993; Wilson et al.,
1998). Concurrently, cells that are able to survive treatments with anti-vascular agents
are usually located in well-oxygenated areas and thus, are sensitive and responsive to
radiation (Horsman et al., 2000; Wilson et al., 1998). A class of agents related to flavone
acetic acid (FAA) has been shown to produce irreversible vascular damage selectively in
tumor vasculature primarily by inducing the production of tumor necrosis factor-a (TNFa) (Flill et al., 1995; Lash et al., 1998; Zwi et al., 1989).
Another potential “target"’ in combined therapies is immunomodulation. Whether
radiation therapy, surgery, or any other modality is the primary option for treatment.
residual tumors generally persist, especially in advanced cases. For example, even with
surgical resection of the liver that has metastatic masses of colorectal cancer, two-thirds
of these patients will still develop recurrence of the tumor (Fong, 1999). The previous
presence of the tumor, the treatment itself, and unforeseen treatment-related effects could
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all contribute to or cause local or systemic immunosuppression and/or decline in immune
surveillance. Thus, in addition to the primary treatment option, immunomodulation has
always been an attractive treatment option. The activation of the host’s own defense
mechanisms to destroy the tumor cells could potentially enhance the primary therapy or
kill any residual tumor cells left behind. Interleukin-2 (IL-2), a-interferon (IFN-a), and
IFN-y have been used in experimental models and in some limited clinical trials.
However, high incidence of side effects has resulted in high dropout rates in the clinical
trials and dampened enthusiasm for expanded studies.

Nonetheless, the concept of

immune upregulation has recently generated great interest, as evidenced by numerous
studies utilizing cancer vaccines and immunogene therapies (Gunji et al., 2000; Overwijk
and Restifo, 2001; Paczesny et al., 2001; Yoshimura et al., 2001). Based on reports thus
far, it appears likely that at least some of these immunotherapeutic approaches will
become incorporated into the treatment regimen for at least some types of human cancers.
Of the many different cytokines used in various combination therapies, TNF-a
has renewed the interest of many researchers in the past decade. Although systemic
application of TNF-a was almost abandoned as a treatment option, due to dose-limiting
toxicities, recent studies using TNF-a in combination with radiation and with other
modalities have demonstrated that TNF-a can still potentially be an important component
of combination therapies (de Wilt et al., 1999; Eggermont et al., 1995; Gridley et al..
1997; Gridley et al., 1994; Manusama et al., 1996; Matsushita et al., 1994; Ten Hagen et
al., 2000). Previous studies done in our laboratory have also confirmed that TNF-a, as a
neoadjuvant to radiation, is effective against various types of tumor cell lines, including a
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human colorectal tumor cell line (Gridley et ai, 1996; Gridley et al., 1997; Gridley et ai.
1994).

C. Tumor Necrosis Factor-a
1. TNF-a gene and protein
The single copy 3.6 kb gene of human TNF-a is found on the short arm of
chromosome 6 (6p23-6ql2) (Spriggs et al., 1992). The gene for TNF-a is 3'’ of the gene
for TNF-(3 and contains 4 exons; exon IV encodes for approximately 80% of the entire
mature sequence. The gene is regulated at the transcriptional level via the 5’ flanking
region of the gene containing several kB homologous sequence enhancer elements and at
the translational level by a UA-rich 3’ untranslated region of the mRNA (Shakhov et al..
1990; Spriggs et al., 1992).
The protein exists in two forms, a soluble form and a membrane bound form. The
mRNA transcript encodes for a 26 kDa precursor protein of 233 amino acids comprised
of a 157 amino acid precursor polypeptide and a highly conserved 76 amino acid
presequence. Initially, the transcript exists as a type II membrane protein anchored to the
membrane by the presequence; amino acid -44 to -26 of the presequence composes the
hydrophobic transmembrane region. The transmembrane protein can then be processed
at amino acid -14 to -1 by a TNF-a converting enzyme to the final 157 amino acid
soluble protein. The 17 kDa active form contains a single, nonessential disulfide bridge
and no methionine residues. It shares about 30% homology with TNF-[3. TNF-a does
not undergo many posttranslational modifications; however, it does contain a number of
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phosphorylation consensus sites. The mature form of TNF-a exists in solution as a
homotrimer of 52 kDa which binds and crosslinks the receptors (Smith and Baglioni,
1987). The homotrimer is arranged in a triangular cone with each monomer having an
interfacing surface with the other two monomers (Baeyens et al., 1999). Each monomer
is approximately 60 A long and 30 A wide and structurally composed of two P-pleated
sheets with each sheet consisting of eight, anti-parallel P-strands in a P-jellyroll topology
(Figure 6).

2. TNF-a receptors
Two high affinity receptors for TNF-a have been described. The 434 amino acid
TNF-a receptor type I receptor (TNFR-1) or CD 120a is a transmembrane protein of 55
kDa (disassociation constant Kd=0.5 nM). The C-terminal intracellular region of TNFR1 contains a death domain involved in mediating apoptosis. The 439 amino acid TNF-a
type II receptor (TNFR-2) or CD 120b is a transmembrane protein of 75 kDa (Kd=1.0
nM). These twro proteins share less than 25% homology in the extracellular region and
no homology in the intracellular region, and thus, are potentially involved in distinct
intracellular signaling pathways. The structure of each receptor takes an elongated, rod
like shape, which aligns parallel to the other receptors along their long axis (Figure 7).
The extracellular region of the receptor is composed of 4 similar subdomains of 30 to 40
amino acids, each having 3 disulfide bridges that binds together three strands connected
by loops (Banner et al., 1993). The receptors deform upon binding the ligands through a
series of hinging movements (Naismith et al, 1996). One receptor binds the TNF-a
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Figure 6. Ribbon structure of a TNF-ct trimer. Each monomer of the trimer is composed
of two P-pleated sheets with each sheet consisting of eight, anti-parallel P-strands in a Pjellyroll topology. Figure was generated using the NCBI’s (National Center for
Biotechnology Information, National Institute of Health, Bethesda, Maryland) Cn3D
software version 3.0 displaying NCBFs MMDB (Molecular Modeling DataBase)
structural data for TNF-a.
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Figure 7. Ribbon structure of TNFR-1. The receptor is elongated and rod-like in shape.
The extracellular region of the receptor consist of repeating units of cysteine clusters
involved in forming a structural scaffold of disulfide bridges where the ligand interacts.
Figure was generated using the NCBTs Cn3D software version 3.0 displaying NCBTs
MMDB structural data for TNFR-1.
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trimer at one of the TNF-a monomer-monomer interfaces, thus, bringing three receptors
together. Although the extracellular domains do not contact each other, the trimerization
of the receptors bring the intracellular regions into close proximity. TNF receptor density
generally ranges from 200-1000 receptors per cell. These receptors are found on almost
all cell types tested with the exception of erythrocytes; TNFR-1 has a more widespread
distribution while TNFR-2 is mainly restricted to hematopoietic cells. Their involvement
in the action of TNF-a is described below. However, no correlation between the number
of receptors and the magnitude of the induced response has been reported (Beyaert and
Fiers, 1994), suggesting a possible threshold response to binding of ligands. Soluble
forms of the receptors have also been reported and may function as decoy receptors in
sequestering TNF-a and thus, preventing its actions (Engelmann et ai, 1990).

3. Mechanism of Action
The binding of a TNF-a trimer clusters three TNF receptors and initiates various
intracellular responses including the activation of myriads of different classes of proteins,
activation of gene transcription, and production of reactive oxygen or nitrogen radicals.
Of the multiple biological effect of TNF-a, its ability to induce cell death is one of the
effects with greatest therapeutic relevance.

TNF-a can induce cell death either by

necrosis or apoptosis (Fiers et al., 1995; Vercammen et ai, 1998).

Necrosis is

characterized by cellular swelling, organelle destruction, and cell lysis, which causes or
occurs within an environment of an inflammatory response. Apoptosis, in contrast, is a
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distinct biochemical process characterized by DNA fragmentation, cell shrinkage, and
formation of apoptotic bodies; it is mediated via a pathway that is initiated at TNFR-1.
TNFR-1 possesses an intracellular death domain (DD), which mediates via DD
homophilic interactions the recruitment of other DD containing proteins (Figure 8).
Upon the ligand-induced formation of TNFR-1 complexes, SODD (silencer of death
domain) dissociates from TNFR-1 and allows the interaction with downstream proteins;
SODD prevents the spontaneous aggregation of DD containing proteins and thus, the
spontaneous activation of TNFR-1.

The DD of TNFR-1 then is able to associate with

the DD of the adapter protein TRADD (TNFR-1-associated death domain protein), which
in turn interacts with the DD of the adaptor protein FADD (Fas-associated death domain
protein) (FIsu et al., 1995; Wajant and Scheurich, 2001). FADD then binds by its death
effector domain to caspase-8 which becomes activated by self-processing; caspases are a
family of proteases that cleave protein substrates after an aspartic acid residue. Caspase8 is then able to activate downstream caspases, such as caspase 3, which results in
proteolysis of various target proteins, such as PART and DNA topoisomerase I, and
finally in apoptosis (Casiano et al., 1998; Denecker et al., 2001) (Figure 9). TNFR-1 can
also mediate other pathways as well. The interaction of TRADD with TNFR-1 can also
mediate interaction with the DD of RIP (receptor-interacting protein) in conjunction with
TRAF-2 (TNF receptor-associated factor 2), to activate the pathway leading to the
activation of NK-kB (nuclear transcription factor-kappa B), which induces expression of
various genes and eventually results in cell survival; the DD-less portion of TRADD can
also interact with TRAF-2 and initiate a cascade involving MAP3K and MAPK K-7 that
can lead to the activation of SAPK (stress-activated protein kinase, also known as c-Jun

26

Figure 8. Schematic view of the TNFR-1 pathways leading to apoptosis. Although
ligand binding to TNFR-1 can induce the pathway leading to apoptosis, a variety of other
pathways can also be induced. Adapted from poster by Alexis Biochemicals (San Diego,
CA).
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Figure 9. Schematic view of the caspase cascade. Once various caspases (i.e., caspase
8, 9, or 10) are activated by upstream activators, these caspases in turn can activate other
effector caspases (such as caspase 3) to eventually result in apoptosis. Adapted from
Croston, G., www.biocarta.com, BioCarta (San Diego, CA).
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NHi-terminal kinase or JNK) (Wajant and Scheurich, 2001; Wang et al., 1998) (Figure
8).
TNFR-2 does not possess a death domain and thus, does not directly promote
apoptosis.

TNFR-2 may be more involved in cell survival via its interaction with

TRADD, which upregulates NF-kB (Rothe et al., 1994) (Figure 10). However, TNFR-2
may indirectly have cytotoxic effects by mediating an autocrine or paracrine production
of endogenous TNF-a, which activates TNFR-1 (Grell et al., 1999). At a relatively low
pH, the TNF-a trimer itself is also able to form a functional ion channel without the
presence of any receptors, thus allowing the entry or escape of ions (i.e., Na+) resulting in
the disruption of the cell’s homeostatic balance of membrane potential and/or osmolarity
(Kagan et al., 1992).

4. Biological Effects
Human TNF-a is a multifunctional cytokine produced during and in response to a
wide variety of conditions. The various conditions in which TNF-a plays a role include
immune stimulation, inflammation, immune response to infections (bacterial, viral, and
parasitic) and tumors, sleep regulation, and embryonic development (de Kossodo et al..
1992; Grunfeld and Feingold, 1991; Pollmacher et al., 2000; Preiss et al., 2001; Tracey et
al., 1988; Vassalli, 1992; Wride and Sanders, 1995).

It also plays a role in various

pathologic conditions such as septic shock and various autoimmune diseases (Cerami and
Beutler, 1988; Segal et al., 2001; Suk et al., 2001). TNF-a is produced and secreted by a
wide variety of hematopoietic and non-hematopoietic cells including the following:
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Figure 9. Schematic view of TNFR-2 pathway leading to the activation of NF-kB.
Adapted from O’Dell, W., www.biocarta.com, BioCarta (San Diego, CA).
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macrophages/monocytes, neutrophils, CD4+ and CD8+ T cells, NK cells, lymphokine
(i.e., IL-2)-activated killer (LAK) cells, B cells, astrocytes, endothelial cells, smooth
muscle cells, and various tumor cells (Cruse and Lewis, 1999).
Of all the previously mentioned biological effects, its ability to cause necrotic
regression in some tumors invoked great interest as a therapeutic agent. TNF-oc has been
observed to cause hemorrhagic necrosis of certain tumors through the destruction of
tumor vasculature in vivo, to have direct cytotoxic effects against some tumor cells in
vitro, and to enhance the tumoricidal activities of macrophages, neutrophils, NK cells,
and cytotoxic T cells (Le and Vilcek, 1987).

TNF-ct also induces alterations in the

endothelium in conjunction with other cytokines and causes cell death either by necrosis
or apoptosis by the pathways mentioned above (Renard et al., 1994).
However, TNF-oc has a low therapeutic index as a systemic agent due to its high
incidence of toxicities. Dose-limiting side effects include hypotension, vascular leakage,
rigors, fever, fatigue, weight loss, leukopenia, thrombocytopenia, and renal and other
organ dysfunction. TNF-ct has a very low maximum tolerated dose of approximately 200
to 350 pg/nT in humans, which is only 2% of the dose that caused tumor regression in
animal models (Feinberg et al., 1988). When administered systemically, the free TNF-ct
protein distributes quickly and widely throughout the body and then is rapidly cleared
from the circulation. The mean residence time in blood for free TNF-oc was reported to
be approximately 24 minutes (van der Veen et al., 1998).

Free TNF-ct accumulates

mostly in the liver and skin with significant amounts in the gastrointestinal tract and
kidneys; very little is absorbed by the spleen (Beutler et al., 1985; Palladino et al., 1987).
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These factors result in low TNF-a accumulation at the tumor site while causing
significant toxicity to normal tissues (Rathjen et al., 1991). Therefore, the systemic use
of TNF-a, as a chemotherapeutic agent, was almost completely abandoned. However,
recent advances have renewed interest in TNF-a as a potential chemotherapeutic agent.
Recent studies have used intratumoral injections of TNF-a protein or plasmid TNF-a,
isolated limb perfusion of TNF-a, or encapsulation of TNF-a to bypass some of the toxic
effects of free TNF-a with some success (Gridley et al., 2000; Li et al., 1998; Manusama
et al., 1998; Manusama et al., 1996). Of these alternative options for TNF-a delivery,
the direct, systemic injection of a liposome encapsulated TNF-a shows promise not only
by decreasing the possible toxicities of TNF-a and increasing the accumulation of TNF-a
at the tumor site, but also by allowing easy administration intravenously rather than by
other laborious techniques such as limb-isolated perfusion.

D. Liposomes
The use of many chemotherapeutic agents is severely limited due to many doselimiting toxicities caused by the agents themselves.

Particularly, small-molecule

chemotherapeutic agents such as doxorubicin or TNF-a, which have large volumes of
distribution, have low therapeutic indices because of the high level of toxicity to normal
tissues (Speth et al., 1988). Thus, encapsulation of these chemotherapeutic agents in
liposomes has been proposed and used to reduce the volume of distribution and increase
the accumulation of the agent at the tumor site, which results in a decrease in nonspecific
toxicities and an increase in the amount of agent at the tumor site (Allen and Hansen,
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1991; Senior et al., 1985; Senior, 1987). When chemotherapeutic agents or drugs are
encapsulated, they reside in the aqueous space within the liposome.

Under optimal

conditions, the liposome containing the drug circulates in the vascular system and
protects the drug from metabolism and inactivation; at the same time, the drug escapes
from the liposome at a sufficient rate to become bioavailable once reaching the tumor.
Liposomes have a tendency to accumulate more in tumors than in normal tissue. The size
limitation to the transport of large molecules across normal, healthy endothelium prevents
liposomes from extravasating into normal tissue (Mayer et al., 1989). However, tumor
vasculature with many discontinuities in the endothelium allows greater extravasation of
large molecules and in conjunction with the impaired lymphatics found in tumors, allows
greater accumulation of the liposomal drug at the tumor (Hobbs et al., 1998; Yuan et al.,
1994).

1. Liposomal physicochemical properties
Liposomes can alter the tissue distribution and rate of clearance of the
encapsulated molecule by ascribing the pharmacokinetic properties of the liposome to the
encapsulated molecule. The pharmacokinetic properties of the liposome depend on the
physicochemical parameters of the liposomes.

These parameters include steric

stabilization, size, surface charge, and membrane lipid packing.

a. Steric stabilization
Current formulations of liposomes have given rise to two general categories of
liposomes: 1) conventional liposomes (CL) and 2) sterically stabilized liposomes (SSL).
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Both types of liposomes consist of a lipid membrane formulated to be relatively
impermeable to amphipathic and highly water-soluble molecules at physiological
temperatures (37°C). This formulation allows stability during storage and in circulation.
However, unlike CLs, SSLs are coated with a polymer coating, most commonly
polyethylene glycol derivatized at the amino position of a phospholipid, which provides
steric stabilization to the liposome (Figure 11). Steric stabilization limits the interaction
of other molecules with the liposome, thus limiting the binding of serum proteins such as
antibodies and other opsinins and reducing the interaction with cells, especially those of
the reticuloendothelial system (RES) (Allen, 1994; Allen and Hansen, 1991; Lasic et al..
1991).

Thus, SSLs have an enhanced circulation time (relatively long half life in

circulation) and increased localization to the tumor over CLs (Papahadjopoulos et al..
1991). A variety of hydrophilic polymer or hydrophilic glycolipids such as PEG or
ganglioside GM1 confer steric stabilization or colloidal stability on the liposome (Allen,
1994; Papahadjopoulos et al., 1991; Torchilin et al., 1995). CLs include a broader array
of liposome formulations. Typically, the lipid compositions of CLs are very high in
phosphatidylcholine (PC) and cholesterol (Choi).

b. Size
Preparation of liposomes of a defined size is achieved by the extrusion of lipid
suspensions through filters with a pore size similar to the desired size (Olson et al.,
1979). The resulting liposomes are slightly larger (20-50%) than the average pore size of
the filter used. Generally for liposomes of similar composition, increasing the size of
liposomes results in a more rapid uptake by the cells of the RES. Increasing the size of
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Figure 11. Schematic view of different liposome types. (A) Conventional liposome, (B)
Sterically stabilized liposome.
Adapted from http://www.malvem.de/laboratory/
appl.htm, Malvern Instruments Ltd.

38

A.

B.

i>

»L

<&

Cr

Si*

39

hydrophilic
polymer

liposomes of differing composition also results in a more rapid clearance, although the
relative rates of clearance due to increasing size differ depending on the lipid
composition (Senior et ai, 1985). Furthermore, the addition of PEG to the liposome
formulation results in a clearance rate that is relatively unaffected by size within the
range of 80 to 250 nm (Allen et al., 1989; Woodle et al., 1992).

Thus the size

dependence for SSLs are relatively less than for CLs. However, the optimization of
liposome size is still preferable (i.e., < lOOnm), especially with CLs, which would
balance size and drug encapsulation efficiencies.

c. Surface charge
Generally, the presence of a negative surface charge increases the rate of
clearance of liposomes; negatively charged lipids such as phosphatidylglycerol (PG),
phosphatidylserine (PS), and phosphatidic acid (PA) (PS > PA > PG) cause a more rapid
uptake of the liposome by the RES compared to neutral liposomes (Figure 12) (Gabizon
and Papahadjopoulos, 1992; Senior et al., 1985). However, the inclusion of certain other
anionic lipids such as ganglioside GM1, phosphatidylinositol (PI), or PEG-PE increases
the blood residence time of the liposomes (Papahadjopoulos et al., 1991; Woodle et al..
1992). The negative charges on these anionic lipids are sterically shielded, thus slows the
clearance of these liposomes compared to neutral liposomes of similar composition.

d. Membrane composition
Membrane composition and fluidity have a substantial influence on the clearance
from circulation of both the liposome and the encapsulated molecule. Lipid composition
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Figure 12. Negatively charged phospholids. Negatively charged lipids such as
phosphatidylglycerol (PG), phosphatidylserine (PS), and phosphatidic acid (PA) (PS >
PA > PG) can cause a more rapid uptake of the liposome by macrophages compared to
neutral liposomes. Adapted from (Champe and Harvey, 1994).
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can impact the stability of the formulation and thus reduce the rate of drug leakage from
the liposome or directly inhibit the binding or penetration of plasma proteins.
Cholesterol (Choi) is especially important in maintaining the stability of
membranes and increasing circulation times (Gregoriadis and Davis, 1979); there is a
negative correlation between clearance rate and the stability of the liposome (Senior and
Gregoriadis, 1982). Particularly in CLs, Choi prevents the destabilization of liposomes
by high-density lipoprotein (HDL) particles, which catalyzes the net exchange of lipid
components to plasma lipoproteins and the resulting release of the associated drug
(Damen et ai, 1980).

Due to the steric stabilization, the stability of SSLs are less

affected by the inclusion or absence of Choi in their formulation; however, Choi is still
necessary to maintain the drug within the interior of the liposome. Furthermore, the
addition of sphingomyelin (SM) can produce an additional stabilizing effect with Choi by
forming intermolecular hydrogen bonds with adjacent Choi (Sankaram and Thompson,
1990).
The phospholipid component of membrane composition is also important in the
maintenance of liposomal stability. To be most effective in decreasing opsonization by
various plasma proteins, phospholipid components such as phosphatidylcholine (PC)
need to have a phase transition that is significantly greater than 37°C (i.e., have saturated
acyl chains) (Gregoriadis and Senior, 1980). A rigid membrane is more likely to reduce
the penetration of the membrane by opsonins and prevent the leakage of the interior
contents (Gabizon et al., 1993). Thus, high phase transition lipids are more likely to form
more stable liposomes that are better in retaining their contents and increasing their
circulation times.
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2. Clearance/Elimination
Due to their relatively large size, liposomes, and thus their contents, are not
filtered and removed by the kidneys. However, liposomes, which remain in circulation,
are cleared by the macrophages of the RES, especially those in the liver and the spleen
(Senior, 1987).
formulations.

Removal of liposomes from circulation varies depending on the
The clearance of CLs exhibited dose-dependence with clearance

accomplished by a saturable mechanism (Gregoriadis and Senior, 1980; Senior et al.,
1985). The blood residence time of CLs increases with increasing lipid dose; the plasma
concentration area under the curve (AUC) increases slowly and then exponentially
increases with increasing lipid dose. Concurrently, the circulation half-life (Ty2 or the
amount of time needed to clear from circulation one-half of the previously measured
concentration) of CLs eventually plateaus with increasing lipid dose indicating that
clearance mechanisms are becoming saturated (Allen and Hansen, 1991). This decrease
in clearance efficiency may indicate that 1) the ingestion of high lipid doses may saturate
the metabolic pathways of RES macrophages that break down complex lipids and thus
impair their phagocytic capacity and/or 2) the majority of plasma proteins responsible for
the opsonization of liposomes are saturated (Cullis et al., 1998; Semple et al., 1996;
Senior et al., 1985). The ingestion of the cytotoxic contents of the liposomes may further
impair the phagocytic function of RES macrophages (Suiting et al., 1996). In contrast.
SSL exhibits a dose-independent, nonsaturable, log-linear pharmacokinetics (Allen and
Hansen, 1991); the plasma concentration AUC increases linearly while its T./2 remains
relatively unchanged. This dose-independence can be attributed to the reduced uptake by
RES macrophages (Senior, 1987). Steric stabilization reduces the direct interaction of the
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liposomes with macrophages and/or reduces the opsonization by plasma proteins, which
results in lower recognition and clearance by the RES (Senior, 1987).
Therefore, at high doses, CLs and SSLs can accumulate in approximately equal
amounts at the tumor site (Parr et al., 1997). At lower doses, SSLs still have a larger
portion of liposomes remaining in circulation and thus, still a greater accumulation in the
tumor (Huang et al., 1992).

The dose-dependent clearance of CLs causes a rapid

clearance at low dosages. However, at high doses, clearance mechanisms are saturated,
resulting in a slower clearance and allowing a comparable accumulation at the tumor site.
However, the high doses required for saturation would result in significant toxicity.

3. Distribution in circulation
The volume of distribution of liposomal drugs has been reported to be similar to
that of total blood volume, indicating that the liposome is contained within the systemic
circulation or the central compartment (Gabizon et al., 1993). The pores found in the
endothelium of blood vessels of most normal, healthy tissue are about 2 nm while the
pores in postcapillary venules are approximately 6 nm (Seymour, 1992).

Since the

majority of liposome formulations produce relatively large liposomes ranging from 45 to
150 nm, liposomes are prevented from passing through these relatively small pores and
are confined within the general circulation.

4. Distribution in tissue
Partially as a result of their relatively large size, liposomes preferentially
accumulate in tissues with discontinuous endothelium. Discontinuous vasculature can be
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found in tumors and organs containing a high population of macrophages such as the
liver and the spleen. Organs with normal, healthy endothelium will have a decreased
tendency to accumulate the liposomes, and thus a decreased potential to accumulate the
contents of these liposomes with the associated toxicities.

5. Distribution to tumors
The long circulation times for liposomes are one of the features that allow
liposomal drugs to preferentially accumulate at the tumor. The longer the liposome is
present in circulation, the higher the probability of the liposome to extravasate into the
tumor. Another feature of tumors that allow for greater accumulation of liposomes and
large macromolecules in tumors is their “leaky” microvasculature and impaired
lymphatic drainage, or the enhanced permeability and retention effect (Huang et al..
1992; Matsumura and Maeda, 1986; Yuan et al., 1994). The pore sizes in tumor blood
vessels range from 100 to 780 nm (Yuan et al., 1995). Although the junctions in healthy,
normal endothelium vary from tissue to tissue, most tissues have openings of less than 2
nm up to 6 nm in postcapillary venules.

In tissues with fenestrated endothelium,

openings in the endothelium have more variable sized pores; the kidney has openings in
the endothelium that range from 40 to 60 nm while in the liver and the spleen.
fenestration sizes can go up to 150 nm (Turn and Malik, 1994; Seymour, 1992). Thus, a
major pathway liposomes enter into tumors is by extravasation through discontinuous
endothelium while transcytosis is a relatively minor pathway (Huang et al., 1992; Yuan
et al., 1994). Although liposomes could also accumulate in the liver and the spleen
(because of the large size of the fenestrations), they can move freely through these organs
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if they escape removal by the resident macrophages. Once liposomes escape from tumor
vasculature, they are confined to a high degree in the interstitium around the tumor by the
large interstitial space, the high interstitial pressure, and the impaired lymphatics (Jain,
1990; Yuan et al., 1994). Thus, the elimination rate of the liposomes from the tumor is
relatively slow and a greater accumulation of liposomes occurs in the tumor.

6. Bioavailability
Once the encapsulated agent reaches the target site, the agent needs to escape
from the liposomal carrier and redistribute within the target and the surrounding tissue to
become bioavailable. Thus, the bioavailability of the liposomal agent is dependent on the
rate of its escape from the liposome.

As mentioned above, the formulation of the

liposome in conjunction with the characteristics of the encapsulated molecule are critical
to maintain the balance required to prevent premature leakage while in circulation and yet
to allow for release once reaching the target. Although only a limited amount of direct
evidence has been uncovered regarding the mechanisms responsible for the eventual
breakdown of the liposome and the release of the encapsulated agent, several possible
mechanisms have been postulated. The liposomes may be destabilized by the tumor
microenvironment (the acidic pH of the interstitium within and around the tumor, lipases
released from dying cells, and inflammatory cells present at the tumor which may release
various enzymes or oxidizing agents) (Amantea et al., 1997; Kong et al., 2000; Wang et
al., 2000). Various immune cells or even the tumor cells themselves may phagocytize
the liposomes, process the liposomes, and release the encapsulated agent or be modified
by the agent (Chu et al., 1990; Storm et al., 1988). Also, the passive release of the
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encapsulated molecule may destabilize the pH or ionic gradient that originally was used
to load and maintained the agent within the liposome, resulting in an accelerated release
of the agent (Cullis et ai, 1997; Madden et al., 1990). Finally, in the case of SSLs, the
liposomes may eventually destabilize as some of the PEGyated components are released
and the liposomes have greater interactions with cells and plasma proteins (Drummond et
al., 1999).

7. Toxicity

CLs and SSLs are generally considered safe and nontoxic. However, empty CLs
and SSLs can cause substantial toxicity to the liver and spleen if present at very high
concentrations (Pamham and Wetzig, 1993; Tartour et al., 2000). The amount generally
used in studies of various SSL formulations is well below the toxic level (Allen et al..
1984; Huang et al., 1992; Papahadjopoulos et al., 1991; Yuan et al., 1994). However, the
very high levels of CLs needed to approximate the accumulation at tumors of comparable
SSLs would cause toxicities such as RES macrophage phagocytosis impairment,
hepatomegaly, splenomegaly, granulomas, and depletion of certain plasma proteins
(Allen et al., 1984; Oja et al., 1996; Pamham and Wetzig, 1993).

Furthermore, the

toxicities associated with the encapsulated molecule are more likely to be dose-limiting
than any associated with the lipid formulation. PEG used in SSLs is also considered
nontoxic and is excreted unmetabolized in the urine (Carpenter et al., 1971).
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8. Benefits of SSL
In view of the above-mentioned properties of liposomes, SSLs have substantial
advantages over CLs in encapsulating therapeutic agents with low therapeutic indices. A
more stable formulation allows less of the agent to escape from the liposome to cause
nonspecific toxicities and allows more of the agent to accumulate at the target site to
result in greater efficacy. The greater stability and accumulation results from the unique
characteristics of the SSLs resulting in the following additional advantages: doseindependent clearance kinetics, lower dosages in multiple dose regimens while having a
greater AUC, and more flexibility in varying lipid composition to tailor the liposome for
special needs without concern for stability. Ultimately, the decrease in toxicities and the
increase in efficacy produce better patient compliance and quality of life.

E. STEALTH® Liposome and STEALTH® encapsulated TNF-a
Although several variations of SSLs are available, the ALZA Corporation (Menlo
Park, CA) has developed a proprietary formulation of sterically stabilized, PEGylated
liposomes named STEALTH® (SL), in reference to their ability to evade clearance by
the cells of the RES.

SL exhibits the majority of the above-mentioned properties

described for the SSLs in general and thus have been used to encapsulate various
chemotherapeutic agents once thought to be too toxic. SL has already been used in
various studies and has been included in a number of clinical trials involving SL
encapsulated chemotherapy agents (Colbem et al., 1999; Gabizon et ai, 1994; Gabizon
and Martin, 1997; Ishida et al., 1999; Ten Hagen et al., 2000; van der Veen et al., 1996).
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As mentioned above, TNF-a has been generally considered too toxic for systemic
application, even though TNF-a has many potent antitumor properties. Thus, using SL,
the laboratory of T. L. M. ten Hagen (Netherlands) has developed a reliable and
consistent method for encapsulating recombinant human TNF-a (SL-TNF-a) in the SL
produced by ALZA Corp (Figure 13). Although SL-TNF-a has been used in a limited
number of preliminary studies, effective extensive use or characterization of its effects
have yet to be documented (van der Veen et ai, 1998).
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Figure 13. Schematic view of the STEALTH® liposome (SL)-encapsulated TNF-a.
TNF-a is encapsulated in a proprietary formulation of a polyethylene glycol (PEG)stabilized liposome. The PEG moiety provides steric stabilization to the liposome,
limiting its interaction with various proteins and cells in the blood. SL is prepared in
sizes of approximately 100 nm in diameter
Adapted from (Martin, 1997).
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CHAPTER TWO

IT OBJECTIVE, HYPOTHESIS, AND AIMS OF THE RESEARCH

As stated in Chapter 1, the search for new therapies for colorectal cancer
continues; improved treatments are especially needed to combat the majority of
colorectal cancer cases that are diagnosed after the tumor has already grown or spread
beyond its primary site. To more closely resemble the clinical situation of colorectal
cancer in the human, the LS174T cell line was used as the tumor model throughout this
study. LS174T is a human colorectal adenocarcinoma cell line originally derived from a
58-year-old Caucasian female with a Dukes' Type B grade tumor (Tom et al., 1976)
(Figure

1).

Due to the rejection of nonsyngeneic tumor implantation in

immunocompetent mice (i.e., rejection of human tumors by immunocompetent rodents),
athymic, immunocompromised, nude mice, which lack the full repertoire of T cells, were
used as the animal model in which the LS174T were grown as a subcutaneous xenograft.
Therefore, using this model system, this research explored the potential usefulness of a
combination treatment. As stated above, radiation is a primary treatment for many types
of cancer. However, to increase the antitumor effects of radiation, TNF-a holds great
potential for use as an adjuvant. Because of the dose limiting side effects frequently seen
with systemic administration of TNF-a, SL-TNF-a may provide a safer alterative to free
TNF-a protein. Therefore, the combination of SL-TNF-a with radiation was proposed as
an alternative treatment for the LS174T colorectal tumor xenografts.
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Figure 1. Schematic view of a Duke's type B colorectal tumor. The tumor of this grade
has progressed into all the layers of the mucosa of the colon, invaded the underlying
muscle and possibly the pericolic fat. However, it has not yet metastasized to a nearby
lymph node. Adapted from (Rubin and Farber, 1994).
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The overall hypothesis of this study is that the combination of SL-TNF-a and
radiation will have greater efficacy and fewer dose-limiting side effects in the LS174T
tumor model than the combination of free TNF-oc and radiation and that this differential
response is at least partly due to the augmentation of innate immune mechanisms by the
SL-TNF-a and radiation combination treatment. As mentioned previously, the different
pharmacokinetics and distribution of SL-TNF-a compared to free TNF-a may contribute
to the differences in how TNF-a causes immunomodulation. To test this hypothesis, the
following specific aims were pursued: 1) determine if SL-TNF-a augments the antitumor
effects of radiation (efficacy), 2) identify potential toxicities of the combination treatment
(safety), 3) compare the efficacy and safety of the SL-TNF-a and radiation combination
with that of free TNF-a and radiation, and 4) determine if the greater efficacy in the SLTNF-a and radiation combination treatment can be correlated to treatment-related
changes in innate immune parameters.
The study described in Chapter Three demonstrates the efficacy and safety of the
combination of SL-TNF-a and radiation by determining its effectiveness in nude mice by
inhibiting progression of the LS174T xenografts without causing unwanted side effects.
This is an important aspect to evaluate whenever potent antitumor agents are used in
concert, since serious and sometimes unexpected toxicities can occur. The combination
of free TNF-a and radiation was included as a control in all studies to compare its
effectiveness with the SL-TNF-a plus radiation combination. To detect presence of any
side effects, mouse body weight and various hematological parameters were measured as
indicators of animal health. Furthermore, hematological and splenic analyses were also
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performed to investigate if any treatment-related changes in innate immune parameters
might be present at the end of the treatment regimen. All major cell populations that
could play a significant role in the immune response were measured.

Chapter Four

further discusses the results presented in Chapter Three and elaborates on the basis and
rationale for the experiments that follow thereafter.
The studies described in Chapters Five and Six include data obtained in continued
pursuit of the innate immune changes exhibited in the previous investigation. To verify
and further clarify the modifications in innate immunity that were evident at the end of
the treatment regimen (i.e., discussed in Chapter Three), innate immune parameters were
followed and compared after a single injection of either TNF-a or SL-TNF-a. The
kinetics of change were evaluated at several time intervals post-treatment. Thus, a major
goal of this portion of the study was to determine the immunomodulatory effects of TNFa and SL-TNF-a alone, without the added contribution of tumor irradiation. Various
hematological and immunological parameters were measured to elucidate which innate
immune changes might be occurring and to identify those that might be correlated with
the enhanced antitumor effects seen with the combination treatment. Furthermore, to
determine if the observed changes in innate immunity might also be reflected at the tumor
site, sections of representative tumors from all previous studies were analyzed in Chapter
Seven. The focus was on the immune cell populations, which, in the previous studies,
had been identified as candidates for the enhanced antitumor effects seen with the
combination treatment.
Chapter Eight further integrates all the findings of the previous studies in a final
discussion. Potential correlations between the combination treatment and the exhibited
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antitumor effects are proposed and examined. Future potential studies are also discussed.
Any methods not mentioned within the published-format chapters, as well as more
detailed elaboration of methods and materials, can be found in Appendix One. Any data
not presented within the published-format chapters as “data not shown” can be found in
Appendix Two.
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A.

CHAPTER INTRODUCTION

To test the hypothesis, this first study was performed to investigate the specific
aims of efficacy and safety of the combination treatment of SL-TNF-a and radiation in a
nude mouse model. This present study will demonstrate for the first time that SL-TNF-a
as a neoadjuvant augments the antitumor effects of radiation against a human colorectal
tumor xenograft. The LS174T human colorectal cell line was used in nude mice to most
closely model the situation found in humans. Certain groups were given free TNF-a
rather than SL-TNF-a to compare its efficacy and safety relative SL-TNF-a.
Hematological and immune parameters were measured in this study to determine if any
changes in the innate immune status and cell populations occurred as a result of the
combination treatment and if any of these changes can be correlated to the demonstrated
antitumor effect.
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ABSTRACT
Recent reports have shown that tumor necrosis factor-a (TNF-a) can augment the
effects of radiation against certain tumor types. However, the high concentrations
of intravenous infusion of TNF-a needed to cause tumor regression can induce
many systemic side effects.

The aim of this study was to determine if TNF-a

encapsulated in sterically-stabilized (STEALTH®), PEGylated liposomes (SL)
augments the antitumor effects of radiation and to compare its efficacy and possible
toxicity with free TNF-a in the LS174T human colon tumor xenograft model. Nude
mice were injected subcutaneously with LS174T cells and treated intravenously with
STEALTH®-liposomal TNF-a (SL-TNF-a), TNF-a and/or radiation when tumor
size was ~200 mm3. In phase 1, a significant decrease {p = 0.047) in tumor growth
was observed with radiation at day 21, but not with SL-TNF-a or free TNF-a alone;
by the end of phase 1 (day 27) with continued treatments, the SL-TNF-a plus
radiation group had significantly smaller tumors {p = 0.044) than those in the free
TNF-a plus radiation group. In phase 2, where a similar tumor growth reduction
pattern was observed, the addition of TNF-a to radiation, either as free protein or
within SL, increased lymphocyte activation and natural killer (NK) cell numbers in
both blood and spleen; the effect was generally more pronounced with SL-TNF-a.
Systemic toxicity, based on hematological analyses and body weight, was absent or
minimal. Collectively, the data show that pretreatment with SL-TNF-a can enhance
more effectively, and possibly more safely the effects of radiation against human
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colon tumor xenografts than can free TNF-a and that the increased antitumor
action may involve upregulation of lymphocytes.
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INTRODUCTION
Advances in liposome technology have made possible the use of many drugs and
immunomodulatory molecules once thought to be too toxic 0). Anti-cancer drugs such as
doxorubicin and cisplatin have been encapsulated in sterically stabilized liposomes,
resulting in enhanced accumulation of the drugs at solid tumor sites, reduced systemic
toxicity, and increased therapeutic efficacy l2*6). Liposome encapsulated drugs have also
been used with moderate success in the treatment of liver and spleen metastases (7'9f The
potential benefits of SL-encapsulated immunomodulatory molecules, such as TNF-ot,
have thus far been only minimally explored.
TNF-a is a multifunctional polypeptide that can cause hemorrhagic necrosis of
tumors in vivo through destruction of tumor vasculature, has direct cytotoxicity against
some tumors cells in vitro, induces inflammation, and activates many cell types l10-11).
Flowever, systemic side effects, such as vascular leakage, hypotension, rigors, fever,
fatigue, weight loss, leukopenia, and renal impairment, limit the usefulness of systemic
administration of TNF-a as an antineoplastic agent U2-13). The maximum dose tolerated
by humans is only 2% of the dose that has been shown to cause tumor regression in
animal models (14-16)

Thus, the dose of TNF-a that could safely be used alone or

together with other agents is severely limited.
However, encapsulation of TNF-a in a sterically stabilized STEALTH® liposomes
(SL) has the potential to decrease systemic toxicity while increasing the efficacy of TNFa treatment. The liposome is coated with polyethylene glycol, a hydrophilic polymer,
and is therefore able to maintain its stability in biological fluids and also escape cells of
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the mononuclear phagocytic system (I7).

Thus, use of an SL increases the blood

residence time of TNF-a, which in turn enhances TNF-a localization within the tumor
(due to the increased permeability of tumor-associated micro vasculature). The
accumulation of SL-TNF-a at the tumor site allows lower dosages of TNF-a to be used,
while the gradual release of the TNF-a increases its concentration and half-life within the
tumor itself (15-18). Furthermore, the TNF-a largely remains encapsulated within the
stabilized liposome while circulating in the blood, thus minimizing the risk for systemic
toxicity.

Previous studies have shown that TNF-a in combination with ionizing radiation can
be effective in tumor growth inhibition (19-22)

Both radiation and TNF-a individually

have some antitumor effects; however, TNF-a may also sensitize tumor cells, resulting in
either additive or synergistic effects when the two agents are administered together. To
date, there are no published reports in which SL-encapsulated TNF-a has been combined
with radiation. The major aim of the present study was to determine if SL-encapsulated
TNF-a could enhance the antitumor effects of radiation while limiting the toxicity of
TNF-a. Immunological and other quantitative assays were performed to correlate any
possible tumor response or hematological toxicities with the combination treatment.
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MATERIALS AND METHODS

Animals
Male athymic mice (outbred background nu/nu; n = 90 in phase 1; n = 100 in phase 2)
were obtained as 6-week-old weanlings (Charles River Breeding Laboratories, Inc.,
Wilmington, MA). They were housed in self-contained filter-top cages (4-9 mice/cage)
and acclimated for 1 to 2 weeks in a facility controlled for temperature, humidity, and a
12:12 hour light:dark cycle under near-sterile conditions. Autoclaved bedding, food, and
water were provided. The animals were weighed two to three times a week, observed
routinely for signs of treatment-related toxicities, and euthanized with CO2 in compliance
with the recommendations of the American Veterinary Medical Association (AVMA)
Panel on Euthanasia. The study was approved by the Animal Care and Use Committee of
Loma Linda University.

Tumor cells
The LS174T cell line (American Type Culture Collection, Rockville, MD) were
grown in RPMI-1640 medium (Sigma Chemical Co., St. Louis, MO) supplemented with
10% bovine calf serum (BCS; Hyclone Laboratories, Logan, UT), 12 mM HEPES buffer
(Mediatech Inc., Herndon, VA), and 1% antibiotic antimycotic solution (10,000 unit/ml
penicillin, 10 mg/ml streptomycin, and 25 pg/ml amphotericin B; Sigma),

The cells

were harvested with 0.25% trypsin, washed, resuspended to 2.5 x 107 cells/ml in
phosphate buffered saline (PBS), and injected subcutaneously (s.c.) in the right thigh (5 x
106 cells/0.2 ml/mouse). Tumors were measured using vernier calipers and volumes were

66

calculated as follows: tumor volume (mm3) = length x width x (height / 2). In phase 1,
the mice were euthanized when the mean tumor volume of the particular group reached a
maximum of 2,200 mm3; in phase 2, all mice were euthanized when the tumor volume of
the tumor-bearing non-treated control group reached ~1,500 mmJ.

SL-TNF-a, SL, and TNF-a
Encapsulated recombinant human TNF-a protein (rh-TNF-a; Boehringer, Ingelheim,
Germany) was prepared using Stealth® liposomes kindly provided by Dr. P. K. Working
(ALZA Corporation, Mountain View, CA) as previous described l18).

Briefly, the

following chemicals were obtained: partially hydrogenated egg phosphatidyl choline
(PHEPC; Lipoid, Ludwigshafen, Germany), cholesterol (Choi; Sigma), and distearoyl
phosphatidylethanolamine (DSPE) derivatized at its amino position with a 1,900 MW
segment of polyethylene glycol (PEG) (PEG-DSPE; ALZA Corp). A mixture of PHEPC
(242.5 mg), cholesterol (64.5 mg) and PEG-DSPE (67.6 mg) in a molar ratio of
1.85:1:0.15 suspended in chloroform/methanol was evaporated in a rotary evaporator.
The dried lipid film was resuspended with HEPES buffer (10 mM HEPES, 150 mM
NaCl), vortexed, and formed into liposomes of specific size by sonication (10-15 min at
amplitude 9) using an ultrasonic disintegrator with a 3.5 mm diameter exponetial
microprobe (Soniprep 150, Sanyo, Leicester, UK). Liposome size was confirmed by
dynamic light scattering (Malvern 4700, Malvern, PA). In the preparation of SL-TNF-a,
TNF-a was encapsulated into these liposomes by adding 2.5 ml TNF-a into the HEPES
buffer (400 pg/ml). Stock solutions of SL-TNF-a (60 pmol/ml at 25 mg rh-TNF-a/100
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I^mol SL) and SL-placebo (60 jamol/ml) were prepared and stored at 4°C until
immediately before intravenous (i.v.) injection into the heat-dilated caudal vein.

A

concentration of 120 pmol/kg was used for each treatment. Recombinant human TNF-a
was purchased from R&D Systems Inc. (Minneapolis, MN), reconstituted in PBS
containing 0.1% bovine serum albumin, aliquoted, and stored at -70°C until immediately
before injection.

Irradiation of tumors
Immediately prior to irradiation, the mice were anesthetized by intraperitoneal
injection of a xylazine (5.2 mg/kg) and ketamine (80 mg/kg) combination. All mice.
including controls with no tumor, were anesthetized. Irradiation was performed using a
60Cobalt (60Co) source from an AECL Eldorado Model gamma (y) irradiation machine
(Atomic Energy of Canada, Ltd., Commercial Products Division, Ottawa, Canada). In
phase 1, a total dose of 6 to 10 Gray (Gy) in 2 Gy fractions was delivered on alternate
days, over a maximum of 15 days. In phase 2, a total dose of approximately 8 Gy was
delivered in 2.6 Gy fractions over a 9-day period. In both phases, the dose rate was 1.7
Gy/min, and the tumors were covered with a bolus (‘superflab’) of 0.5 cm thickness.
Only the tumor and the underlying normal tissue of the leg were exposed to radiation.

Treatment protocol
At the time of tumor cell injection, the animals were assigned to groups (n = 8 - 18
mice/group) and treatment began when the tumor volume of the tumor control group
reached an average of 200 mm3. In both phases, TNF-a, SL, SL-TNF-a, or PBS was

68

injected i.v. into heat-dilated tail veins on days 11, 14, and 18; in phase 1, one-half of the
mice in the TNF-oc plus radiation and SL-TNF-oc plus radiation groups continued to
receive i.v. injections on days 21 and 25. The appropriate groups were always irradiated
20-24 hr after injection (i.e., days 12, 15, and 19); in phase 1, one-half of the mice in the
TNF-oc plus radiation and SL-TNF-ct plus radiation groups continued to be irradiated on
days 22 and 26. In phase 1, only tumor size and body weight were evaluated. In phase 2,
additional assays were performed (described below).

Relative spleen weights, splenic leukocyte counts, and LPS-induced and spontaneous
blastogenesis
Spleens were excised, weighed, and relative spleen weights (RSW) were calculated:
RSW = [spleen weight (g) x 104] / body weight (g). The spleens were then processed into
single-celled suspensions, washed, and centrifuged. Erythrocytes in cell pellets were
lysed by incubation in 2 ml ACK (ammonium-chloride-potassium) solution for 4 min at
4°C. The remaining leukocytes were washed, suspended in 1 ml of medium, counted
(Vet ABC-Diff Hematology Analyzer. HESKA Corporation, Waukesha, WI), and
adjusted to 2 x 106 cells/ml in RPMI 1640 medium supplemented with 10% heatinactivated FBS (Hyclone), antibiotics, and mercaptoethanol. The mitogen-induced assay
has been previously described in detail (Gridley et al. 1997). Briefly, aliquots of each
cell suspension were dispensed into wells of microtiter plates either with or without
lipopolysaccharide (EPS; E. coli serotype 0111:134; Sigma) and incubated at 37°C in 5%
CO2 for two days. During the last 4 hr of incubation, [3H]-thymidine ([3H]-TdR; specific
activity = 46 Ci/pmol; ICN Radiochemicals, Irvine, CA) was added at 1 pCi/50 pl/well.
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The uptake of radioactivity (counts per minute; cpm) was quantified and expressed as a
stimulation index (SI): SI = (cpm with LPS - cpm without LPS)/cpm without LPS. To
assay spontaneous blastogenesis, 50 pi aliquots of the cells were diluted with 150 pi of
complete RPMI 1640 medium and 1 pCi [ H]-TdR in 50 pi of medium was immediately
added. Each mouse was tested in triplicate in 96-well microculture plates. The cells
were incubated for 3 hr at 37°C in 5% CO2, and the uptake of radioactivity was quantified
as described above. The leukocyte counts/ml and the volume tested were used to convert
the cpm into cpm/106 leukocytes.

Peripheral blood leukocyte, erythrocyte, and thrombocyte evaluation, and spontaneous
blastogenesis
Whole blood, collected in EDTA-containing tuberculin syringes by cardiac puncture
immediately after euthanasia, was evaluated using the Vet ABC-Diff Hematology
Analyzer (HESKA).

The measurements included white blood cell (WBC) counts,

lymphocyte, monocyte, and granulocyte counts and percentages, red blood cell (RBC)
and thrombocyte counts, hemoglobin, hematocrit (percentage of whole blood composed
of RBC), mean corpuscular volume (MCV; volume of an average RBC), mean
corpuscular hemoglobin (MCH; amount of hemoglobin in an average RBC), and mean
corpuscular hemoglobin concentration (MCHC; concentration of hemoglobin in the RBC
component of blood). To assay spontaneous blastogenesis, 50 pi aliquots of whole blood
were assayed as described above for splenocytes.
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Analysis of lymphocyte populations in blood and spleen
Lymphocyte populations in blood and spleen were quantified using a FACSCaliberTM
4-channel flow cytometer (Becton Dickinson, Inc., Rutherford, NJ). The CD3+ T, CD4+
T helper (Th), CD8+ T cytotoxic (Tc), CD19+ B, pan-NK+ natural killer (NK) cells, and
lymphocytes expressing CD25 and CD71 activation markers were identified using 4color, 2-tube mixtures of fluorescence-labeled monoclonal antibodies (MAb). The MAb
mixtures were specially designed by Pharmingen (San Diego, CA) in collaboration with
Becton Dickinson. The MAb were labeled with fluorescein isothiocyanate (FITC), Rphycoerythrin (PE), allophycocyanin (APC), or peridinin chlorophyll protein (PerCP).
Analysis was performed using CellQuest™ software version 3.1 (Becton Dickinson). To
obtain the number of cells for each lymphocyte population, the following formula was
used: number of cells in population/ml = number of leukocytes/ml x percentage of the
population.

Statistical analysis
The data were assessed using one-way analysis of variance (ANOVA) and the
Tukey's pairwise multiple comparison test (SigmaStatTM Statistical Software version
2.03; SPSS Inc., San Rafael, CA). A p value of <0.05 was taken as indicating significant
differences among groups.
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RESULTS
Tumor incidence and volume
In both phases, treatment was initiated on day 11 when tumors were measurable
(-200 mm ). Figures la and lb show the mean tumor volumes obtained over time for
each group in phase 1 and phase 2, respectively. In phase 1, significantly smaller tumors
were present at day 21 in the groups receiving radiation compared with the non-treated
tumor control group; only the SL-TNF-a plus radiation group showed significant
inhibition of tumor progression compared with radiation alone.

Due to AVMA

restrictions regarding maximal allowable tumor size, further comparison among all the
groups beyond day 21 was not possible. However, comparison of the two combination
groups, which received each modality 5 times, showed that tumors in the SL-TNF-a plus
radiation group were significantly smaller than those in the free TNF-a plus radiation
group by day 27. In phase 2, all groups receiving radiation also showed significantly
slower tumor growth compared to the non-treated control group, whereas none of the
other single agent groups (TNF-a, SL. or SL-TNF-a) showed significant difference from
the control.

However, the administration of either SL-TNF-a or free TNF-a in

combination with radiation resulted in significantly smaller tumor volumes than those in
the groups receiving only radiation, SL-TNF-a, or TNF-a.

Body weight, RSW, and toxicity
In phase 1, there were no significant differences in mouse weight among the groups
(all of which had tumor); the mean values at euthanasia ranged from 22.0 ± 0.4 g (TNF-a
plus radiation) to 24.9 ± 1.2 g (SL).

In phase 2, all groups with tumor eventually
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weighed less compared to the normal, non-tumor-bearing control mice; mean body
weight for the control group was 27.6 ± 0.4 g by the time of euthanasia, whereas the
means for tumor-bearing animals ranged from 22.2 ± 0.4 g (radiation) to 25.8 ± 0.8 g
(SL). However, there were no significant differences among the groups with tumor,
indicating that type of treatment had no effect on body weight. Spleen weights in relation
to body weights (i.e. RSW) of all irradiated mice showed significant (p<0.05) decreases
(22% to 36%) compared to tumor control mice [mean RSW ranged from 22.6 ± 0.8
(radiation) to 27.7 ± 2.3 (TNF-a plus radiation); data not shown for other groups].
There were no readily detectable (external) signs of treatment-related toxicity
observed at any time.

However, the lowest RBC count, hemoglobin concentration,

hematocrit, and MCV were observed in the TNF-a group; the lowest MCH was observed
in the TNF-a plus radiation group (Table 1). There were no significant differences in the
MCHC and platelet counts.

Leukocyte counts and spontaneous and mitogen-induced blastogenesis
The leukocyte count in the blood was consistently lower in all tumor-bearing groups
compared to the control group with no tumor, but statistical significance was obtained
only for the groups receiving radiation (Fig. 2a). In the spleen, all mice with tumor had
significantly lower leukocyte numbers than those obtained for the control group (Fig. 2b).
The basal proliferation rates of circulating WBC, as determined by [3H]-TdR
incorporation into DNA, were highest in the groups receiving TNF-a plus radiation and
SL-TNF-a plus radiation (Fig. 2c). In the spleen, the highest values were observed in the
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groups receiving TNF-a (Fig. 2d). Splenocytes did not show any differences in response
to LPS stimulation among the groups.

SI values ranged from 56.8 ± 9.1 (no tumor

control) to 98.8 ± 12.6 (radiation).

Non-lymphoid cell populations
Although neither granulocyte nor monocyte numbers in the blood were significantly
different among the groups, the percentage of granulocytes was increased in all tumor
bearing mice, and monocyte percentage was increased in groups receiving SL-TNF-ct
(Fig. 3a-d). In the spleen, the numbers of both cell types were significantly lower in all
groups with tumor compared to the non-tumor-bearing control group, but the depression
was especially pronounced in irradiated animals (Fig. 3e-h).

Flow cytometry analysis of lymphocyte populations
The evaluation of lymphocyte populations showed that the decreases can be attributed
to at least three possible causes (Fig. 4-7, Table 2). Tumor-bearing mice exhibited some
depression in most lymphocyte populations and cell activation in both the blood and
spleen. In the blood (Fig. 4-5), low values were obtained for total lymphocyte, B cell.
and activated lymphocyte counts; in the spleen (Fig. 6-7), reduced numbers of total
lymphocytes, B cells, T cytotoxic cells, and activated lymphocytes were found.
Furthermore, irradiation also caused depression in lymphocyte parameters. Significant
radiation-associated decreases were seen in the B cell count, activated lymphocyte count
and percentage, and B cell count and percentage in the blood and in the activated
lymphocyte, activated B, and NK cell counts in the spleen. Finally, free TNF-a also
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caused decreases in many different lymphocyte types, especially spleen cells with
activation markers and spleen NK cell percentage (data not shown). Significant TNF-aassociated decreases in the blood occurred in activated lymphocyte and activated B cell
percentages.
However, the data in Figures 4-7 also showed that the immunodepressive effect of
radiation was counteracted to some degree by the addition of TNF-a, either free or
encapsulated, although statistical significance was not always obtained.

The

administration of TNF-a alone, either free or encapsulated, induced increases only in the
blood NK cell count and numbers of activated NK and T cells.

However, the

combination of radiation plus either TNF-a of SL-TNF-a resulted in increased blood
lymphocyte, B cell, NK cell, and activated NK cell counts.

In the spleen, the

combination groups had increased total lymphocyte, total T cell, T helper cell, activated
T cell, NK cell, and activated NK cell counts; the percentages of activated T, NK, and
activated NK cells were also higher than radiation alone.

Furthermore, only the

combination of radiation and SL-TNF-a showed increases in total activated lymphocyte
and activated B cell counts in the blood and in spleen, total activated lymphocyte count
and percentage and activated B cell percentage.
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Table 1. Peripheral blood parameters

Group

RBC

HGB

HCT

MCV

MCH

MCHC

PLT

No tumor control

8.2 ± 0. la

14.1 ±0.3

43.1 ±0.8

52.4 ±0.6

17.2 ±0.3

32.9 ±0.3

601 ±25

Tumor control

6.7 ±0.5

11.2 ± 0.7b 34.2 ±2.4

50.9 ±0.3

16.9 ±0.3

32.9 ± 0.4

540 ±32

TNF- a

5.9 ± 0.6b

9.6 ± 0.9b 29.3 ± 3.0b

49.7 ± 0.2b 16.3 ±0.2

32.9 ±0.3

646 ± 29

SL

7.0 ±0.4

11.4 ± 0.6

35.6 ± 1.9

51.3 ±0.7

16.5 ± 0.3

32.3 ±0.2

589 ±35

SL-TNF-a

6.7 ±0.5

11.0 ± 0.7b 34.1 ±2.3

51.2 ±0.5

16.7 ±0.2

32.5 ± 0.3

523 ±31

Radiation

7.4 ±0.3

12.0 ±0.4 37.8 ±1.4

51.2 ± 0.4

16.4 ± 0.1b 32.1 ±0.3

483 ± 18

TNF-a + Radiation

7.2 ±0.4

11.5 ±0.6 36.7 ±2.2

51.2 ± 0.3

16.1 ±0.1b 31.6 ± 0.3

565 ± 40

SL ± Radiation

7.4 ±0.4

12.1 ±0.7

38.1 ±2.3

52.0 ±0.4

16.5 ±0.2

32.0 ±0.3

496 ± 27

SL-TNF-a ± Radiation

7.0 ±0.4

11.5 ±0.6

36.2 ±1.9

51.5 ±0.5

16.4 ±0.2

32.1 ±0.2

567 ±25

aMean ± SEM for 8 - 18 mice.
bSignificantly lower than No tumor control (p < 0.05).
RBC: red blood cells (106/ml); HGB: hemoglobin (g/dl): HCT: hematocrit (%); MCV: mean corpuscular volume (fl);
MCH: mean corpuscular hemoglobin (pg); MCHC: mean corpuscular hemoglobin concentration (g/dl); PLT: platelet
(103/ml).
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Table 2. T

lymphocyte activation

(CD3+/CD25+)

Blood
Group

Spleen

103/ml

%

104/ml

No tumor control

1.91 ± 0.43a

0.11 ±0.03

1.19 ± 0.43

0.196 ±0.082

Tumor control

1.40 ±0.81

0.16 ±0.05

2.30 ±0.70

0.592 ±0.168

TNF-a

2.31 ±0.47

0.19 ±0.05

1.39 ±0.42

0.359 ± 0.092

SL

1.91 ±0.34

0.17 ±0.06

2.58 ±0.43

0.519 ±0.085

SL-TNF-a

2.49 ±0.32

0.44 ± 0.20

2.90 ±0.72

0.604 ±0.124

Radiation

3.39 ±0.69

0.80 ± 0.24b

1.02 ±0.21

0.658 ±0.132

TNF-a ± Radiation

1.98 ±0.24

0.24 ± 0.06

1.46 ±0.49

0.547 ±0.115

SL ± Radiation

2.96 ±0.50

0.63 ± 0.16

0.90 ±0.27

0.458 ±0.078

SL-TNF-a ± Radiation

2.40 ±0.34

0.36 ± 0.08

1.66 ±0.30

0.618 ± 0.095

aMean ± SEM for 8 - 18 mice.
bSignificantly greater than No tumor control (p < 0.02).
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%

FIG. 1.

Tumor volume with time after LS174T cell injection. Each point represents the mean ±

SEM for 8-18 mice, (a) Phase 1; (b) Phase 2; 1: significantly lower than Tumor control and SL

ip < 0.05); 2: significantly lower than Tumor control, SL, and SL-TNF-a {p < 0.01), 3:
significantly lower than Tumor control, SL, SL-TNF-a, and TNF-a {p < 0.04), 4: significantly
lower than Tumor control, SL, SL-TNF-a, TNF-a, and Radiation (p < 0.02), 5: significantly
lower than TNF-a plus Radiation {p < 0.05), 6: significantly lower than Tumor control, SL, TNFa, SL-TNF-a, Radiation, and SL plus Radiation {p < 0.05). black arrow: i.v. treatment; dotted
arrow: irradiation.
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FIG. 2.

Leukocytes. Each bar represents the mean ± SEM for 8 - 18 mice, (a) Number of

leukocytes in the peripheral blood, (b) Number of leukocytes in the spleen, (c) Basal leukocyte
proliferation in the blood, (d) Basal leukocyte proliferation in the spleen; groups: (A) No tumor
control, (B) Tumor control, (C) TNF-ct, (D) SL, (E) SL-TNF-a, (F) Radiation, (G) TNF-a plus
Radiation, (H) SL plus Radiation, (I) SL-TNF-a plus Radiation. 1: significantly greater than No
tumor control, Tumor control, SL, SL-TNF-a, and Radiation (p < 0.04).
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FIG. 3.

Non-lymphoid cells. Each bar represents the mean ± SEM for 8 - 18 mice. Groups:

(A) No tumor control, (B) Tumor control, (C) TNF-o, (D) SL, (E) SL-TNF-a, (F) Radiation, (G)
TNF-a plus Radiation, (H) SL plus Radiation, (I) SL-TNF-a plus Radiation.

1: significantly

lower than No tumor control {p < 0.03), 2: significantly lower than Tumor control {p < 0.03), 3:
significantly lower than Radiation {p < 0.03), 4: significantly greater than No tumor control {p <
0.001), 5: significantly greater than Tumor control (/? < 0.05).
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FIG. 4.

Lymphocyte populations in the peripheral blood. Each bar represents the mean ± SEM

for 8 - 18 mice. Groups: (A) No tumor control, (B) Tumor control, (C) TNF-a, (D) SL, (E) SLTNF-a, (F) Radiation, (G) TNF-a plus Radiation, (H) SL plus Radiation, (I) SL-TNF-a plus
Radiation 1: significantly lower than No tumor control (p < 0.05), 2: significantly lower than
Tumor control (p < 0.05).
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FIG. 5.

Activated lymphocytes in the peripheral blood. Each bar represents the mean ± SEM

for 8 - 18 mice. Groups: (A) No tumor control, (B) Tumor control, (C) TNF-ot, (D) SL, (E) SLTNF-a, (F) Radiation, (G) TNF-a plus Radiation, (H) SL plus Radiation, (I) SL-TNF-a plus
Radiation. 1: significantly lower than no tumor control (p < 0.02), 2: significantly lower than
tumor control (p < 0.03), 3: significantly lower than radiation (p < 0.02).

86

0.7
^

£

0.6

8
5

0.3

z

0.1

1

1

(D

20

■8
75

15

.§

1

03

1,2 1,2 1 2

nnn

0.0

0

4

c

NK cells (Pan-NK+/CD71+)

i 5
0)

2

3

8

2

6
z

1

.2

1,2,3

10
5

d

NK cells (Pan-NK+/CD71+)

3

"o

4

1,2 1,2

1,2

1,2

o

3?

1,2

0.2

6

b

JL
1

0.4

i■S

Lymphocytes (CD45+/CD71+)

25

E °-5
-8

30

a

Lymphocytes (CD45+/CD71+)

8

1

i
8

2

:

1

•S
1

0

0

25
0.5

B cells (B220+/CD71+)

e

t

f

B cells (B220+/CD71+)

20

"o

CCD

04

S 15
.2
1 ,0

0.3

1

.1

S °'2~
o

o

1

OJ

1

1

X

0.1

1,2

1,2

1,2

1,2

'o

1,2

1,2
5

1,2 1.2 1i2

nnn

0.0

1

ABCDEFGH

0
ABCDEFGH

I

Group

Group

87

I

FIG. 6.

Lymphocyte populations in the spleen. Each bar represents the mean ± SEM for 8-18

mice. Groups: (A) No tumor control, (B) Tumor control, (C) TNF-a, (D) SL, (E) SL-TNF-a, (F)
Radiation, (G) TNF-a plus Radiation, (H) SL plus Radiation, (I) SL-TNF-a plus Radiation. 1:
significantly lower than no tumor control (p < 0.05), 2: significantly lower than tumor control (p
<0.02).

88

8

E

6

E

g

d

z

6

1

1

4

_L

T

b

i

1

T

*g

1
1

1

2

10
8
E
6

M

g

4

d

z:

1

1

1

2

1

1

2

T cells

I

C

d

Tc cells

E

co

1

g

1

I1

I

X

d
z

2

1

0.4

Th cells

e

1 X

0

0

0

NK cells

f

5
E
cn

0.3

1

4

c.
^
g

d
z

3 -

2
1 0

1

o

4

6

1
rX.

1

0

d
z

B cells

CD^

to
^

8

a

Lymphocytes

I

I

=
g

0.2

d
z

0.1

§
ABCDEFGH

I
2 X

2

0.0
ABCDEFGH

I

Group

Group

89

FIG. 7.

Activated lymphocytes in the spleen. Each bar represents the mean ± SEM for 8-18

mice. Groups: A) No tumor control, B) Tumor control, (C) TNF-a, (D) SL, (E) SL-TNF-a, (F)
Radiation, (G) TNF-a plus Radiation, (H) SL plus Radiation, (I) SL-TNF-a plus Radiation. 1:
significantly lower than no tumor control (p < 0.05), 2: significantly lower than tumor control (p
<0.05).
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DISCUSSION
Although surgery is the primary treatment for colorectal cancer, radiotherapy is
frequently administered in attempts to reduce the rate of local recurrence and increase
survival time (23). Clinical trials have convincingly demonstrated that the addition of
radiation to the regimen can improve treatment (23-26)

American Cancer Society

statistics show that colorectal cancer is the third most common cancer in the U.S.A., and
recently, it has even been linked to cigarette smoking (27-29) Thus, the development of
new treatment strategies that are not only safe and effective but also have the potential to
enhance innate defense mechanisms is of paramount importance in order to further
improve the management of colorectal cancer.
The present study shows, for the first time, that i.v. pre-treatment with SL-TNF-a
significantly enhances the antitumor effects of radiation in a human colon
adenocarcinoma xenograft model. A study from our laboratory has previously shown that
pretreatment with free TNF-a can moderately enhance the antitumor effects of radiation
in this model (19f In the current study, the combination of SL-TNF-a and radiation
produced a greater than expected slowing of tumor progression; SL-TNF-a alone had no
effect on tumor growth in phase 1 and only a slight but not significant effect in phase 2,
which can be easily explained by response variability in different animals. Radiation
alone had only a modest effect, which was augmented significantly by the addition of
either SL-TNF-a or TNF-a. However, as shown in phase 1, continued treatment with
SL-TNF-a plus radiation produced the greatest response compared to all of the other
treatments, including TNF-a plus radiation.
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The mechanisms by which TNF-a exerts its anti-tumor effects may involve both nonimmunological and immunological host factors. As mentioned above, SL encapsulation
leads to an increased blood circulation time that allows a greater accumulation of the
encapsulated substance at the tumor site. In addition, once TNF-a is released from the
SL at the tumor site, TNF-a itself can also increase local leakage of the tumor
vasculature, further facilitating its own accumulation (30-32) Therefore, the properties of
both SL and TNF-a contribute to the increased accumulation of TNF-a at the tumor site.
As a result, the higher concentration of TNF-a can exert a stronger anti-tumor effect or
better augment any ionizing effects of radiation.

These alterations in the

pharmacokinetics give more flexibility regarding the total dose of TNF-a that could be
safely administered.
Furthermore, the stabilized encapsulation by SL reduces the possibility of TNF-a
toxicity from premature release of TNF-a, allowing higher concentrations and multiple
dosages to be administered (18f Thus, any side effects associated with TNF-a could be
abated and perhaps prevented from interfering with any positive effects. In mice, doses
of approximately 400 pg/kg of TNF-a are required to induce tumor regression when
administered alone. Because humans can tolerate only 8 pg/kg (2% of the effective dose
in mice) as a bolus infusion, TNF-a alone is not considered a viable treatment option at
the necessary concentrations (,3’33) Although combination with radiation could lower the
needed dose of TNF-a, our results show that even with the relatively low concentration
of free TNF-a (30 pg of TNF-a/kg body weight), mild signs of toxicity were apparent
especially in certain blood parameters. However, no signs of toxicity were observed with
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SL-TNF-a administered at an equivalent TNF-a dose (30 jag of TNF-a encapsulated in
SL/kg body weight).

Overall, our results indicate that SL-TNF-a is well tolerated.

causing no prohibitive side effects under the conditions used.
In addition to direct, non-immunological effects, various immunological factors also
seem to be involved in the efficacy of the combination treatment. Although nude mice
are athymic, a small but significant number of competent T-lineage cells in the spleen
and lymph nodes are present, aside from a normal population of B lymphocytes and other
leukocytes (34).

Thus, the immunological response from the treatments included

evaluations of T cells. Although radiation has direct tumor-inhibiting effects, it also
causes decreases in various leukocyte populations. However, these decreases appeared to
be somewhat attenuated by the addition of TNF-a, free or encapsulated, but in some
cases, only when encapsulated. Without radiation, there were no significant differences
among the treatment groups in most of the lymphocyte populations. However, with the
addition of radiation, differences due to TNF-a inclusion became more pronounced,
although the overall cell counts were less than those for the non-irradiated groups. This
augmenting effect was observable in the blood (total lymphocyte and B cell number and
level of activation) and in spleen (total lymphocyte, B cell, T cell, and NK cell number
and degree of activation).

Thus,

this TNF-a-mediated

attenuation of the

immunodepressive effects of radiation may play a role in the efficacy of the combination
treatment. It appears that TNF-a may trigger an upregulation of certain lymphocytic
parameters that is not evident in the absence of radiation.

Furthermore, in a study

recently completed in our laboratory, tumors were histologically evaluated for tumor cell
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death (i.e., necrosis and/or apoptosis), and tumor-infiltrating cells were identified and
quantified using immunohistostaining and laser scanning cytometry (manuscript in
preparation).

The results demonstrated that treatment with SL-TNF-a significantly

increased the infiltration of three different types of non-specific effector cell populations
(NK cells, macrophages and neutrophils) compared to free TNF-a and that the increased
accumulation correlated to the extent of tumor cell death observed.
In many of these measurements, the administration of SL-TNF-a or free TNF-a
caused very similar effects that may be related to their antitumor effect. Many of the
responses seen in the leukocytic and lymphocytic populations, and their activation status
mirrored each other. However, the systemic injection of free TNF-a, but not SL-TNF-a,
also had the additional effect of depleting certain lymphocytic populations and down
regulating their activation status, especially in the spleen, in addition to the above
mentioned effects on the blood panel. Although the amount of free TNF-a used was
minimal compared to published concentrations

needed for tumor regression,

hematological results suggestive of mild anemia were evident in the group receiving only
the protein. Thus, the use of even modestly higher concentrations of free TNF-a may
lead to unwanted consequences. These apparently detrimental actions of free TNF-a
could explain, at least partly, the greater efficacy and safety of SL-TNF-a when
combined with radiation.
Our findings support the concept of SL-TNF-a as a potentially useful adjunctive
modality in the radiotherapy of colon adenocarcinoma and possibly other types of
cancers. While having the benefits of TNF-a, SL-TNF-a decreases the risk for side
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effects or antagonist effects associated with systemic administration of free TNF-a
protein. Therefore, SL-encapsulation may permit the more widespread use of TNF-a as
an adjunctive form of therapy that could significantly augment radiation effects in the
treatment of a variety of cancers.
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CHAPTER FOUR

IV. INTERVENING DISCUSSION ONE

In conjunction with the discussion of the previous chapter, this chapter will
further elaborate on the results of the previous study. The overall evaluation of the data
in Chapter Three showed that SL-TNF-a enhanced the antitumor effects of radiation.
Phase one of the study demonstrated that the combination treatment significantly
inhibited tumor growth compared to the non-treated control group, radiation alone group,
and either one of the TNF-a groups. Phase two further demonstrated that after multiple
treatments, the difference in tumor growth inhibition between SL-TNF-a plus radiation
and free TNF-a plus radiation became significant.

In addition, SL-TNF-a did not

produce any of the measurable side effects that were present with free TNF-a.
Furthermore, upregulation and/or modulation occurred in a number of the measured
immune parameters in the SL-TNF-a plus radiation group that were not observed in any
of the other groups. In some of these measured parameters, similar changes were not
observed with the other treatments and appeared to correlate with the enhanced antitumor
effects seen with the combination treatment of SL-TNF-a and radiation. Each of these
summary points will be addressed in the following sections.
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A. Efficacy of SL-TNF-cc and radiation
Statistically comparing the tumor volumes as a measure of tumor growth
inhibition, the previous study showed that tumor progression was indeed significantly
decreased by SL-TNF-oc and radiation. As a result, the conclusion was reached that the
combination treatment does work well in the LST174T/nude mouse model and may also
be efficacious in other tumor systems.

Flowever, statistically comparing numerical

means does not necessarily translate into a meaningful increase in tumor control in a
clinical situation. Thus, Figure 1 of the present chapter further analyzes and shows the
growth delay resulting from the treatments using the data from phase 1 that is described
in Chapter Three.

Only the radiation and the combination modality groups will be

elaborated upon here to focus the discussion on the most pertinent findings. This figure
compares the length of time for the tumor to grow from 400 mm3 to 1,400 mm3, i.e.
equivalent to about 1.8 doubling time for the tumor. The untreated control tumors took
seven days to grow 1,000 mm3 while the tumors treated with SL-TNF-oc plus radiation
took 13.5 days, or almost twice as long. LS174T cell doubling time in vitro has been
reported to be 24 hours (Trainer et al.. 1988). Flowever, by measuring the length and
width of 60 individual cells under the microscope using the C.A.S.T. (Computer Assisted
Stereological Toolbox) Grid system software (Olympus, Albertslund, Denmark), the
average volume was calculated for a single tumor cell.
ellipsoid [(4tt

x

length x width2)

-r-

Using the equation for an

3] as a general formula for a generically shaped

LS174T cell, assumed to be in an ellipsoid shape, the average volume/cell was calculated
to be 3.33 x 10' mm . Therefore, a tumor with a volume of 400 mm on day 12 (i.e., the
o

mean tumor size in the control group) should consist of approximately 1.2 x 10 LS174T
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Figure 1. Length of time for LS174T tumor xenografts to grow from 400 mm3 to 1400
mmJ. Data is compiled from the tumor volume with time after LS174T cell injection in
phase 1. Treatment began on day 11 as described in Chapter 3 and continued until the
tumor reached approximately 1500 mm3 for each group.
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cells. These calculations were performed to generally illustrate a point, and did not take
into account the likely presence of various other cell populations in the tumor such as
endothelial cells, immune cell infiltrates, and areas of necrotic cells. If 5 x 106 cells were
originally injected into the hind leg of each mouse (day 0), approximately 4.6 doublings
should have occurred by 12 days to reach the 1.2 x 108 hypothesized cell number. Thus,
the doubling time in our experiments before any treatment was given is roughly every 2.6
days in vivo, rather than the reported 1 day in vitro. In a tumor with a volume of 1,400
mm3, there should be approximately 4.2 x 108 LS174T cells present.

Thus, if the

untreated control tumor takes 7 days to reach 1,400 mm3 or 1.8 doublings, the doubling
time slows to approximately every 3.9 days during this phase of its growth. For the
tumors treated with radiation (8.5 day delay), free TNF-ct plus radiation (9 day delay),
and SL-TNF-a plus radiation (13.5 day delay), the doubling times are approximately 4.7
days, 5 days, and 7.5 days, respectively.
Therefore, the results of the study described in Chapter Three can alternatively be
interpreted in days that the tumor volume doubling time is extended (Hall, 2000). With
radiation, the doubling time is increased by less than 1 day, while the free TNF-oc plus
radiation treatment increased the doubling time by just over 1 day.

However, the

combination of SL-TNF-a and radiation increased the doubling time by almost 4 days, or
almost two-fold longer than that for the non-treated tumors. Another way to examine the
data is to note that tumor growth itself (to reach 1400 mm3) is delayed by the SL-TNF-a
plus radiation treatment almost 7 days longer than no treatment, almost 5 days longer
than TNF-a plus radiation, and almost 6 days longer than radiation alone. Therefore, it
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seems reasonable to assume that the statistically significant decrease in tumor volume
measurements could translate into significant clinical benefit. If the doubling time for a
tumor is extended to twice its original time by the treatment of SL-TNF-cc and radiation,
the treatment could potentially extend a patient’s survival long enough to warrant its
administration. Furthermore, in phase 1, only 2.0 Gy fractions were given; in phase 2,
2.6 Gy fractions were given and resulted in a more robust inhibition of tumor growth
(i.e., a greater difference was observed between the radiation alone versus the SL-TNF-a
plus radiation groups in phase 2 than in phase 1). Therefore, increasing the radiation
dose/fraction in the SL-TNF-a plus radiation regimen may take greater advantage of the
SL-TNF-a “priming” effect and result in additionally delayed tumor growth. It should be
noted that the 2.6 Gy is well within the range of doses that could be safely administered
in a single fraction to tumors in most body sites.
As noted above, not only was the SL-TNF-a plus radiation combination
significantly more inhibiting to tumor growth than the tumor control group, it was also
significantly more inhibiting than free TNF-a plus radiation. By examining the tumor
volume measurements or especially the tumor growth delay and doubling time delay, SLTNF-a plus radiation appears to be a more promising option. This conclusion is further
supported when the decrease in toxicity is considered in conjunction with the increase in
efficacy.
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B. Decreased toxicity of SL-TNF-a
When measuring toxicity in an in vivo model, external, overt changes are
observed. Appetite, skin changes, weight changes, diarrhea, and other external signs are
noted, if present. In the previous study, none of these external signs were noted in any of
the treatment groups. The administered concentrations of free TNF-ot and the TNF-a in
the SL (which were in equal concentrations) were considerably lower than the maximum
tolerated dose in mice, though substantially higher than the maximum tolerated dose in
humans (Feinberg et al., 1988).

Thus, overall, no obvious signs of toxicity were

expected.
However, as a possibly more sensitive indicator of toxicity, hematological
analyses were performed on the blood of the tested mice. Somewhat unexpectedly, signs
of toxicity were observed in some of the blood parameters with free TNF-a that were not
evident with SL-TNF-a. However, since these adverse signs were not found in the group
given free TNF-a plus radiation, it appears that the effects of the radiation may have
altered or masked the changes observed with free TNF-a alone. Thus, the findings in the
group injected with free TNF-a were used to emphasize the potential toxicities that may
occur when the TNF-a protein is administered systemically.
Only the free TNF-a group exhibited signs of microcytic anemia (low RBC and
hematocrit with low MCV or mean corpuscular volume). Anemia is diagnosed when
lower than normal values of hemoglobin concentration, hematocrit, or erythrocyte count
are demonstrated (Bonner and Erslev, 1994). In humans, anemia can become manifested
as tachycardia, shortness of breath, angina, fainting spells, and weakness. Furthermore,
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the MCV data show that the mean RBC size in the TNF-a groups was smaller than
normal. Microcytosis is commonly caused by disturbances in hemoglobin production
related to various imbalances in the body’s homeostasis (Bonner and Erslev, 1994).
Collectively, signs of toxicity, although not many, were clearly apparent.
Although the concentrations used did not necessarily warrant the appearance of toxicity,
the groups given free TNF-a clearly exhibited the early signs of toxicity; administration
of SL-TNF-a did not result in any of these signs. Therefore, in conjunction with the
greater efficacy seen with SL-TNF-a as an adjuvant to radiation, the decreased toxicity
also adds additional promise to SL-TNF-a as a safer alternative to free TNF-a.

C. Potential Immunomodulation by SL-TNF-a
In the study described in Chapter Three, various immune cell populations and
their activation state were measured to gauge the impact that the treatments, as well as
tumor presence, might have on the overall immune status of the mice. The leukocyte
populations and the markers used to identify specific subsets and level of cell activation
are shown in Table 1 of the present chapter. Because the animal model used in this study
(athymic nude mouse) is not fully immunocompetent, analyses of the data were limited
primarily to innate, natural immune mechanisms. However, although nude mice are
lacking a thymus, and thus do not possess a full complement of T cells, some of these
cells, though few, attain some degree of maturity and function (Holub, 1989).

The

animals have B lymphocytes and retain an intact innate immune system, consisting in
part of NK cells, monocytes/macrophages, and neutrophils. Thus, not only can innate
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Table 1. Cell markers used during this research to detect the various immune cell
populations.

Cell Type

Cell marker

Leukocytes

CD45 (Leukocyte Common Antigen)

Macrophages

Mac-3

Neutrophils

Ly-6G

NK cells

Pan-NK
Asialo-GM i

B cells

B220

T cells (mature)

CDS (T3 antigen)

T cytotoxic cells

CD8 (T8 antigen)

T helper cells

CD4 (T4 antigen)

Activation marker

CD71 (Transferrin receptor)
CD25 (IL-2 receptor)
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immune functions be demonstrated and evaluated, some inferences to potential adaptive
(i.e., T cell) immune responses may be proposed.
Although an even wider variety of immune cells could have been measured, only
the

following

individual

monocytes/macrophages,

NK

cell
cells,

populations
B

cells,

were
and

T

measured:

neutrophils,

cells.

Neutrophils,

monocytes/macrophages, and NK cells were measured due to their integral functions in
innate immunity and/or their known roles in tumor defense. B cells and T cells were also
measured as potential indicators of how adaptive immune mechanisms may respond to
the treatment regimen.

1. Monocytes/Macrophages
Monocytes are bone marrow-derived cells that briefly circulate in the blood,
migrate into tissues, and further differentiate into macrophages. The ability of these cells
to phagocytize bacteria and other particulate materials has been well known for decades.
More recently, it has been demonstrated that these cells are also integral in the host’s
overall immune responses; however, these responses are nonspecific (Cruse and Lewis,
1999). In this context, ‘nonspecific’ refers to the innate ability to produce a generalized.
but focused, immune response. Monocyte/macrophage function is not induced against a
specific antigen through specific receptor-ligand interactions (i.e., they do not require
prior contact with an immunogenic peptide and are not MHC-restricted). As avid
phagocytes, they are able to ingest and kill microbes through the generation of unstable
oxygen radicals and degradative enzymes that are present in their abundant lysosomes.
Monocytes/macrophages may play a significant role in antitumor responses. They are
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able to phagocytize various foreign proteins (such as tumor antigens), process them, and
present critical peptides in the groove of their MHC II molecules to specific T helper
lymphocytes. Macrophages can also release their lysosomal contents, which contain
various degradative enzymes and reactive oxygen intermediates (ROI), or release TNF-ct,
which can induce the target cell to die directly or affect the vasculature to promote
hemorrhagic necrosis. Furthermore, they are able to kill tumor cells via a mechanism
known as antibody-dependent cell-mediated lysis (ADCC). For example, macrophages
can bind via their Fey receptor to the Fc portion of IgG antibodies which are attached to
tumor cells and then release cytotoxic molecules, resulting in death of the tumor/foreign
cell (Figure 2 of present chapter).
Macrophages are highly mobile cells that are found throughout the body in
various organs, such as the lung, nervous system, skin, liver, spleen, and lymph nodes.
Monocytes are adherent to blood vessels from which they extravasate and enter various
tissues becoming macrophages.

(Monocytes comprised approximately 3-4% of the

leukocytes measured in the normal control nude mice in our studies.) They exhibit
chemotaxis to various signals including TNF-oc and express receptors for antibodies,
complement components, and a variety of cytokines (Cruse and Lewis, 1999). They are
also able to secrete many different types of factors including the following: Cl, C2, C3,
C4, and C5 complement components, factors B and D (regulatory proteins in the
complement family), IL-1, TNF-a, and other cytokines, acid hydrolase, proteases.
lipases, and many others. In innate immunity, macrophages are the principal source of
cytokines (Abbas and Lichtman, 2001).
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Figure 2. Schematic view of macrophage-mediated killing of a tumor cell. Lysis can be
induced be several mechanisms. Macrophages can release their lysosomal contents
containing various degradative enzymes and reactive oxygen species. They can also
release TNF-a, which can induce the target cell to die directly or can affect the
vasculature to promote hemorrhagic necrosis. Adapted from (Cruse and Lewis, 1999).
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TNF-a can function as both a chemoattractant and an activator of macrophages.
Upon activation by TNF-a, their ability to phagocytize and their bactericidal and
tumoricidal properties are both enhanced and accentuated (Grimshaw and Balkwill,
2001).

The cells can also induce the release of various enzymes that are growth

inhibiting for some tumors.

2. Neutrophils
Neutrophils represent another type of phagocytic cell that is integral in innate
immune responses, but (like the monocyte/macrophages) plays a nonspecific role. These
leukocytes have lobulated nuclei, usually appearing tri-lobed, and are thus, also referred
to as polymorphonuclear cells (PMN). The neutrophils accounted for approximately 3545% of the leukocytes measured in the non-tumor bearing nude mice in the present study.
These cells are the principal cells of acute inflammation and are the first cellular line of
defense in the immune response (Cruse and Lewis, 1999). They are attracted to various
sites by a variety of chemoattractants such as C5a (a breakdown component generated
during activation of either the classical or alternative complement cascades) and actively
phagocytize foreign organisms. Neutrophils circulate in the blood until they are induced
to marginate to the blood endothelium, and via diapedesis, migrate from the blood into
the site of immune activity, where they carry out their effector function and then die after
a few hours; unlike neutrophils, macrophages are able to survive an extended period of
time after they extravasate from the blood (Abbas and Lichtman, 2001). TNF-a can
function as both a chemoattratant and an activator for neutrophils; TNF-a also enhances
and stimulates phagocytosis and the cytotoxicity of neutrophils (Shalaby et al., 1985).
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3. Natural killer (NK) cells
NK cells are lymphocytes that are vital to innate, natural immunity (Bonavida et
ai, 1993). They are large granular lymphocytes and make up only a small portion of the
total lymphocyte population.

They comprised approximately 4-6% of the measured

leukocytes in the peripheral blood in the normal control nude mice in the present study.
These cells also do not require prior exposure to an antigen and their ability to respond is
not MHC-restricted; they are generally considered to be the most important cell type in
immune surveillance against neoplastic cell growth. NK cells are cytotoxic to various
nucleated cells including tumor cells and virus-infected cells (Cruse and Lewis, 1999).
One potential way NK cells are able to mediate killing is by their ability to recognize
foreign cells. An activating, kill signal can be generated against a cell if the NKR-P1
receptor on a NK cell detects a foreign glycoprotein on the membrane of another cell.
However, this kill signal can be inhibited if the Ly49 receptor on the NK cell can interact
with a self-MHC I molecule on the other cell, if present.

Therefore, normal cells

expressing the correct, self-MHC I complex will not be killed, but foreign cells with a
non-self MHC or no MHC (i.e., on a tumor cell) can not prevent the activation of the NK
cell. Another potential way NK cells are able to mediate killing of foreign cells is by
ADCC (Figure 3 of the present chapter). Therefore, antibodies produced by B cells can
coat foreign cells and induce NK cell cytotoxicity against those cells. ADCC is also
exhibited by neutrophils and macrophages. An indirect way by which NK cells are able
to mediate killing of foreign cells is through the synthesis and release of IFN-y, which
can strongly enhance the function of macrophages. Macrophages, in turn, produce IL-12,
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Figure 3. Schematic view of NK cell-mediated killing of a tumor cell. Direct interaction
of NK cells and tumor cells can result in target cell death. When NK cells are activated,
they release perforins, granzyme, and/or TNF-a to induce the death of a tumor cell. NK
cells can also mediate tumor cell death by antibody-dependent cell-mediated cytotoxicity.
Adapted from (Cruse and Lewis, 1999).
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which enhances the activity of NK cells. NK cells, like T cytotoxic cells, mediate cell
killing by the release of perforins, which produces pores in the target cell and causes
lysis. NK cells can also release granzymes A and B, which can enter the target cells and
induce apoptosis. Apoptosis can also be induced by activated NK cells via their Fas
ligand (FasL), their TNF-related apoptosis-inducing ligand (TRAIL), or their membranebound TNF-ot (Seaman, 2000). TNF-a also functions as a chemoattractant and activator
for NK cells, as it does for the aforementioned cell types (Pilaro et al., 1994).

4. B and T Lymphocytes
In athymic nude mice, T lymphocyte development is mostly stunted due to the
absence of the thymus, the major organ where negative and positive selection occur
during T cell maturation. Because T cells play the key role in adaptive immunity, the
overall status of adaptive immunity (i.e., the number of T cells and the dependent
function of B cells) in nude mice is muted. Thus, their role in the antitumor response
observed in this study is somewhat limited and is only briefly described below.
The great majority of lymphocytes can generally be divided into the following
two major subdivisions: B and T cells. Morphologically, they are very similar and thus,
are more distinguished by the different surface molecules they express and the functions
they perform. T cells, and to a lesser extent also B cells, are highly specific. For
example, each T cell expresses receptors for only one type of peptide that must be
presented in the context of either an MHC class I or class II molecule.
B cells mediate the humoral branch or portion of adaptive immunity by their
production of antibodies. Antibodies, also known as immunoglobulins, can bind to a
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wide variety of antigens (Cruse and Lewis, 1999). Upon binding, antibodies can function
to neutralize the function of the bound antigen, neutralize the activity of the bound
microorganism, participate in ADCC, and cause increased recognition and clearance by
phagocytes (Abbas and Lichtman, 2001). There are five isotypes of antibodies: IgG,
IgA, IgM, IgD, and IgE. The IgG isotype is the one that is most abundant in serum and
also the one that is involved in ADCC mediated by the NK cells, macrophages, and
neutrophils.
T cells are responsible for the cell-mediated portion of adaptive immunity. They
are generally divided into T cytotoxic (Tc) and T helper (Th) subsets, based on the panel
of lymphokines they characteristically secrete upon activation (Cruse and Lewis, 1999).
The Tc subset can effectively kill virus-infected cells and neoplastic cells.

Via the

presentation of tumor/foreign antigens in MHC I complexes and its interaction with a
specific T cell receptor, Tc cells are specifically sensitized (or primed) to combat the
foreign cell. Upon second encounter with the same antigen, the cells become activated
and proliferate. In addition, they are now able to secrete cytokines that attract other
effector cells to the site and release serine proteases and perforins to induce lysis of tumor
cells (Figure 4 of the present chapter). They are also able to secrete other cytokines (i.e..
IFN-y) to activate effector cells such as macrophages (Seaman, 2000). Tc cells also
participate in ADCC when tumor-specific IgG antibodies bind to tumor cells (Cruse and
Lewis, 1999).

Helper T lymphocytes are critical in regulating the immune response

against foreign antigens. Via their T cell receptors, they are activated by the recognition
of foreign antigens presented in the MHC class II context. Once activated, they produce
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Figure 4. Schematic view of cytotoxic T cell-mediated killing of a tumor cell. Upon
interaction of a tumor peptide within the groove of a major histocompatibility complex
(MHC) class I molecule with the appropriate T cell antigen receptor, the T cell is
activated to release perforin and granzymes to induce death of the tumor cell, as well as
secrete cytokines that can activate and attract other cells. Adapted from (Cruse and
Lewis, 1999).
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and secrete critical cytokines (such as IL-2) that affect the function of majority of other
cells in the immune system (Abbas and Lichtman, 2001).

5. Immune changes with combination treatment
As discussed in Chapter One, TNF-a is a multi-functional cytokine with a number
of immunomodulatory activities. Therefore, the administration of TNF-a, either free or
encapsulated, should induce some degree of immune activation and recruitment.
However, if this immune upregulation contributes significantly to the antitumor effect
when combined with radiation in this particular model is unknown.

Furthermore,

encapsulating TNF-a in SL changes the distribution and pharmocokinetics of TNF-a,
adding to the potential differences in immunomodulation.
In the study described in Chapter Three, the aforementioned immune cell
populations and their level of activation were measured to determine the general, overall
changes in immune status after multiple treatments of the combination regimen and to
potentially correlate these changes to the observed antitumor effects. From the obtained
data, the following general observations can be made:
1) either TNF-a or SL-TNF-a alone did not, in most cases, significantly change
the measured immune parameters.
2) radiation alone generally decreased the numbers of the measured cell
populations.
3) combining TNF-a or SL-TNF-a with radiation “attenuated” (or resulted in
compensation for) the decreases seen when radiation was used alone, and

124

4) SL-TNF-ct tended to attenuate the immunodepressive effect of radiation more
than free TNF-a when compared to the radiation controls.
However, several qualifications to these observations must be considered. Because the
measurements were taken at the end of the treatment regimen, the effects due to radiation
are difficult to completely distinguish from those of the injected treatments.
treatments were given over 11 days.

Three

Because some SL-TNF-a can still remain in

circulation and the effects of TNF-a were likely to be still ongoing when the mice were
irradiated 24 h later (van der Veen et al., 1998), the individual effects of the two
modalities overlapped multiple times in the groups receiving both modalities. Therefore,
the “attenuation” seen with the SL-TNF-a and free TNF-a can either be due to a greater
increase in leukocyte numbers after radiation because of induction of reconstitutive
mechanisms or due to a lesser radiation-induced depression. Furthermore, the
measurements taken at the end of these treatments reflect the cumulative effects of the
treatment (as well as continued increase in tumor size) and not necessarily the process
that caused the antitumor effect.
Nevertheless, significant treatment-related changes did occur.

Table 2 of the

present chapter summarizes the data obtained for the various immune cell populations
where SL-TNF-a plus radiation trended towards producing the greatest attenuation of the
radiation effect. Of these changes, there are several that may have contributed to the
observed delay in tumor growth. In the blood, although the neutrophil number was not
significantly different among the groups, the neutrophils made up a greater proportion of
the leukocytes in the SL-TNF-a plus radiation group than they did in the TNF-a plus
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Table 2. List of the immune cell populations and activation markers that were most
attenuated by SL-TNF-oc plus radiation.

Although not all changes were statistically

significant, a general trend toward less radiation-induced suppression was evident when
SL-TNF-ct was included in the treatment regimen.

Immune parameter changes
Blood
Granulocyte percentage
Lymphocyte activation
Lymphocyte activation percentage
Activated NK cells
Activated B cells
Spleen
NK cells
Activated lymphocytes
Activated lymphocyte percentage
Activated B cell percentage
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radiation group. Furthermore, it can be inferred that since TNF-a is known to activate
neutrophils, these neutrophils may also, in turn, have a greater activation status caused
more by the SL-TNF-a than the free TNF-a (Shalaby et ai, 1985).

NK cells, as

mentioned above, have important tumoricidal properties; therefore, although the number
of NK cells in the blood was not significantly different among the groups, more of those
in the SL-TNF-a plus radiation group were activated. In addition, the NK cell population
in the spleen was greater in the SL-TNF-a plus radiation group than the free TNF-a plus
radiation group. While lymphocytes in the immunocompetent mice may play a more
significant role in the antitumor effect, in the nude mice, they play a slightly smaller role.
However, the increases in their activated number and percentage signal that they could
potentially play a greater role in an immunocompetent model and even a possible role in
this model. For example, B cell activation was higher in the SL-TNF-a plus radiation
group than in the free TNF-a plus radiation group. Due to the lack of Th cells, the B
cells cannot undergo class switching or affinity maturation in the nude mice and thus, are
able to produce antibodies only of the IgM isotype. However, in an immunocompetent
model, if a class switch occurred to the IgG isotype and if any of these antibodies were
directed against the tumor, they could be possibly be involved in the antitumor effect
(i.e., ADCC) (Palladino et al., 1987).
As stated above, these measurements of the immune cell populations were taken
at the end of the treatment regimen and thus, reflect the final, overall immune status after
the treatments. SL-TNF-a has been shown to have a different distribution, temporally
and spatially, compared to the free TNF-a protein (Beutler et ai, 1985; van der Veen et
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al., 1998). Since TNF-cc functions both as a chemoattractant and by direct induction.
these differences in distribution and pharmocokinetics may have a profound effect on
how SL-TNF-a produces its effect and possibly also how it contributes to the observed
antitumor efficacy. For example, besides the tumor itself, the spleen is one of the organs
in which SL-TNF-a accumulates; as a possible indication of this fact, some of the more
prominent changes observed in the immune cell populations occurred in the spleen with
SL-TNF-a, but not with free TNF-a, treatment. The study in Chapter Three is limited to
analyzing the final outcome of the immune changes due to these differences between SLTNF-a and free TNF-a.
Therefore, Chapters Five, Six and Seven will further explore these immunological
differences that may potentially be due to the differences in the distribution and
pharmocokinetics between SL-TNF-a and free TNF-a.

In Chapter Five, a single

intratumoral injection of TNF-a or SL-TNF- a was given to nude mice with LS174T
xenografts.

At appropriate times after the injections, the mice were euthanized and

immune measurements similar to those in the study in Chapter Three were undertaken to
determine the temporal and spatial changes in the immune response after a single
injection that may correlate to the observed antitumor effect. In Chapter Six, the results
from this study will be further discussed. In Chapter Seven, the immune changes due to
the differences in SL-TNF-a and free TNF-a will be further analyzed at the tumor site
itself.

Different immune cell populations infiltrating into the tumors (excised and

preserved from the mice in previous studies) were measured to determine if the
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differences seen in blood and spleen from SL-TNF-a and free TNF-oc treated groups are
reflected in recruitment and infiltration of immune cells into the tumor.
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A.

CHAPTER INTRODUCTION

The previous study demonstrated for the first time that the SL-TNF-cc augments
the antitumor effect of radiation in the LS174T xenograft model. The data demonstrated
that this combination of SL-TNF-a plus radiation was more effective in inhibiting the
tumor growth than radiation alone or the combination of free TNF-cc plus radiation.
When various immune parameters were measured (due to the fact that TNF-a has many
immunomodulatory properties that may increase the antitumor efficacy), many of the
measured cell populations and their activation exhibited differences between the groups
including between SL-TNF-a plus radiation and free TNF-a plus radiation. However,
since the measurements were taken at the end of multiple treatments, the sequential and
spatial changes that were occurring due the TNF-a (encapsulated vs. free) were difficult
to distinguish in the previous study; only the final changes in immune status were
gauged.
Therefore, up to this point, data supporting the hypothesis that the combination of
SL-TNF-a plus radiation is both efficacious and safe has been presented. Furthermore,
the differences in efficacy and safety between free TNF-a plus radiation and SL-TNF-a
plus radiation have also been shown. The previous study also began to address the
differences in immunomodulation by the two different combination groups. However, to
elaborate on the immune changes that may occur due SL-TNF-a and TNF-a
administration, the following studies were performed.
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In the previous study, the mice were irradiated in the right hind leg approximately
24 h after the administration of SL-TNF-ot or free TNF-a.

The differences in the

combination group may be due to the differences in how these agents affect the immune
system before the administration of radiation; the administration of SL-TNF-cc and TNFa may differentially prime the animal to respond differently to irradiation. Thus, to test
this second part of the hypothesis (innate immunomodulation), the study presented in the
chapter was performed. This study will demonstrate the different temporal and spatial
changes that occur in the measured immune parameters after a single injection of SLTNF-a or TNF-a. Hematological and immune parameters were measured at set intervals
(6, 18, 36, and 96 h post-injection) to evaluate the changes that occurred as a result of
these injections and to correlate any of these changes to the differential antitumor
response of SL-TNF-a and TNF-a.
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Abstract Encapsulation of tumor necrosis factor-a (TNF-a) in liposomes has renewed
interest in the use of TNF-a as an adjuvant therapy for cancer because it limits the
systemic side effects caused by concentrations required to mediate tumor regression.
Studies have shown that TNF-a encapsulated in sterically-stabilized PEGylated
STEALTH® lipososmes (SL) can better and more safely augment the efficacy of other
treatment modalities than free TNF-a. The aim of this study was to examine the effects
of SL-TNF-a in the LS174T human colon tumor xenograft model and to correlate its
administration with alterations in innate immune system parameters. Nude mice (n =
128) were injected subcutaneously with LS174T cells and treated intravenously with SLTNF-a, SL-placebo, or free recombinant human TNF-a when tumor size reached ~200
mm3. Each modality was administered once and the animals were euthanized at 6, 18,
36, and 96 h after injection. Significant increases in leukocyte, granulocyte, monocyte,
and NK cell numbers were observed early (6 h) in the blood from both SL-TNF-a and
free TNF-a treated mice compared to the control group. In contrast, during the 18 to 36
h interval, SL-TNF-a induced significantly higher leukoctyte, T cell, and NK cell
numbers, basal leukocyte proliferation, and CD25+ activation marker expression; the
modulation occurred primarily in the spleen. These data indicate that both SL-TNF-a
and free TNF-a can induce dramatic upregulation in leukocyte populations early after
injection. However, the upregulation produced by SL-TNF-a was more prolonged and
pronounced than that of TNF-a and had a better correlation with measures of activation.
These findings suggest that sustained leukocyte recruitment and/or activation may be an

134

important factor in the greater than additive or synergistic antitumor effects observed
when SL-TNF-a is used in combination with other cancer therapies.

Key words

Immunotherapy • PEGylated liposomes • LS174T colon adenocarcinoma.
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Introduction

Previous studies have shown that tumor necrosis factor-a (TNF-a) in combination with
conventional treatment modalities, such as ionizing radiation and chemotherapeutic
drugs, can enhance the efficacy of tumor growth inhibition [3, 4, 9]. Studies with TNF-a
together with new experimental agents have also shown promising results [23, 24]. The
addition of TNF-a as an adjuvant or neoadjuvant has often caused a greater than additive
or synergistic outcome to the combination therapies. The mechanisms by which TNF-a
exerts its antitumor effects may involve immunological and/or non-immunological host
factors. TNF-a, a multifunctional cytokine, induces a variety of responses, including
hemorrhagic necrosis of tumors in vivo through destruction or alteration of tumor
vasculature, direct cytotoxicity against some tumor cells in vitro, inflammation, and
activation of many cell types [2, 22]. TNF-a may also sensitize the tumor cells or the
host response, resulting in synergistic effects when combined with other agents.
However, systemic injections of TNF-a can lead to severe toxicities that can prevent
the administration of even the minimal effective dose [11, 27, 31]. Therefore, TNF-a
encapsulated in sterically stabilized STEALTH^ liposome (SL) has been used to decrease
systemic toxicity while increasing the efficacy of TNF-a treatment [25, 28].

The

liposome is coated with polyethylene glycol, a hydrophilic polymer, which gives the
liposome increased stability in biological fluids and delays its removal by cells of the
mononuclear phagocytic system [17], Thus, SL encapsulation alters the pharmacokinetic
behavior and tumor localization of TNF-a [28]. SL increases the blood residence time of
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TNF-a, which in turn enhances its accumulation within the tumor (due to the increased
permeability of tumor-associated microvasculature).

Furthermore, TNF-a largely

remains encapsulated within the stabilized liposome while circulating in the blood, which
minimizes the potential for dose-limiting side effects.

Thus, the alterations in the

biodistribution of TNF-a and the properties of the SL-TNF-a itself may affect the
mechanisms by which TNF-a produces its antitumor effects.
Our laboratory has previously shown that SL-TNF-a in combination with radiation
has a greater than additive antitumor effect against human colon tumors without doselimiting toxicities [16].

Several aspects of innate immunity, as well as colon

adenocarcinoma growth, were compared in athymic mice treated with radiation in
combination with either SL-TNF-a or free TNF-a protein. The combination of SL-TNFa plus radiation was significantly more effective in the inhibition of tumor growth than
free TNF-a plus radiation after multiple treatments. The data collected at the end of
multiple treatments suggested that various immune cells could be involved in the
effectiveness of the SL-TNF-a as a neoadjuvant in this combination treatment. Based on
these findings, the major aims of the present study were to 1) examine the effects of SLencapsulated TNF-a on several leukocyte populations at various time points after
injection and 2) correlate its administration with any cellular alterations that could
account, at least partly, for its enhancement of adjuvant therapies with diverse
mechanisms of action.

Other assays were also performed to identify possible

hematological toxicities associated with treatment.
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Materials and methods
Animals
Male athymic nude mice (outbred background nu/nu; n = 128) were purchased from
Charles River Breeding Laboratories, Inc., Wilmington, MA as 6-week-old weanlings.
The animals were acclimated for 2 weeks in microisolator cages (4-7 mice/cage) under
conditions appropriate for immunocompromised rodents. The mice were weighed twice
each week, observed for signs of treatment-related toxicities, and euthanized with CO2 as
recommended by the American Veterinary Medical Association (AVAMA) Panel on
Euthanasia. The study was approved by the Animal Care and Use Committee of Loma
Linda University.

Tumor cells
The human LS174T colon adenocarcinoma cell line (American Type Culture Collection,
Rockville, MD), originally established by Tom et al. [26] were cultured in complete
RPMI-1640 medium (Sigma Chemical Co., St. Louis, MO) containing 10% bovine calf
serum (BCS; Hyclone Laboratories, Logan, UT), 12 mM HEPES buffer (Mediatech Inc.,
Herndon, VA), and 1% antibiotic antimycotic solution (10,000 unit/ml penicillin, 10
mg/ml streptomycin, and 25 pg/ml amphotericin B; Sigma). The cells were harvested
with 0.25% trypsin, washed, and adjusted to 2.5 x 107/ml in phosphate buffered saline
(PBS). The mice were injected subcutaneously in the right thigh with 5 x 106 cells/0.2
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ml. Tumors were treated at 11 days post-implantation when the average volume was
~200 mm3.

SL-TNF-a, SL-placebo, and TNF-a

Recombinant human TNF-a protein (Boehringer Ingelheim Austria GmbH, Vienna,
Austria) was encapsulated in STEALTH® liposomes (ALZA Corporation, Mountain
View, CA) as previously described [28]. Stock solutions of SL-TNF-a (60 pmol/ml at
25 pg TNF-a/100 pmol liposome) and SL-placebo (60 pmol/ml) were diluted in PBS
immediately before intravenous (i.v.) injection into the heat-dilated caudal vein.

A

liposome concentration of 120 pmol/kg body weight was administered per mouse.
Recombinant human TNF-a, purchased from R&D Systems Inc. Minneapolis, MN as a
lyophilized powder (reported activity: 5 x 106 units/mg as determined by cytotoxicity
assay using the murine L929 cell line) was reconstituted in sterile PBS with 0.1% bovine
serum albumin, aliquoted, and stored at -70°C until immediately before injection. The
amount of free TNF-a injected i.v. per mouse was equivalent to the amount injected as
SL-TNF-a (TNF-a concentration of 30 pg/kg).

Treatment protocol
At the time of tumor cell implantation, the animals were assigned to groups {n = A mice
for no tumor control group; n-1 mice for each treatment group at each time point) as
follows: A) no tumor control - PBS injected, B) tumor control - PBS injected, C) free
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TNF-a, D) SL, and E) SL-TNF-a. Eleven days later, a single treatment of PBS, free
TNF-ct, SL, or SL-TNF-a was injected i.v. into the heat-dilated tail vein of mice in the
appropriate groups. A subset from these groups was euthanized at 6, 18, 36, and 96 hr
following treatment (4 time points x 5 treatment groups). Blood, tumor, and selected
organs (spleen, liver, kidney) were taken from the animals at each time of euthanasia for
a series of assays (described below).

Relative spleen weights, splenic leukocyte counts, and mitogen-induced blastogenesis

Spleens were weighed at the time of euthanasia and relative spleen weight (RSW) values
were calculated: RSW = [spleen weight (g) x 104] h- body weight (g). Spleens were then
aseptically dispersed into single-celled suspensions, filtered, washed, and centrifuged.
After red blood cells (RBC) removal with cold lysing buffer, the remaining viable
leukocytes were washed, suspended in 2 ml of medium, and counted using the Vet ABCDiff Hematology Analyzer (HESKA Corporation, Waukesha, WI).

To quantify

responsiveness to mitogen, the cells were adjusted to 2 x 106/ml in RPMI 1640 medium
supplemented with 10% heat-inactivated fetal bovine serum (FBS; Hyclone), antibiotics,
and mercaptoethanol.

Aliquots (100 pi) of each cell suspension were dispensed in

triplicate into 96-well microtiter plates and lipopolysaccharide (LPS; Sigma) from E. coli
serotype 0111:134 was added at 0.02 pg/100 pl/well; control wells received 100 pi
medium with no mitogen. [JH]-thymidine ([^Hj-TdR; specific activity = 46 Ci/pmol;
ICN Radiochemicals, Irvine, CA) was added at 1 pCi/50 pl/well for the final 4 h of a 48
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h incubation at 37°C in 5% CCb.

The cells were harvested, and the amount of

incorporated radioactivity (counts per minute; cpm) was quantified in a beta scintillation
counter. The results were expressed as a stimulation index (SI): SI = (cpm with LPS cpm without LPS) 4- cpm without LPS.

Blood leukocyte, erythrocyte, and thrombocyte enumeration

Samples of whole blood (12 pi), collected in K^EDTA-containing syringes at the time of
euthanasia, were evaluated using the Vet ABC-Diff Hematology Analyzer (HESKA
Corp.). The measurements included leukocytes counts (WBC); lymphocyte, monocyte,
and granulocyte counts and percentages; red blood cell (RBC) and thrombocyte counts;
hemoglobin concentration; hematocrit (percentage of whole blood composed of RBC);
mean corpuscular volume (MCV; volume of an average RBC); mean corpuscular
hemoglobin (MCH; amount of hemoglobin in an average RBC); and mean corpuscular
hemoglobin concentration (MCHC; concentration of hemoglobin in the RBC component
of blood).

Spontaneous blastogenesis of leukocytes in blood and spleen

To assay basal DNA synthesis, 50 pi of spleen leukocyte and whole blood samples were
diluted with 150 pi of complete RPMI 1640 medium and 1 pCi [3H]-TdR in 50 pi of
medium was immediately added,

Each mouse was tested in triplicate in 96-well

microculture plates. The cells were incubated for a total of 3 h at 37°C in 5% CO2, and
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the uptake of radioactivity was quantified as described above for the mitogen-induced
blastogenesis assay. The leukocyte counts and the tested volume were used to convert
the raw cpm data into cpm/106 leukocytes values.

Flow cytometry analysis of lymphocyte populations in blood and spleen

Lymphocyte populations were quantified using standard direct-staining techniques and a
FACSCalibur TM 4-channel flow cytometer (Becton Dickinson, Inc., Rutherford, NJ). The
CD3+ T, CD4+ T helper (Th), CD8+ T cytotoxic (Tc), CD19+ B, and pan-NK+ natural
killer (NK) cells were identified using four-color, two-tube mixtures of fluorescencelabeled monoclonal antibodies (MAb). Additional mixtures of the appropriate MAb were
used to identify lymphocytes expressing CD25 and CD71 activation markers. The MAb
(Pharmingen, San Diego, CA) were labeled with fluorescein isothiocyanate (FITC), Rphycoerythrin (PE), allophycocyanin (APC), or peridinin chlorophyll protein (PerCP).
Analysis of 10,000 lymphocyte events/sample was performed using CellQuest TM
software version 3.1 (Becton Dickinson). The number of cells in each population was
based on the total leukocyte count/ml and the percentage of cells expressing the
marker(s) of interest.

Detection of recombinant human TNF-a

Tumor, liver, and plasma from each mouse were collected at euthanasia and stored at 70°C until immediately before assay. Up to three representative tumors and livers were
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each weighed before processing. Frozen tissues were cut into small pieces and further
dispersed in PBS. After centrifugation at 400 g for 10 min, supernatants were collected
and volumes were measured. Thawed plasma from mice within each group was pooled.
All samples were then assayed for cytokine content in enzyme-linked immunosorbent
assays (ELISA). Quantikine™ High Sensitivity Human TNF-a Immunoassay kits were
purchased from R&D Systems Inc. (Minneapolis, MN) and the tests were performed
according to the manufacturers’ instructions. The optical density of each sample was
determined using a microplate reader set at 490 nm with a 620 nm wavelength correction.
TNF-a concentration was calculated using the optical density and the generated standard
curves. The total amount in plasma was expressed directly as pg/ml; for supernatants
from tissues the following formula was used: pg/mg of tissue = [pg/ml x total volume of
supernatant (ml)] 4- tissue weight (mg).

Normalization of data from SL-TNF-a, SL, and TNF-a groups
Data from the treated groups were normalized to more readily identify any variations due
exclusively to treatment and to minimize any immunomodulatory effects that may be due
to tumor presence. Normalization was accomplished by first assigning a value of 1 to the
means obtained in each assay for the control mice with tumor (injected i.v. with PBS).
Values from tumor-bearing animals treated with SL-TNF-a, SL, or free TNF-a were then
expressed in relation to the mean of the tumor control group from each assay. The
control mice with no tumor were included in this study to ensure that assays were
performed with no or minimal technical or other errors.
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Statistical analysis
The data were subjected to one-way and two-way analysis of variance (ANOVA) and
Tukey's pair-wise multiple comparison test using SigmaStat™ software version 2.03
(SPSS Inc., San Rafael, CA). Outlying values (greater than two standard deviations from
the mean) were excluded from analysis. Differences giving a P value of <0.05 were
considered significant.
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Results

Tumor incidence and hematological toxicity

Mean values of the tumor control group from the relevant assays are listed in Tables 1
and 2. By day 11, all tumor-injected groups had detectable tumors (~200 mm3) and
treatment was initiated. There were no observable signs of toxicity during the four days
after treatment initiation. However, blood analysis showed (Fig. 1A-D) that RBC count,
hematocrit, hemoglobin, and platelet number were initially (6 h) decreased due to any of
the three treatments, but recovery occurred by 18 h. However, the group injected with
free TNF-a exhibited residual (96 h) effects, as evidenced by lower levels of RBC and
platelets and significantly (R<0.04) lower hematocrit and hemoglobin levels compared
with the tumor-bearing control group. Furthermore, although groups given free TNF-a
and SL-TNF-a had significantly (T><0.02) decreased platelets at 6 h, the SL-TNF-a group
rapidly returned to baseline while the free TNF-a group remained significantly (.P<0.01)
decreased compared with all other groups until 36 h at which time a rebound was seen.
resulting in significantly (P<0.02) greater platelet numbers than the group receiving SLTNF-a (Fig. ID). Other blood parameters (i.e. MCV, MCH, and MCHC) did not show
significant differences among groups (data not shown).
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Leukocyte counts, RSW, and spontaneous and mitogen-induced blastogenesis

The leukocyte counts in the blood from groups given free TNF-a and SL-TNF-a were
significantly (/^O.OT) greater than in the tumor control group at 6 h after treatment (Fig.
2A). By 36 h, leukocytes in the free TNF-a-treated group had substantially decreased
while the counts in the SL group were maintained.

The basal proliferation rates of

circulating WBCs, as determined by [3H]-TdR incorporation into DNA, were
significantly (RcO.OOl) elevated in the groups receiving either SL-TNF-a or free TNF-a
at 18 h compared with the tumor control group (Fig. 2B).
In the spleen, TNF-a and SL-TNF-a had significant but opposite effects on leukocyte
counts at 6, 18, and 36 h; the pattern for SL resembled that of SL-TNF-a, but was less
pronounced (Fig. 2C). The basal proliferation rates of the splenocytes from the SL-TNFa group were significantly (/><0.04) increased at 18 h when compared with the tumor
control and TNF-a groups and at 96 hr when compared with the tumor control group
(Fig. 2D). Spleen weights in relation to body weights (RSW) were significantly (RO.Ol)
increased in the TNF-a and SL-TNF-a groups compared with the tumor control group by
6 h but returned to basal RSW thereafter (Fig. 2E).

There were no differences in

splenocyte responsiveness to LPS among the groups, except for the SL group, which had
significantly (PO.Ol) higher SI values by 96 h (Fig. 2F).
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Non-lymphoid cell populations

In the blood, granulocyte and monocyte numbers for the groups receiving free TNF-a
and SL-TNF-a were significantly (PO.Ol) higher at 6 h compared with the tumor
bearing control group (Fig. 3A, B). By 18 h, the counts for both cell types in these
groups were similar to those in the tumor control group.

However, at 36 h, the

granulocyte count for the TNF-a group was significantly (PO.Ol) lower than that of the
SL-TNF-a and SL groups, and at 96 h, it was significantly (P<0.02) elevated compared
with those groups.
Granulocyte and monocyte/macrophage numbers in the spleen were increased at 6 h
after treatment in the group receiving free TNF-a compared with the tumor control group
(Fig. 3C, D). Although granulocyte number was slightly increased in the group receiving
SL-TNF-a compared to the tumor control group at 6 h. statistical significance was
lacking and no significant differences were observed in the monocyte/macrophage
counts.

By 96 h, the granulocyte and monocyte/macrophage numbers in all groups

receiving treatment were similar to those in the tumor control group. However, both cell
types in the two groups receiving liposomes were significantly fP<0.03) increased at 18 h
compared to the tumor control and free TNF-a groups.
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Flow cytometry analysis of lymphocyte populations

At 6 h after treatment, the total number of lymphocytes in the blood from the group
receiving free TNF-a was significantly (P<0.05) decreased while their activation (i.e.
CD25+ or CD71+ lymphocytes) was significantly (.PO.OOS) increased compared with
the tumor-bearing control group, before returning to baseline at later time points (Fig. 4A,
C, E). The mice receiving SL-TNF-a did not show any significant differences in these
measurements compared with the tumor-bearing control group.

In the spleen, total

lymphocyte numbers changed in a reciprocal manner between groups receiving TNF-a
and SL-TNF-a; at 6 and 36 h, lymphocyte counts with TNF-a treatment were
significantly (F><0.01) greater than with SL-TNF-a treatment (Fig. 4B).

The only

significant fPO.05) increase in the number of lymphocytes expressing activation marker
CD25 occurred in the SL-TNF-a-treated group at 18 h (Fig. 4D).

In contrast.

lymphocytes expressing the CD71 activation marker were increased for the TNF-a group
at 6 h. while both groups receiving liposomes were activated at 18 h (Fig. 4F).
In the blood, the NK cell numbers were significantly (.PO.OOl) elevated at 6 h for the
groups receiving TNF-a and SL-TNF-a compared with the tumor control group; with
SL-TNF-a treatment, the enhancement was still elevated at 18 h (Fig. 5A). However, in
the spleen, the NK cells for the TNF-a and SL-TNF-a groups were not significantly
(P<0.02) elevated until 18 h post-treatment (Fig. 5B). In addition, the SL-TNF-a group
had significantly fPO.OOl) more NK cells than did the TNF-a group at this time point.
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The B cells in the blood mirrored the pattern seen with total lymphocyte numbers.
Administration of free TNF-a resulted in significant B cell depletion by 6 h. followed by
a significant (/><0.02) increase at 18 h compared with the tumor control (Fig. 5C). The B
cells in the SL-TNF-ct group followed a similar pattern, although not to the same degree.
In the spleen, B cell counts were higher at all measured time points following TNF-a
treatment compared with the group receiving SL-TNF-a, and statistical significance
(PO.OOl) was obtained at 6 h and 36 h (Fig. 5D).
In the blood, total T cell numbers were significantly (/><0.02) increased in the TNF-a
group compared with the tumor control group at 6 h, decreased to baseline by 36 h, and
increased (PO.Ol) again by 96 h (Fig. 6A). The two groups receiving the liposome
showed significant (P<0.01) increases compared with the tumor control group at 18 h. A
significant (T><0.03) increase in the number of activated T cells (CD3+/CD25+) within the
total T cell population, however, was apparent in both the TNF-a and SL-TNF-a groups
at 6 h, returning to baseline activation at all other measured time points (Fig. 6G). CD4+
Th and CD8+ Tc cells followed a pattern that was similar to that of the total T cells (Fig.
6C, E). In the spleen, total T cells were significantly (/^O.OOl) increased only in the
group receiving SL-TNF-a at 18 h compared with the tumor control, SL, and TNF-a
groups (Fig. 6B). However, the total number of T cells expressing CD71 (CD3+/CD71+)
was increased at 6 h following TNF-a treatment and was elevated in the SL-TNF-a
group at 18 h (Fig. 6H). The Th cells in the spleen followed a similar pattern to the Th
cells in the blood (Fig. 6D).

In contrast, splenic Tc cell counts were significantly
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CPO.Ol) elevated in the TNF-a group at 36 h compared with the tumor control and SLTNF-ct groups (Fig. 6F).

Recombinant human TNF-a levels

At 6 h, recombinant human (rhu) TNF-a was elevated in the plasma, tumor, and liver in
the groups receiving either free TNF-a or SL-TNF-a (Fig. 7A-C). By 36 h, the levels
returned to baseline in all three of these sites in the group receiving free TNF-a.
However, with SL-TNF-a treatment, rhuTNF-a levels remained high in the plasma
during the entire measured period and until 36 h in the tumor and liver.
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Table 1

Blood parameters of the control group with tumor at the time of euthanasia.

18 h

6h

36 h

96 h

Red blood cells (xl06/ml)

8.34 ± 0.17a

7.61 ±0.17

7.79 ±0.12

7.99 ±0.12

Hematocrit (%)

43.8 ± 1.0

40.8 ±0.9

40.1 ±0.7

42.6 ±0.8

Hemoglobin (g/dl)

14.2 ±0.3

13.1 ±0.3

12.6 ±0.2

13.7 ±0.2

Platelets (106/ml)

638 ±9

624 ± 25

719 ± 9

774 ± 23

White blood cells (106/ml)

5.01 ±0.52

3.75 ±0.05

3.86 ±0.23

5.29 ±0.39

[3H]-TdR (cpm/106 cells)

3,891 ±359

6,947 ± 832

5,898 ±447

5,390 ± 845

Granulocytes (xl06/ml)

2.34 ±0.27

1.99 ± 0.15

2.26 ±0.19

2.79 ±0.21

Monocytes (xl06/ml)

0.19 ±0.03

0.20 ±0.00

0.26 ±0.03

0.20 ± 0.00

Lymphocytes (xl06/ml)

3.59 ±0.44

1.67 ±0.05

2.21 ±0.15

2.88 ±0.36

CD25+cells (xl04/ml)

0.55 ±0.04

0.71 ±0.08

0.38 ±0.08

0.44 ±0.16

CD71+cells (xl06/ml)

0.72 ±0.06

0.77 ±0.07

0.45 ±0.05

1.06 ± 0.16

NK cells (xl06/ml)

0.20 ±0.03

0.26 ±0.05

0.41 ±0.03

0.36 ±0.04

B cells (xl06/ml)

3.36 ±0.40

1.43 ±0.16

1.81 ±0.13

2.65 ±0.37

T cells (xl04/ml)

0.56 ±0.07

0.40 ±0.08

1.77 ±0.75

0.97 ±0.13

Th cells (xl04/ml)

0.14 ±0.02

0.17 ±0.05

1.52 ±0.60

0.37 ±0.07

Tc cells (xl04/ml)

0.18 ±0.03

0.27 ± 0.07

0.38 ±0.06

0.31 ±0.05

CD3+CD25+ cells (xl04/ml)

0.30 ±0.07

0.08 ±0.02

0.29 ±0.07

0.14 ±0.05

CD3+CD71+cells (xl04/ml)

0.64 ±0.10

0.22 ± 0.03

0.55 ±0.10

0.61 ±0.13

aMean ± SEM.
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Table 2

Spleen parameters of the control group with tumor at the time of euthanasia.

18 h

6h

36 h

96 h

White blood cells (xl06/ml)

54.7 ± 4.0a

64.9 ± 10.6

78.2 ±2.5

85.6 ±6.8

[3H]-TdR (cpm/106 cells)

21,883 ±2666

19,244 ±1665

13,860 ±1951

22,327 ±2065

Relative spleen weight

33.4 ±0.8

44.9 ±3.3

42.2 ± 1.6

48.9 ±2.8

LPS-induced SI

263 ± 43

448 ± 52

318 ± 48

147 ± 17

Granulocytes (xl06/ml)

13.4 ± 1.5

14.0 ±2.0

21.5 ± 1.1

23.1 ±2.7

Monocytes (xl06/ml)

2.71 ±0.29

3.00 ±0.52

4.17 ± 0.17

4.71 ±0.52

Lymphocytes (xl06/ml)

22.5 ±2.1

14.7 ±3.4

45.9 ±2.0

27.9 ±2.5

CD25+cells (xl05/ml)

0.13 ±0.03

0.18 ±0.02

0.16 ±0.04

0.27 ± 0.05

CD71+cells (xl06/ml)

0.81 ±0.17

1.08 ±0.21

1.73 ±0.30

2.50 ±0.36

NK cells (xl06/ml)

2.25 ±0.11

2.61 ±0.050

3.75 ±0.15

2.51 ±0.27

B cells (xl06/ml)

25.6 ±2.4

14.3 ± 1.6

40.1 ± 1.8

22.2 ± 2.2

T cells (xl05/ml)

1.35 ±0.22

0.48 ±0.05

2.60 ± 0.23

1.98 ±0.42

Th cells (xKLVml)

0.25 ±0.08

0.17 ±0.05

0.75 ±0.18

0.29 ±0.06

Tc cells (xl05/ml)

0.24 ±0.07

0.27 ± 0.07

0.15 ±0.04

0.15 ±0.04

CD3TD71+cells (xl05/ml)

0.11 ±0.02

0.17 ±0.03

0.24 ± 0.04

0.21 ±0.04

aMean ± SEM
SI, stimulation index
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Fig. 1A-D

Normalized data of blood parameters. Each point represents the normalized

mean ± SEM for seven mice. A Red blood cells. B Hematocrit. C Hemoglobin. D
Platelet. Free TNF-a (•), SL (O), SL-TNF-a (T); 1: significantly lower than tumor
control and SL; 2: significantly lower than tumor control, SL, and SL-TNF-a; 3:
significantly greater than tumor control and SL-TNF-a; 4: significantly greater than SLTNF-a.
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Fig. 2A-F

Normalized data of blood and spleen parameters. Each point represents the

normalized mean ± SEM for seven mice. A White blood cells in blood. B Spontaneous
blastogenesis in blood.

C

Splenic white blood cells.

D

Splenic spontaneous

blastogenesis. E Relative spleen weight. F EPS stimulation index. Free TNF-a (•),
SL (O), SL-TNF-a (▼); 1: significantly greater than tumor control and SL; 2:
significantly greater than tumor control and TNF-a; 3: significantly lower than SL and
SL-TNF-a; 4: significantly greater than SL; 5: significantly lower than TNF-a; 6:
significantly greater than tumor control; 7: significantly greater than tumor control, SL,
and SL-TNF-a.
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Fig. 3A-D

Normalized data of non-lymphoid cells.

Each point represents the

normalized mean ± SEM for seven mice. A Blood granulocytes. B Blood monocytes.
C Splenic granulocytes. D Splenic monocytes. Free TNF-a (•), SL (O), SL-TNF-a
(▼); 1: significantly greater than tumor control and SL; 2: significantly greater than
tumor control; 3: significantly lower than SL and SL-TNF-a; 4: significantly greater than
SL and SL-TNF-a; 5: significantly greater than tumor control and TNF-a; 6:
significantly greater than SL.
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Fig. 4A-F

Normalized data of lymphocyte parameters.

normalized mean ± SEM for seven mice.

A

Each point represents the

Blood lymphocytes.

B

Splenic

lymphocytes. C Blood CD25^ activated cells. D Splenic CD25+ activated cells. E
Blood CD71+ activated cells. F Splenic CD71+ activated cells. Free TNF-a (•), SL
(O), SL-TNF-a (▼); 1: significantly lower than tumor control; 2: significantly greater
than SL; 3: significantly greater than SL-TNF-a; 4: significantly greater than tumor
control, SL, SL-TNF-a; 5: significantly greater than tumor control and TNF-a; 6:
significantly greater than TNF-a.
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Fig. 5A-D

Normalized data of NK cell and B cell numbers. Each point represents the

normalized mean ± SEM for seven mice. A Blood NK cells. B Splenic NK cells. C
Blood B cells.

D

Splenic B cells.

Free TNF-oc (•), SL (O), SL-TNF-ct (▼); 1:

significantly greater than tumor control and SL; 2: significantly greater than SL; 3:
significantly lower than tumor control and SL; 4: significantly lower than tumor control,
TNF-cc, and SL-TNF-ct; 5: significantly greater than tumor control; 6: significantly
greater than tumor control and TNF-oc; 7: significantly lower than tumor control; 8:
significantly greater than SL-TNF-ct.
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Fig. 6A-H

Normalized data of T cell parameters. Each point represents the normalized

mean ± SEM for seven mice. A Blood T cells. B Splenic T cells. C Blood Th cells. D
Splenic Th cells. E Blood Tc cells. F Splenic Tc cells. G Blood activated T cells
(CD25+). H Splenic activated! cells (CD71+). Free TNF-a (•), SL (O), SL-TNF-a
(▼); 1: significantly greater than tumor control; 2: significantly greater than tumor
control and TNF-a; 3: significantly greater than tumor control, SL, and SL-TNF-a; 4:
significantly greater than tumor control, TNF-a, and SL; 5: significantly greater than
tumor control and SL-TNF-a; 6: significantly greater than tumor control, SL, and SLTNF-a; 7: significantly greater than SL.
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Fig. 7A-C

Levels of recombinant human TNF-a (rhu-TNF-a). Each point represents

the mean of pooled samples from two to three mice. A Plasma. B Tumor. C Liver.
Tumor control (•), TNF-a (O), SL (T), SL-TNF-a (V).
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Discussion

Previous studies have shown that treatment with TNF-a 18 to 24 h before radiation can
be more effective than when administered after radiation; the actions of TNF-a prior to
irradiation may play a role in the enhanced antitumor effect of combination therapies [810]. Moreover, our laboratory has shown that encapsulated TNF-a plus radiation inhibits
tumor progression significantly better than free TNF-a plus radiation, at least partly
resulting from a differential modulation of measured immune parameters [16].

The

present study shows that SL-TNF-a and free TNF-a produce different temporal and
spatial alterations in leukocyte populations within hours after injection. Because nude
mice were used in this present study to ensure implantation of a human tumor xenograft
and to further elucidate the findings of previous studies using the same model, the
analyses of the measured immunological responses primarily focused on innate immune
mechanisms. However, nude mice, although athymic, possess a small but significant
number of T-lineage cells in the spleen and lymph nodes that can attain some degree of
maturity and function [12]. Thus, T as well as B cells (which require T cell help for
optimal function) were included for analysis.

The data show that both of these

populations were significantly upregulated by SL-TNF-a and, to a lesser extent, by TNFa. In a syngeneic system, T lymphocyte activation could potentially have beneficial
consequences.
With most of the evaluated cell types, the injection of free TNF-a produced an
increase in counts at 6 hours and a return to baseline or a decrease of the counts by 36
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hours in both the blood and spleen.

Since the free protein is rapidly distributed

throughout the body, these numerical changes may reflect a) the initial, indiscriminate
effects of free TNF-a after bolus i.v. injection, and b) the resulting delayed secondary (or
compensatory) effects and/or toxic effects of TNF-a as TNF-a is quickly cleared from
circulation [21]. In addition, the increased cell numbers did not correlate well with the
levels of spontaneous proliferation or cells with activation markers. Although some cell
populations were also increased at 6 h after SL-TNF-a treatment, the most striking
differences between the free TNF-a and SL-TNF-a groups were seen at 18 hr post
injection. (i.e., frequently, the values in the SL-TNF-a group were significantly greater
than in the free TNF-a group or the values in the free TNF-a group were significantly
lower than in all other groups). Furthermore, the spontaneous proliferation and activation
state of these cells correlated well with their increased numbers at this time point. The
accumulation of SL-TNF-a primarily within the spleen, which occurred only minimally
with free TNF-a, and the increased blood residence time may partially account for the
somewhat delayed, but sustained, activation observed with SL-TNF-a but not with the
free protein [1, 18, 28].

Because of the many differences in the biodistribution and

pharmacokinetics of TNF-a and SL-TNF-a in vivo, variable effects on leukocyte
populations are expected.

Our distribution data, though somewhat limited in scope,

generally confirm previous studies in that recombinant human TNF-a was detected at
high levels in tumor, plasma, and liver of the mice in the SL-TNF-a group. However, the
length of time during which the high levels persistent was longer than reported in studies
using rats or radiolabeled-TNF-a [1, 28].
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The toxicity of free TNF-a, even at the relatively low dose used, is clearly reflected
in the blood parameters. Anemia and other blood alterations are some of the side effects
that limit the use of free TNF-a. Although thrombocytopenia was seen in the present
study with both TNF-a and SL-TNF-a, only free TNF-a produced a sustained drop in
the thrombocyte count. TNF-a has been reported to cause thrombocytopenia by inducing
a mast cell release of platelet agonists [20]. The initial decrease in platelet numbers seen
with SL-TNF-a may reflect the small release of TNF-a from the liposome that occurs
within the first 12 hours after injection [28].
SL itself may also be responsible for some of the observed changes. Studies have
shown that the placebo liposomes can circulate even longer than SL-TNF-a, partially
because an empty SL does not have the initial release of liposome-associated TNF-a
[28], Although SL is able to avoid (and thus delay) its removal from circulation, residual
liposomes that do not accumulate in the targeted site(s) are eventually taken up by
macrophages in end organs such as the liver. In addition, some of the liposomes are
phagocytized by monocytes and other cells directly while circulating in the blood [13,
30]. Therefore, at least a minimal effect on nonspecific immune cells could be expected
from the SL itself. However, previous studies have confirmed that SL alone does not
induce any significant antitumor response without an encapsulated tumoricidal agent [3,
5-7, 19, 29].
The enhanced antitumor response seen in our previous studies, in which SL-TNF-a
was combined with radiation treatment [16], may be attributed to radiation being
administered at 20-24 h, i.e. close to the time of greatest leukocyte upregulation (18 h)
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seen in the present study.

However, additional factors may also be involved.

As

mentioned above, our present data show that early after the injected treatments (i.e. at 6
h), the number of treatment-responsive cells was elevated; however, the increase in
number did not correspond well to the activation status of the cells at that time as it did at
18 h.

Because free TNF-a is so widely distributed and so quickly cleared from

circulation, its effects are widespread, quickly initiated, and transient.

Thus, cell

responses are not sustained by a continuous stimulation of an elevated concentration of
TNF-a (as seen with SL-TNF-a), which may be a requirement for readily measurable
enhancement. Furthermore, many of the effects of free TNF-a may be counterproductive
or directly toxic. With SL-TNF-a, a sustained stimulation of leukocytes is possible with
many of the toxic effects avoided. In addition, with exposure to radiation, immune cell
populations are drastically changed [14, 15].
compared

to

other

lymphocyte

NK cells are relatively radioresistant

populations,

some

of

which

can

exhibit

immunosuppressive activities. Thus, if radiation is applied after approximately 24 h, the
sustained upregulation of NK cell numbers seen in our present data with SL-TNF-a may
be further enhanced not only by their increase in number caused directly by SL-TNF-a,
but also by destruction of potentially immunosuppressive cells in the blood which
become irradiated as they circulate through the exposed leg. Furthermore, the increased
number of various immune cell populations in the spleen at 18 h seen with SL-TNF-a
treatment may provide spatial protection from irradiation; unlike with free TNF-a
treatment, SL-TNF-a caused a greater accumulation and/or sequestration of these
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immune cells in the spleen during the time that we had irradiated in earlier studies [16],
and thus minimized the amount of radiation exposure of these cells.
In summary, the data show that a significant and sustained upregulation of various
host leukocytes occurs in response to i.v. injection of SL-TNF-a. It seems likely that the
activated cells may contribute to or augment any direct antitumor effects of SL-TNF-a
when used alone or in combination with other modalities. Recently completed studies in
our laboratory of tumor-infiltrating populations support this premise (manuscript in
preparation). Collectively, our data warrant further investigation of SL-TNF-a as an
adjuvant modality that could be utilized together particularly with radiotherapy. This
combination approach may be especially significant in cases where metastatic disease
exists and chemotherapeutic drugs are not well tolerated.
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CHAPTER SIX

VI.

INTERVENING DISCUSSION TWO AND SUPPORTING IN VITRO
DATA

This chapter will further elaborate the results of the study described in Chapter
Five.

To summarize the previous study, the overall evaluation of the data

demonstrated that SL-TNF-a produced a spatial and temporal difference in the
modulation of the measured immune parameters compared to free TNF-a. These
differential changes may account for the greater enhancement of the radiationinduced antitumor effects seen with SL-TNF-a described in Chapter Three.
Furthermore, the data also supports the previous study’s finding that hematological
disturbances occurred after free TNF-a administration but not after SL-TNF-a
injection.
In this study, free TNF-a again caused signs of anemia; by 96 h after
treatment administration, both the hemoglobin concentration and hematocrit were
significantly decreased in the TNF-a group. Although the mean residence time of
TNF-a has been reported to be approximately 24 minutes (van der Veen et al., 1998),
the effects of TNF-a administration were detected for up to 96 hours in our model
system.

As previously mentioned, the concentration of TNF-a given in our

experiments was significantly below the reported maximum tolerated levels for mice;
however, signs of toxicity were present even with a single injection and continued for
some time. In the previous studies, multiple injections and irradiation were needed to
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produce a significant antitumor effect. Therefore, if a single i.v. injection of free
TNF-a was able to cause initial signs of toxicity, multiple injections that overlap the
previous injection’s effects could further intensify these side effects. Therefore, it
appears that the use of multiple injections of free TNF-a as an adjuvant will be
limited by its toxicity. SL-TNF-a did not induce any of these toxicities and could.
therefore, be a safer alternative, not only in a single administration, but also when
repeatedly administered.
The data described in Chapter Five also showed significant alterations of the
measured immune parameters within hours of free TNF-a and SL-TNF-a
administration. Four general trends were observed in the majority of the measured
immune parameters:
1)

at 6h post injection, both SL-TNF-a and free TNF-a caused an increase in
the measured parameter compared to normal controls.

2)

at 18 h, SL-TNF-a-injected mice had higher mean values in the measured
parameters relative to TNF-a-injected animals,

3)

at 36 h, the reciprocal of the 18 h findings occurred where mean values for
SL-TNF-a-injected mice were lower relative to TNF-a-injected animals, and

4)

in some of the measurements, both SL-TNF-a and TNF-a induced similar
sequential changes, but SL-TNF-a injection frequently resulted in a greater
modulatory effect.

These trends were exhibited in both the blood and the spleen; however, the changes
were more pronounced in the spleen.
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Many of the changes in the measured immune parameters were statistically
significant.

However, to examine if these changes correlated with the antitumor

response from the treatment, comparisons were made with the in vitro findings.
Figure 1 of the present chapter illustrates the degree of [3H]-TdR incorporation into
DNA of LS174T cells cultured in vitro after incubation with SL-TNF-a or TNF-a
and subsequent exposure to radiation. The time points of analysis in this in vitro
study were similar to those of the previous in vivo study. (Assay description can be
found in Appendix One). [3H]-TdR incorporation is an indicator of the proliferative
ability of the surviving cells after the various treatments. Both TNF-a and SL-TNFa, without radiation, significantly decreased [3H]-TdR incorporation; significantly
lower values were also obtained with radiation. However, the combination of either
SL-TNF-a or TNF-a in conjunction with radiation appeared to have only an additive
effect. Without radiation, both SL-TNF-a and TNF-a decreased the cpm to about
75-85% of the mean for the PBS-treated control cells. With radiation (at all doses
tested), SL-TNF-a and free TNF-a still decreased the cpm to only about 65-85% of
the control cells. There were slightly greater percentage decreases (down to about
50% of the control group) with SL-TNF-a and free TNF-a at the higher radiation
doses (3 and 4 Gy) but the increased effect was transient (seen at only 36 h).
Furthermore, no differences between SL-TNF-a and TNF-a were measured at any
time points for any of the treatment combinations, even at the higher radiation dose.
Therefore, the in vitro and in vivo data differ considerably. In Chapter Three,
the i.v. administration of either TNF-a or SL-TNF-a did not produce any significant
inhibition of tumor growth; however, in culture, significant depression in DNA
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Figure 1. [3H]-thymidine incorporation by LS174T cells in vitro after treatment. TNF-ct
or SL-TNF-a treatment were administered at 0 h. Irradiation of cells occurred at 24 h
after treatment. The reported hours are times after the initial treatment of TNF-a and/or
TNF-a. * indicates significance difference compared to PBS-treated control cells (p <
0.05).
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synthesis occurred in the tumor cells. This effect in vitro may be due to several
factors. Although the in vitro concentrations of TNF-a and SL-TNF-a were similar
to those injected in vivo, the in vitro concentrations turned out to be substantially
higher than the concentrations measured within the xenografts (data shown in Figure
7 of Chapter Five). Higher concentrations of TNF-a, either encapsulated or free, had
greater direct cytotoxic effects on the LS174T cells. Furthermore, it can be argued
that because SL-TNF-a accumulated in greater concentrations at the tumor site in
vivo, the higher concentration could explain the greater efficacy of SL-TNF-a
compared to free TNF-a. However, the relatively higher concentration alone is not
sufficient to explain the tumor growth differences seen in vivo or the differences
between SL-TNF-a and TNF-a (for the concentration at the tumor at 6h after
injection was essentially the same for free TNF-a and SL-TNF-a in our model). The
study presented in Chapter Three shows that TNF-a and SL-TNF-a have essentially
no inhibitory effect on progression of the xenografts. However, once radiation was
added to the treatment, significantly greater tumor inhibition occurred than with
radiation alone (in spite of the fact that SL-TNF-a and TNF-a alone had no effect on
tumor growth). Therefore, TNF-a must be affecting one or more components in vivo
that are not present under in vitro conditions. Furthermore, the effect that TNF-a is
having in vivo is different depending on the form of TNF-a employed (free vs.
encapsulated).

As

mentioned

in

Chapter One,

vasculature

effects

and

immunomodulation are two of the more promising potential targets for TNF-a action.
Therefore, of the two potential targets, the study described in Chapter Five pursued
the innate immunomodulation potential of TNF-a.
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Table One summaries the data presented in Chapter Five by compiling the
data according to the three trends mentioned above. As seen from the table, many of
the measured cell populations, including those known to have tumoricidal activity,
fall under the three general trends. At 6 h, many immune cells increased as a result of
TNF-cc, both free and encapsulated, resulting in expanded populations that could
potentially be directed towards the xenograft. Flowever, since the magnitude of the
changes were similar between SL-TNF-oc and free TNF-a, these early (6 h) findings
may not be responsible for the differences in tumor growth seen between the SLTNF-a/radiation and free TNF-a/radiation groups. Between 18 h to 36 h, especially
in the spleen, differences in immunomodulation by SL-TNF-a and TNF-a become
apparent. The differences are likely to be due to the previously discussed properties
of SL-TNF-a that are not present with free TNF-a (i.e., pharmocokinetics and/or
distribution and/or the SL-TNF-a complex itself). The data suggest that these cell
populations are being recruited into spleen by SL-TNF-a and/or that SL-TNF-a is
stimulating cell proliferation within the germinal centers of the spleen at the 18 h time
point; this effect is transient in that it is no longer evident by 36 h. The upregulation
of splenic populations was further confirmed by taking the spleen to blood ratio of the
raw cell counts (Table 2 of the present chapter). The possible benefits of this increase
in spleen leukocytes at 18 h are at least two-fold. First, SL-TNF-a accumulates at
higher levels in the spleen than does free TNF-a (van der Veen et al., 1998). If the
SL-TNF-a acts as a chemoattractant to recruit the immune cells to the spleen, it may
also activate them once they arrive.

(The spleen is also the location where a

significant amount of antigen presentation occurs.) Thus, upon activation, these cells
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Table 1. Compilation of the measured immune parameters of Chapter Five according to
three general trends.

Cell population

Immune parameter change
1) Increased at 6 h by both
free TNF-a and SL-TNF-ot

2) SL-TNF-a > TNF-a at 18 h and
SL-TNF-a < TNF-a at 36 h

3) Similar sequential changes but
SL-TNF-a > TNF-a
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Blood
• Total Leukocytes
• Granulocytes
• Monocytes
• NK cells
• Activated T cells
Spleen
• Relative spleen weight
• CD25+ cells
Spleen
• Total Leukocytes
• [3H]-thymidine incorporation
• Granulocytes
• Monocytes
• Lymphocytes
• CD25+ cells
• CD71+cells
• Tc cells
Blood
• Lymphocytes
• NK cells

Table 2.

Spleen to blood ratio of various immune cell populations.

Blue shading

represent the greater ratio and yellow shading represent the lesser ratio.

Time after injection adminstration (h)
6
NK cells

Neutrophils

Monocytes

Total WBC

B cells

T cells

Tc cells

Tumor control
TNF-a
SL-TNF-a
Tumor control
TNF-a
SL-TNF-a
Tumor control
TNF-a
SL-TNF-a
Tumor control
TNF-a
SL-TNF-a
Tumor control
TNF-a
SL-TNF-a
Tumor control
TNF-a
SL-TNF-a
Tumor control
TNF-a
SL-TNF-a

18
5.9
2.8

9.1
8.1

7.1

2.3

1.9

2.3

5.5

5.7

7.0
5.2

9.5
15.4
6.2
16.0
29.4
11.5

6.2
8.3
6.8
7.8
23.6
18.5
14.3
16.2
9.2
12.5
8.4
8.6

11.3

4.6
3.9
14.3
10.3
7.1
10.9
10.4
7.3

7.6
26.6
7.6

10.4
15.0
11.4
23.1
17.3
13.0
21.4
14.3
8.9
10.6
19.5
4.8
13.2

20.3

29.6
12.6
22.2

13.9
12.5

5.0

2.8

27.1
12.9
13.0
24.9
10.5
4.1
6.9

4.0

3.0

2.0

27.2

11.8
7.5
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96

36

5.4

7.2

18.5
7.2

14.1
4.9
2.1
5.5

can migrate out of the spleen, perhaps to another location which has a high level of
TNF-a (such as the tumor site). Second, if a greater portion of the measured cell
populations is in the spleen at 18 h, these cells could potentially be protected from the
effects of radiation, since it is only locally delivered to the xenograft, located in the
right hind leg. Because the rest of the body is not irradiated, the spleen is also not
irradiated.

A 25 g mouse has about 2.25 ml of total blood volume (using the

conversion of 90 ml of total blood volume/kg of mouse body weight) (Podolsky and
Lukas, 1999).

At a heart rate of 310 beats/min (reported range of 310 to 840

beats/min) and at a heart stroke volume of 1.3 ml/beat (reported range of 1.3 to 2.0
ml/beat), the mouse heart can pump out a cardiac output of at least 403 ml of blood
per minute (1.3 ml/beat x 310 beats/min) (Jacoby and Fox, 1984). At the radiation
doses given (between 2 to 3 Gy), the radiation exposure times ranged from about one
minute thirty seconds to almost two minutes. This length of time is sufficient for a
substantial portion of the total blood volume to have been exposed to a significant
amount of radiation while circulating through the right hind leg. However, with SLTNF-oc administration, a greater portion of the measured immune cells is located
within the spleen, compared to free TNF-a, when the tumor is irradiated. Therefore,
these immune cells survive, since they are essentially protected in the spleen during
irradiation, and thus are available to migrate out of the spleen at a later time. These
immune cells could possibly then be recruited directly to the tumor where they may
initiate their effector functions, or they could function away from the tumor site
(either paracrine or endocrine) by releasing cytotoxic agents (i.e., IFN-y or TNF-a) or
stimulatory cytokines that can activate other cells, or both.
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Nevertheless, further examination of these differences in the spatial and
temporal modulation of the immune cell populations caused by SL-TNF-oc as
compared to free TNF-ot are needed to more precisely characterize how these changes
translate into augmentation of the radiation-induced antitumor effects.

Therefore,

Chapter Seven presents the results of the effects that SL-TNF-a and free TNF-a have
on the immune cell infiltration into tumors. If SL-TNF-a and free TNF-a causes
differences in the spatial and temporal distribution of immune cell populations in the
blood and the spleen, they may also cause some of these immune cell populations
(particularly NK cells, macrophages, and neutrophils) to be differentially recruited to
the tumor site; the differences in the recruitment of these cells to the tumor may
potentially account for, at least in part, the differences seen in the antitumor responses
of free TNF-a and SL-TNF-a.

Tumors excised from the previous studies were

examined for three prominent effector cells involved in innate immunity: neutrophils,
macrophages, and NK cells. In addition to qualitative examination of the tumors,
quantitative analysis of these cell populations in the tumor tissues was performed to
compare the effects of free TNF-a and SL-TNF-a.
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A.

CHAPTER INTRODUCTION

The first study (Chapter 3) in this research demonstrated that SL-TNF-a
augments the antitumor effect of radiation without the dose-limiting side effects
associated with the systemic injection of free TNF-a. That study also showed that SLTNF-a was more efficacious than free TNF-a when combined with radiation and that
SL-TNF-a modified the measured innate immune parameters differently than free TNFa.

The second study (Chapter 5) expanded the research demonstrating that the

differential modification of innate immune parameters was due to SL-TNF-a injection.
That study also showed that SL-TNF-a spatially and temporally modulated the cells
important in innate immunity in a potentially beneficial way, as discussed in Chapter Six.
To further explore whether the modulation of innate immune cells was reflected in the
tumor, by differential infiltration, the following study was performed. Excised tumors
were analyzed by immunohistochemistry to quantitate the infiltration of immune cells
that have the potential to be tumoricidal. The levels of neutrophil, macrophage, and NK
cell infiltration of the tumors among the different treatment groups were compared.
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Summary: The toxicity associated with systemic injections of TNF-a has prevented its
use as an adjuvant to conventional antitumor therapies. However, encapsulation of TNFa in a sterically stabilized STEALTH® liposome may increase the potential use of TNFoc as an adjuvant in cancer treatments. Previous studies performed in our laboratory have
shown that the combination of SL-TNF-a plus radiation was more effective in inhibiting
tumor growth than radiation alone or than free TNF-a plus radiation. This increase in
efficacy was coincident with a modulation of the measured immune parameters.
However, in those studies, the majority of the measurements were performed on the
blood and spleen. Therefore, the aim of this study was to determine if infiltration of
immune cells with important tumoricidal activities [natural killer (NK) cells,
macrophages, and neutrophils] into the tumors was altered by SL-TNF-a, and whether
these changes were potentially contributing to the antitumor effects associated with SLTNF-a treatment. Sections of excised tumors from two previous studies were stained
with hematoxylin and eosin (H&E) and examined histologically. Quantitative analysis
was also performed by immunofluorescence using a laser scanning cytometer.

The

extent of necrosis was similar in all groups after multiple treatments with free TNF-a,
SL-TNF-a, and/or radiation. It is of interest that the SL-TNF-a plus radiation group had
the smallest tumors, but also had the same level of necrosis as groups with larger tumors,
and the necrotic areas had signs of recent and/or continuing cell death. Furthermore, the
SL-TNF-a plus radiation group tended to have the highest percentages of NK cell and
macrophage infiltrates.

After single treatment injections, SL-TNF-a induced

significantly greater infiltration of the tumor by NK cells, macrophages, and neutrophils
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at 6 h post injection compared to the controls (p < 0.03). A decrease was noted during
the 18 to 36 h interval, which correlated with previously reported changes occurring in
the blood and the spleen following a single SL-TNF-ct injection. However, at 96 h, an
increase was again seen in these same cell populations with SL-TNF-ct, coinciding with
the increased necrosis observed in H&E stained tumor sections. These findings suggest
that the increased efficacy seen with SL-TNF-ct compared to free TNF-ot was potentially
due to the enhanced infiltration of NK cells, macrophages, and neutrophils into the tumor.

Key words: PEGylated liposomes, LS174T colon adenocarcinoma, natural killer cells.
macrophages, neutrophils.
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INTRODUCTION

Studies using various tumor models have demonstrated the added or synergistic
benefits of tumor necrosis factor-a (TNF-a) used in combination with other agents such
as radiation or melphalan (1-4). However, due to the associated high level of toxicity, the
use of systemic injections of TNF-a as an adjuvant antitumor therapy is limited.
Recently, sterically stabilized STEALTH® liposomes (SL) have been used to encapsulate
TNF-a to decrease systemic toxicity while increasing the efficacy of TNF-a treatment (5,
6). The liposomes are coated with polyethylene glycol, a hydrophilic polymer, which
maintains liposome stability in biological fluids and prevents their removal by cells of the
mononuclear phagocytic system (7). Thus, SL encapsulation alters the pharmacokinetic
behavior and increases tumor localization of TNF-a (5). The encapsulation increases the
blood residence time of TNF-a, which in turn enhances the accumulation of TNF-a
within

the

tumor

(due

to

the

increased

permeability

of tumor-associated

micro vasculature); in addition, since TNF-a largely remains encapsulated within the
stabilized liposome while circulating in the blood, SL minimizes the potential for doselimiting side effects. These alterations in the biodistribution of TNF-a and the properties
of the SL-TNF-a itself may affect the mechanisms by which TNF-a induces its
antitumor effects.
Our laboratory has previously shown that SL-TNF-a in combination with
radiation has a greater than additive antitumor effect against LS174T human colon tumor
xenografts without dose-limiting toxicities.
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Several aspects of innate immunity were

compared in athymic mice treated with radiation in combination with either SL-TNF-cc or
free TNF-a protein [Kim, 2001 #49]. The combination of SL-TNF-cc plus radiation was
significantly more effective in the inhibition of tumor growth than free TNF-a plus
radiation after multiple treatments. The data collected at the end of multiple treatments
suggested that various immune cells may be involved in the effectiveness of the SL-TNFa as a neoadjuvant in this combination treatment. In a subsequent study (manuscript in
review), data was collected at various time points after i.v. injection of either SL-TNF-a
or TNF-a. In the blood, significant increases in the numbers of granulocytes, monocytes,
and NK cells (all three cell types are known to be capable of tumoricidal activity) were
observed with either SL-TNF-a or free TNF-a compared to the control group 6 h after
administration.

In contrast, during the 18 to 36 h interval, SL-TNF-a induced

significantly higher T cell and NK cell numbers, basal DNA synthesis by leukocytes, and
CD25+ activation marker expression; these observations were noted predominantly in the
spleen. The findings indicated that both SL-TNF-a and free TNF-a can induce dramatic
upregulation of leukocyte populations in a relatively short time period (36 h) following
injection.

However, the effects of SL-TNF-a appeared to be more prolonged and

pronounced than that of free TNF-a and correlated better with measures of cellular
activation.
These findings suggested that sustained leukocyte recruitment and/or activation
observed when SL-TNF-a was used in combination with other cancer therapies may be
an important factor in its greater than additive or synergistic antitumor effects. Because
TNF-a can be chemotactic for neutrophils and has numerous other immunomodulatory
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properties, and because SL-TNF-oc accumulates within the tumor to a greater extent than
free TNF-cc, we speculated that the changes measured in the blood and spleen may also
be reflected at the tumor site, and thereby establish a correlation between the inhibition of
tumor growth and inflammatory cell infiltrate into the tumors. Thus, the present study set
out to measure: 1) histological parameters (necrosis, apoptotic bodies, and mitotic
figures) in representative tumors obtained from previous studies that assessed the
different treatment strategies, 2) quantitative levels of tumor-infiltrating cells (NK cells.
macrophages, and neutrophils) using immunohistostaining and laser scanning cytometry,
and 3) if the histological status of the tumor tissue and the cellular infiltration of the
tumor correlated with or could account, at least in part, for the enhancement of the
antitumor efficacy of radiation when SL-TNF-oc is added to the regimen.
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MATERIALS AND METHODS

Animals, tumor cell injection, and tumor volume
The methods have been previously published (8, 9). Briefly, male athymic nude mice
(outbred background nu/nu; n = 128 in phase 1; n = 100 in phase 2) were purchased from
Harlan Inc. (Indianapolis, Indiana) as 6-week-old weanlings. The human LS174T colon
adenocarcinoma cells were purchased from American Type Culture Collection
(Rockville, MD). Cells were harvested with 0.25% trypsin, washed, and resuspended at
2.5 x 107 cells/ml in phosphate buffered saline (PBS),

The mice were injected

subcutaneously in the right thigh with 5 x 106 cells in 0.2 ml PBS.

Tumors were

measured three times a week using vernier calipers and volumes were calculated as
follows: tumor volume (mm3) = length x width x (height / 2). Tumors were treated at 11
days post-implantation when the average volume of the tumors was ~200 mm3.

Treatment protocol
At the time of tumor cell implantation, the animals in phase 1 were assigned to
treatment groups (n = 4 mice in the no tumor control group, and n ^ 7 mice for each
treatment group for each time point) as previously described [Kim, In review #50].
Briefly, the groups were: A) no tumor control - PBS injected, B) tumor control - PBS
injected, C) free TNF-a, D) SL, and E) SL-TNF-a. Eleven days later, a single treatment
of PBS, free TNF-a, SL, or SL-TNF-a was injected i.v. into the heat-dilated tail vein of
mice in the appropriate group. A subset of mice from these groups was euthanized at 6,
18, 36, and 96 h following treatment (4 time points x 5 treatment groups). Blood, tumor,
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and selected organs (spleen, liver, kidney) were taken from the animals at each time of
euthanasia.
The animals in phase 2 were assigned to treatment groups (n = 8 - 18 mice/group) as
follows as previously described [Kim, 2001 #49]: A) no tumor control - PBS injected, B)
tumor control - PBS injected, C) free TNF-a, D) SL, E) SL-TNF-a, F) radiation, G) free
TNF-ct + radiation, H) SL + radiation, and I) SL-TNF-a + radiation. Briefly, TNF-a, SL,
SL-TNF-a, or PBS was injected i.v. into heat-dilated tail veins on days 11, 14, and 18.
The appropriate groups were always irradiated 20-24 hr post injection (i.e., days 12, 15,
and 19). The animals were euthanized when the average tumor volume in the tumor
control group reached approximately -1,500 mm3. Blood, tumor, and selected organs
(spleen, liver, kidney) were taken from the animals at the time of euthanasia.

Irradiation of tumors
In phase 2, immediately prior to irradiation, the mice were anesthetized by
intraperitoneal injection of xylazine (5.2 mg/kg) combined with ketamine (80 mg/kg). To
control for the stress of anesthesia, all mice, including controls without tumors, were
anesthetized. Irradiation was performed using a 60Cobalt (60Co) source from an AECL
Eldorado Model gamma (y) irradiator (Atomic Energy of Canada, Ltd., Commercial
Products Division, Ottawa, Canada). A total dose of approximately 8 Gy was delivered
in 2.6 Gy fractions over a 9-day period. The dose rate was approximately 1.7 Gy/min,
and the tumors were covered with a bolus (‘superflab’) of 0.5 cm thickness. Only the
tumor and the underlying normal tissue of the leg were exposed to radiation.
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Hematoxylin and eosin staining procedure
At euthanasia, tumors from selected tumor-bearing mice were excised and
preserved in 10% buffered formalin solution. Tumors (two from each group) were then
processed through a graded series (50-100%) of alcohol and then embedded in paraffin.
Sections (5 pm thickness) of paraffin-embedded tumors were taken, processed, and
stained with hematoxylin and eosin (H&E) using standard procedures (10).
Sections were analyzed under high power fields (400x) using a descriptive,
qualitative grading scale under the guidance of a pathologist who had no prior knowledge
of treatment groups. The sections were analyzed for the presence of necrosis using a
semi-quantified grading scale (grades + to ++++), based on the average percentage of
necrosis observed per high field (400x); + indicates <10%, ++ indicates 11-50%, +++
indicates 51-89%, and ++++ indicates >90%.

In addition, apoptotic bodies (average

number per high power field) and mitotic figures (average number per high power field)
were noted. A minimum of 12 high power fields was evaluated per section. General
observations of tumor morphology under low and high magnification were also recorded.
Images were taken using an Olympus BX-60-based microscope (Scientific Instruments,
Temecula, CA). The images were viewed and captured using an OLY-750 analog color
camera and Image Pro Plus software (Media Cybernetics, Silver Springs, MD).

Immunofluorescence and laser scanning cytometer analysis
At euthanasia, tumors from selected tumor-bearing mice were excised and frozen
in HistoPrep tissue-embedding medium (Fisher Chemicals, Fair Lawn, New Jersey) at 70°C.

Representative tumors (three from each group) were stored at -70°C until
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sectioning. Sections (5 jum) of the tumors were fixed in -20°C cold acetone or -20°C
70% ethanol for 5-10 min. Following three washes with PBS, sections were blocked with
serum and then immunolabeled for macrophages, neutrophils, and NK cells using
primary antibodies directed against the following markers found on mouse leukocytes:
Mac-3

(1:10;

BD

PharMingen International), Ly-6G (1:50;

BD

PharMingen

International), and asialo GM1 (1:2500; Wako Chemicals USA, Inc., Richmond, VA).
Sections were incubated overnight at 4°C, washed three times with PBS containing
0.05% Tween-20. The washed sections were incubated with secondary anti-rabbit or
anti-rat Cy2-conjugated antibodies (1:100; CHEMICON International, Inc., Temecula,
CA) overnight at 4°C. The sections were washed to remove excess secondary antibodies
with PBS/Tween-20 and incubated with propidium iodide (PI; 5 pl/ml) for 60 min at
room temperature.

The sections were rinsed with PBS and protected with a glass

coverslip and Permaflour (Fisher Scientific, Pittsburgh, PA).
The slides were analyzed using a microscope-based multiparameter laser scanning
cytometer (ESC; CompuCyte Corporation, Cambridge, MA) and Wincyte™ software
(CompuCyte Corp.) as previously described (11). Each slide was scanned with argon and
helium-neon excitation lasers along a raster scan path at 0.5-pm spatial intervals. On the
basis of fluorescent light intensity, scanning parameters were adjusted to create a contour
of the PI nuclear labeling, which delineated individual cells. To quantify the individual
cells of interest, which were labeled with both red and green, gating parameters were set
to contour the red (PI) and to sum the green fluorescence intensity (Cy2). The green
fluorescence intensity reflected the specific binding of the membrane receptor on the cells
of interest. Concurrently using a phantom contour overlay allowed for a standardized and
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uniform counting of cells in an individual tumor section and among different tumor
sections. Settings and thresholds adjustments were confirmed by visual inspection using
a CCD camera attached to the microscope. Optimized protocols and display settings
were saved in protocol files and were used for all samples within an experimental set.
The LSC scanned the entire tumor section or until 15,000 -20,000 cells were counted.
Images were taken using an Olympus BX-60-based microscope (Scientific Instruments,
Temecula, CA) equipped with a 100-W mercury lamp and epi-fluorescence filters of 470,
535, and 630 nm emission wavelengths. The images were view and captured using an
OLY-750 analog color camera and Image Pro Plus software (Media Cybernetics, Silver
Springs, MD).

Statistical analysis
The data were assessed using one-way and two-way analysis of variance
(ANOVA) followed with pairwise comparisons using the Tukey's HSD (honestly
significant differences) Test. A p value of <0.05 was taken as indicating significant
differences among groups. These analyses were performed with SigmaStat Statistical
Software version 2.03 (SPSS Inc., San Rafael, CA).
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RESULTS

Comparative histology of xenografts with different treatments
Qualitative analyses of H&E-stained sections were made under high power
objective (400x). Compilations of the observations are listed in Table 1 and Table 2.
After a single injection of TNF-oc or SL-TNF-oc (phase 1 protocol), the number of
apoptotic bodies or mitotic figures per high power field was not significantly different
among the groups at any of the measured time intervals (Table 1). The tumor control
group exhibited a slightly higher number of mitotic figures. Overall, when areas of focal
necrosis were found, they were generally located at the sub-periphery; for example, on a
cross-section of the tumor, the areas of necrosis were predominantly in an area between
the center and the edge of the tumor cross-section (Figures 1-2). The tumors from the
control group exhibited very few areas of necrosis. The greatest amount of focal necrosis
was observed in the TNF-a and SL-TNF-oc groups at the later time points (i.e., at 36 h
and 96 h).
In the H&E sections of tumors that received multiple treatments of TNF-a or SLTNF-a and/or radiation (phase 2 protocol), the number of apoptotic bodies and mitotic
figures were similar among the groups (Table 2). Tumors in this phase were excised
when the mean tumor volumes for each group were substantially larger than those in
phase 1. The extent of necrosis was generally similar for most of the treatment groups
(Figures 3-4). However, the quality of the necrotic areas differed. In the tumor control
group (the largest tumors), large, confluent areas of early (the nucleus was still present
but was pyknotic and the cytoplasm appeared swollen) and advanced necrosis (the
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nucleus was no longer present, the cytoplasm lost its basophilia, and only the general
outlines of the cells remained) were observed.

The TNF-ct and SL-TNF-a groups

showed less extensive, but advanced, necrosis while the SL group showed less extensive,
early necrosis. The tumors receiving radiation alone showed many areas of advanced
necrosis, while slightly less was found in the tumors of the radiation plus free TNF-a
group. The radiation plus SL showed an even more reduced amount of focal, early
necrosis. However, the tumors from the radiation plus SL-TNF-a group exhibited an
extensive level of early necrosis in addition to having the smallest tumor volume.

Quantitative analyses of immune cell infiltrate of the xenografts
Using the laser scanning cytometer, quantitative analyses of the sections
immunolabeled for NK cells, macrophages, and neutrophils were performed (Figure 5).
A summary of the results from phase 1 is listed in Table 3. At 6 h post treatment
injections, NK cells were significantly increased in the SL-TNF-a group compared to all
other groups, including the one treated with free TNF-a {p < 0.03).

However, the

number of NK cells detected at the later time points decreased for all groups, however,
the SL-TNF-a group maintained a moderate number even at 96 h.

The number of

macrophages was also significantly elevated for the SL-TNF-a compared to the other
groups at 6 h (/? < 0.03). However, at the later time points, no significant differences
were detected among the groups except the SL group at 96 h. The neutrophil counts were
elevated in both the TNF-a and SL-TNF-a groups. At 18 h, the neutrophil numbers were
significantly greater in the SL-TNF-a group than the TNF-a group (p < 0.02). By 96 h,
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neutrophils were decreased in all the groups, but were sustained at moderate levels in the
SL-TNF-oc group.
Overall, the tumors from phase 2 had significant differences among the groups in
regard to for the percentage of NK cell infiltration (p < 0.05) (Table 4). However,
although post-hoc pairwise comparisons did not show significant differences, the SLTNF-oc plus radiation group approached statistical significance in the NK cells compared
to some of the control groups (p < 0.07). No significant differences were detected in the
percentages of macrophages within these tumors taken from mice at the completion of a
10-day treatment regimen. Neutrophil percentages were significantly greater in the single
treatment groups compared to the non-treated tumor control (p < 0.05), but not in any of
the combination treatment groups.

The neutrophil infiltration of the SL-TNF-cc plus

radiation group had the lowest of all the treatment groups.

4
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TABLE 1. Qualitative histological analysis of tumor sections for phase 1.

Groups

18 h

6h

36 h

96 h

+

+

++

++

+/++

++/+++

Necrosis
Tumor control
TNF-a

+

SL

+

SL-TNF-a

+

+

Apoptotic bodies/HPF
Tumor control

1-2

2-3

1-2

1-2

TNF-a

2-3

1-2

1-2

3-5

SL

1-2

2-3

1-2

1-2

SL-TNF-a

3-5

1-2

1-2

1-2

Mitotic figures/HPF
Tumor control

4-6

5-10

5-10

5-10

TNF-a

5-10

5-10

4-6

4-6

SL

4-6

4-6

4-6

4-6

SL-TNF-a

4-6

4-6

4-6

4-6

HPF: high power field (400x)
+: <10% necrosis/HPF
++: 11-50% necrosis/HPF
+++: 51-89% necrosis/HPF
-H-++: >90% necrosis/HPF
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TABLE 2. Qualitative histological analysis of tumor sections for phase 2.

Necrosis

Apoptotic bodies/HPF

Tumor control

+++

1-2

4-6

TNF-a

+++

1-2

4-6

SL

+++

1-2

4-6

SL-TNF-a

+++

1-2

4-6

Radiation

+++

1-2

4-6

TNF-a + Radiation

++/+++

1-2

4-6

SL + Radiation

++

1-2

4-6

SL-TNF-a + Radiation

+++

1-2

4-6

Groups

HPF: high power field (400x)
+: <10% necrosis/HPF
++: 11-50% necrosis/HPF
+++: 51-89% necrosis/HPF
++++: >90% necrosis/HPF
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Mitotic figures/HPF

TABLE 3. Percentage of immune cells infiltrating the tumor in phase 1.

Groups

36 h

18 h

6h

96 h

Natural killer cells3
Tumor control

1.1 ±0.4 i

4.5 ± 1.4

1.5 ±0.2

0.4 ±0.2

TNF-a

1.1 ±0.5

1.2 ± 0.52

0.7 ±0.3

0.6 ± 0.1

SL

0.8 ±0.5

1.6 ± 1.4

1.3 ± 1.1

4.9 ± 1.8 2,3

SL-TNF-a

7.7 ±0.1 2,3,4

2.9 ±0.4

1.6 ±0.8

2.1 ±0.8

Macrophages 5
Tumor control

1.7 ±0.2

0.8 ±0.1

1.6 ±0.7

0.9 ±0.6

TNF-a

1.7 ± 1.0

0.3 ±0.2

1.2 ±0.3

0.3 ±0.2

SL

1.5 ±0.2

1.1 ±0.3

0.6 ±0.4

4.1 ± 0.82,3'4

0.6 ±0.4

0.5 ±0.3

0.5 ±0.3

SL-TNF-a

5.7 ± 1.1

2,3.4

Neutrophils5
Tumor control

5.8 ±0.2

4.4 ±0.5

3.6 ±2.2

2.1 ±0.3

TNF-a

7.5 ± 1.74

2.9 ±0.3

3.6 ±0.8

2.0 ±0.4

SL

1.7 ±0.4

3.3 ± 1.1

1.1 ±0.5

4.1 ±0.1

SL-TNF-a

10.5 ±2.54

9.8 ± 0.83,4

1.2 ±0.2

5.2 ±2.3

i

Mean ± SEM

Significantly greater than Tumor control group (p < 0.03)
Signficantly greater than TNF-a group (p < 0.02)
Significantly greater than SL group (p < 0.02)
Significantly different among the groups (p < 0.02)
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TABLE 4 Percentage of immune cells infiltrating the tumor in phase 2.

Groups

Natural killer cellsb

Macrophages

Neutrophilsb

Tumor control

2.8 ± 0.4a

3.8 ±0.5

1.2 ±0.6

TNF-a

1.4 ± 0.6

5.2 ±0.8

7.6 ± 0.2d

SL

1.7 ±0.7

4.7 ± 1.0

8.3 ±0.2d

SL-TNF-a

1.7 ±0.5

3.8 ± 1.0

11.3 ± 3.0C

Radiation

1.7 ±0.9

6.0 ±0.9

6.9 ± 0.4d

TNF-a + Radiation

4.1 ±0.4

4.9 ±0.1

5.7 ±0.5

SL + Radiation

2.8 ±0.2

3.9 ± 0.1

4.0 ± 1.3

SL-TNF-a + Radiation

5.4 ± 1.9

6.6 ±2.0

3.4 ±0.6

aMean ± SEM
bSignificantly different between the groups (p < 0.05)
Significantly greater than tumor control. SL-TNF-a plus radiation, SL plus radiation (p < 0.02)
Significantly greater than tumor control (p < 0.05)
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Figure 1. H&E-stained LS174T tumor xenograft sections after single treatment injection
of phase 1, part 1 (lOOx). (A) 6 h after injection, (B) 18 h after injection. At 6 h, very
little necrosis was observed in any of the groups. By 18 h, some necrosis was apparent in
many of the groups, a: tumor control, b: TNF-a, c: SL, d: SL-TNF-a.
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Figure 2. H&E-stained LS174T tumor xenograft sections after single treatment injection
of phase 1, part 2 (lOOx). (A) 36 h after injection, (B) 96 h after injection. With
increasing time, area of necrosis became more numerous, a: tumor control, b: TNF-a, c:
SL, d: SL-TNF-a.
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Figure 3. H&E-stained LS174T tumor xenograft sections after multiple treatments of
phase 2 (40x). The extent of necrosis were similar in all the groups although the sizes
were significantly different among the groups. The average tumor volume in SL-TNF-a
plus radiation groups (h) was the smallest; the average tumor volume of the tumor control
group (a) was the largest, a: tumor control, b: TNF-a, c: SL, d: SL-TNF-a, e: radiation,
f: TNF-a plus radiation, g: SL plus radiation, h: SL-TNF-a plus radiation.
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Figure 4. H&E-stained LS174T tumor xenograft sections after multiple treatments of
phase 2 (200x). Although the different groups had similar extent of necrosis, the quality
of the necrosis was different among the groups. An example of advanced necrosis is seen
in the radiation group (e); an example of early necrosis is seen in the SL-TNF-a plus
radiation group (h). a: tumor control, b: TNF-a, c: SL, d: SL-TNF-a, e: radiation, f:
TNF-a plus radiation, g: SL plus radiation, h: SL-TNF-a plus radiation.

214

Figure 5. Representative positively-stained cells in LS174T tumor xenograft sections
(400x). (a) natural killer cells, (b) macrophages, and (c) neutrophils. Propidium iodide
(red) is a DNA intercalating fluorescent stain that identifies the nuclei of cells. Cy-2conjugated secondary antibodies (green) labels the primary antibodies, which are bound
to the specific receptor found only on the cell of interest. The laser scanning cytometer
identifies positive cells as those which fluoresces both red and green.
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DISCUSSION

In previous studies, SL-TNF-a differentially modulated leukocyte population and
cell activation markers, in the blood and spleen when compared to non-treated controls
and free TNF-a. In addition, the combination of SL-TNF-a and radiation produced a
greater tumor inhibition than radiation alone or free TNF-a plus radiation (manuscripts
accepted or in review). These initial studies, which measured changes in the blood and
spleen, demonstrated that the upregulation of the measured cell populations (especially
neutrophils, monocytes, and NK cells) correlated well with the antitumor response when
SL-TNF-a was administered alone or in combination with radiation. Additionally, other
studies have shown that 1) TNF-a can recruit neutrophil, macrophage, and NK cell
migration to a tumor or to sites of high TNF-a concentration (12-15), and that 2) the
infiltration of these immune cells into a tumor can apparently result in potent antitumor
responses (16-18). Therefore, the findings presented in this study of histological analyses
of the tumor sections and quantitative assessment of NK cells, macrophages, and
neutrophils are consistent with previously published data.
When assessed at the end of multiple treatments (phase 2, Table 1), tumors from
mice given different treatments did not show many histological differences with respect
to the number of apoptotic bodies and cells undergoing mitosis. The extent of necrosis
seen in the tumor sections was also similar among the groups, although the tumor size
and the stage of necrosis were strikingly different among the treatment groups. Early and
late necrosis each have distinctive characteristics (early: pyknotic nucleus and swollen
cytoplasm; advanced: no nucleus, cytoplasm is no longer basophilic, and only general
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cell outlines remain).

In the largest tumors (approximately 1,200 mm3 to 1,600 mm3 •in

the tumor control, free TNF-oc, SL, and SL-TNF-a), which were at least 2-2.5 times
larger by volume than the smallest tumors, large areas of focal, advanced necrosis were
present. This finding is consistent with necrotic cell death due to deficiencies in nutrients
and oxygen caused by the inability of neoangiogenesis to keep up with the increased
metabolic needs of a rapidly growing tumor.

However, in the smaller sized tumors

(which were found in the groups receiving radiation, and having tumors of approximately
600 mnT to 1,000 mm3), the extent of necrosis was similar. Therefore, tumor size alone
cannot fully account for the amount of necrosis seen. All groups receiving radiation
showed similar amounts of necrosis with the free TNF-a plus radiation group and the
radiation alone groups exhibiting advanced necrosis. Advanced necrosis indicates that
the causative insult occurred earlier than the insult causing early necrosis (i.e., an insult
that has occurred more recently). The necrosis found in the SL-TNF-a plus radiation
group was quite extensive and of the early type. This observation potentially signals that
in the SL-TNF-a plus radiation group, the insult was still ongoing or at least, that it had
occurred more recently than in the groups with advanced necrosis (e.g., free TNF-a plus
radiation group). Thus, it appears that in the SL-TNF-a plus radiation group, the process
of tumor cell killing may continue longer and/or had occurred closer to euthanasia than in
the other groups.
Furthermore, since 1) NK cells and macrophages are vital to the induction of
tumor cell death, and 2) NK cells and macrophages are reported to be more radioresistant
compared to other leukocyte types (19), and therefore, are more likely to survive during
circulation through the field of irradiation, the sustained high percentage of NK cells and
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macrophages present in the tumors after multiple treatments of SL-TNF-a plus radiation
correlates well with the qualitative characteristics of the necrosis (phase 2, Table 4).
Although lower values were noted in all irradiated groups compared to the SL-TNF-a
group, the reduction was not statistically significant. In addition, the low neutrophil
counts in the SL-TNF-a plus radiation group may be due to the late timing of the
measurement (after 10 days); neutrophils reportedly infiltrate early into tumors after
TNF-a administration and tend to die off as they complete their cytotoxic effects (12).
Macrophages, conversely, migrate to the tumor after the neutrophils are already present at
the tumor site, where they are able to remain viable longer.
The histological observations from tumors early after a single treatment injection
(phase 1) also seem to follow similar trends as phase 2; no differences in the number of
apoptotic bodies and mitotic figures were present among the groups. However necrotic
areas (early morphology) became increasingly larger with time (after 36 h) for all the
groups, but especially in the tumors from the mice treated with free TNF-a and SL-TNFa (Table 1). Concurrently, more cellular infiltrate was seen early at 6 h; the levels of NK
cells, macrophages, and neutrophils were all significantly elevated in the SL-TNF-a
group compared to virtually all the groups at 6 h, the only exception being neturophils in
the groups given free TNF-a. Since SL can increase the concentration of TNF-a at the
tumor site up to 13 times (5), a greater chemotactic effect would be expected. As time
passes (i.e., 18 h), some of the SL-TNF-a could start to accumulate in organs with
fenestrations, such as the spleen, where previous studies showed an increased number of
these immune cells at 18 h in the spleen with SL-TNF-a. In the tumor at 18 h, there was
a decrease in the NK cell and macrophage percentages, reflecting a potential relative
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decrease in infiltration of the tumor as more were retained in the spleen. However, a high
percentage of neutrophils still remained in the tumor at 18 h and thus, their antitumor
activity appears to have been sustained. By 36 h, all the measured cell groups remained
decreased.

Although previous studies showed that at 36 h, a greater proportion (as

compared between the spleen and blood) of these measured cell types were again in the
blood with SL-TNF-ct, this greater release of these cells from the spleen was not reflected
in tumor until 96 h when the number of NK cells and neutrophils were again elevated in
the SL-TNF-a group. Although SL also produced similar effects as SL-TNF-oc, our
previous studies have shown that while SL-TNF-a has a concomitant increase in
activation markers with the increase in cell number, SL does not. Therefore, the chnages
in the histological appearance of necrosis with increasing time could reflect not only the
growth in the tumor, but also the action of these inflammatory cells as they infiltrate early
after injection whose effects only begin to manifest histologically after 36 h.
Overall, the results demonstrate that SL-TNF-a significantly increased the
infiltration of three different types of nonspecific effector cells into LS174T tumor
xenografts. Early at 6 h, greater infiltration by NK cells, macrophages, and neutrophils
are seen with SL-TNF-a, followed by a relative decrease at 18 h (except for neutrophils)
and at 36 h (reflective of the changes occurring between the blood and the spleen), and
then again, a slight increase at 96 h; these increases are sustained to a degree when
multiple treatments are given and radiation is added. In addition, the changes in the
infiltration of these cells with SL-TNF-a correlated with the histological changes
observed. Since these changes either did not occur or occurred only to a much lesser
extent with free TNF-a, the alterations caused by the encapsulation of TNF-a in SL
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appears to play a critical role. Furthermore, it is important to note that TNF-a is not only
a strong chemotactic factor for inflammatory cells, but also promotes respiratory burst
activity, phagocytosis, and release of tissue degradative enzymes from granules in these
cells (20, 21). Thus, the data indicate that the differential changes in the infiltration of
measured immune cells at the tumor site with SL-TNF-a compared to free TNF-a
correlates well with the modification of immune cells observed in the blood and spleen
by SL-TNF-a and may account, at least in part, for the increased antitumor efficacy seen
with the use of SL-TNF-a.
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CHAPTER EIGHT

VII.

FINAL DISCUSSION

A major reason given by many cancer patients who refuse treatment, show low
compliance, or drop out of treatment is the high incidence of nonspecific toxicities.
These side effects are often perceived as more unbearable than the consequences of the
disease itself.

To the patients, the choices of treatments available to them seen

unreasonably limited. Thus, every attempt to decrease unwanted systemic effects needs
to be pursued.

In pursuit of more treatment options that are potentially less toxic.

combinations of different, promising treatments have been attempted. However, since it
is well known that the combination of various anti-cancer modalities can lead to
unexpected side effects, as well as increased severity of known toxicities, each new
combination approach must be carefully evaluated for both efficacy and safety in preclinical studies.
The combination of TNF-a and radiation has shown much potential as an
antitumor treatment in many pre-clinical models. However, due to the dose-limiting
toxicity of a systemic injection of the free TNF-a protein in humans, the combination has
stirred only limited enthusiasm. However, the encapsulation of the potentially effective,
yet highly toxic, TNF-a may allow its more widespread use. Encapsulating TNF-a in a
sterically stabilized liposome, STEALTH®, potentially increases the efficacy of TNF-a
and decreases its toxicity. Thus, the overall hypothesis of this research was that the
combination of SL-TNF-a and radiation will have greater efficacy and fewer dose-
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limiting side effects in the LS174T tumor model compared to the combination of free
TNF-a and radiation and that this differential response is at least partially due to the
augmentation of innate immune mechanisms by the SL-TNF-a treatment. In pursuit of
data supporting this hypothesis, the present research demonstrated for the first time the
effectiveness and safety of using SL-TNF-a in combination with radiation in a nude
mouse model. TNF-a alone, either as free protein or encapsulated, was demonstrated to
have very minimal effects on LS174T tumor xenograft progression at the total doses
used. However, when employed as a neoadjuvant (or an adjuvant that is given prior to
the “primary” treatment) (Hallahan et al., 1990), TNF-a, either as free or encapsulated,
produced a greater than expected inhibition of tumor growth. However, with multiple
treatments, the combination of radiation with encapsulated TNF-a (SL-TNF-a) produced
a greater effect than radiation plus free TNF-a after multiple treatments. As shown either
as statistical differences in volume measurements at the end of the treatments or as
differences in the doubling time and/or delay in tumor growth, SL-TNF-a plus radiation
demonstrated the largest inhibition of tumor growth compared to all the other tested
regimens.
In addition, the data of this research showed that SL-TNF-a caused no signs of
obvious toxicity when used alone or together with tumor irradiation.

Recombinant

human TNF-a used in this study is less effective (and less toxic) than murine TNF-a to
the murine cells in our nude mouse model (Smith et al., 1986; Takahashi et al., 1994).
Therefore, free TNF-a was expected to show very minimal or no obvious signs of
toxicity. However, signs of toxicity (i.e. anemia, low hematocrit, and hemoglobinemia)
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were detected in the groups receiving free TNF-ct that were not seen with SL-TNF-a.
Because radiation can also produce similar toxicities, these changes were not as obvious
in the combination groups. Nevertheless, in support of the hypothesis, encapsulating
TNF-a in SL essentially eliminated the associated toxicity of the systemic injections of
TNF-oc.
Numerous studies have shown that TNF-a can interact with many different cells
and tissues, resulting in a broad range of biological effects, as discussed already in the
previous chapters. The most relevant antitumor mechanisms involve direct cytotoxic
effects, vasculature effects, and immunomodulation. At higher concentrations, the data
showed that TNF-a and SL-TNF-a have direct cytotoxic effects in vitro, although the
cytotoxic effects appeared additive when combined with radiation (Chapter 6, Figure 1).
Unlike these in vitro results, our in vivo studies showed an unexpected, greater than
additive effect with the combination therapy when no or very minimal effects were seen
with free TNF-a or SL-TNF-a alone. Although greater TNF-a concentration can be
achieved with SL-TNF-a at the tumor site and can partially account for the greater effect
of SL-TNF-a, the ELISA results show that tumor TNF-a concentrations were similar in
the free TNF-a and SL-TNF-a groups early after injection (6 h) in our studies. Thus,
additional mechanisms apart from direct cytotoxicity appeared to be involved. Because
both radiation and TNF-a have been previously shown to have potent immunological
effects and because of the immunological changes seen in this research’s earlier studies,
the underlying immunomodulatory mechanisms of combination therapy were furthered
explored in support of the hypothesis. Since LS174T human colorectal adenocarcinoma
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cells can only be grown in immunocompromised rodents (that lack T cells but have
competent innate immunity), only innate immune mechanisms were examined. Changes
in the NK cell, macrophage/monocyte, and neutrophil populations were especially
explored because of their accepted roles in an antitumor response.

Other immune

parameters were also measured to further access the general status of innate effector cells.
However, because innate immunity is integrally related to adaptive or acquired immunity
(i.e., B cells and T cells), changes in the status of innate immunity can give clues with
respect to potential impact in the immunologically intact host. Therefore, B and T cell
population and activation changes were also observed.
At the end of multiple treatments, the data showed that SL-TNF-a more
effectively upregulated the innate immune cells than free TNF-a after radiation exposure.
As discussed in Chapters Three and Four, various leukocyte populations were activated
by TNF-a, either free or encapsulated.

However, either the differences in

pharmocokinetics or perhaps, the liposome/TNF-a complex itself resulted in
maintenance of these populations to a greater extent when SL-TNF-a, rather than free
TNF-a, was administered in conjunction with radiation. Thus, the direct tumoricidal
effects of both radiation and TNF-a may be modulated in a beneficial way by various
facets of innate immunity to a greater degree by use of the SL-TNF-a than by the use of
free TNF-a. This potential mechanism of enhanced efficacy of SL-TNF-a was furthered
explored in subsequent studies as discussed in Chapters Five, Six, and Seven. Possibly
due to the increased concentration at the tumor, increased blood circulation time, and/or
different tissue distribution of SL-TNF-a, the measured parameters were significantly
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different in the SL-TNF-a-treated groups compared to the free TNF-oc treated groups.
The number of certain innate immune cells (i.e., NK cells, monocytes/macrophages, and
neutrophils) and/or their activation markers were increased early (6 h) after TNF-a or
SL-TNF-a injection when measured in the blood and spleen. At the tumor site, however,
these cells were significantly elevated by SL-TNF-a, but only minimally or none at all by
free TNF-a. At 18 h to 36 h, spatial and temporal differences in the measured immune
cells of the blood and spleen appeared between SL-TNF-a and free TNF-a, which also
seemed to influence a decrease in the percentage of cell infiltration into the tumor. SLTNF-a caused a relative increase over TNF-a of the measured cells in the spleen at 18 h
and a relative decrease compared to free TNF-a at 36 h. In conjunction with these
population measurements, the activation markers were expressed in these cells to a
greater degree for a longer period of time with the SL-TNF-a-treated groups. These
differences between the immunomodulatory effects of SL-TNF-a and free TNF-a could
be potentially accounted for by the following observations: 1) SL-TNF-a accumulates at
the tumor site and at the spleen more than free TNF-a; 2) once at these sites in greater
concentration with SL-TNF-a, the chemotactic and other properties of TNF-a may
influence the cells by attracting them to these sites and activating them upon arrival; and
3) after injection of SL-TNF-a, its greatest concentration is reported to be initially in the
tumor, but as time passes, increasingly more SL-TNF-a is cleared from the blood by the
spleen and liver and thus the concentration of SL-TNF-a in these organs. Therefore,
although initially, the increased accumulation of the inflammatory cells occurs at the
tumor site, with time, an increased accumulation of the inflammatory cells also occur
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within the spleen. This accumulation in the spleen coincides relatively well with the time
of radiation exposure (usually 24 h after treatment injections if radiation is given). This
suggests that the leukocytes that had accumulated within the spleen were not directly
exposed to the tumor-localized radiation. Also of interest, and not emphasized before,
are the changes seen with SL alone. In several of the measurements, SL produced an
effect similar to SL-TNF-a, but to a lesser extent. However, the limited changes seen
with SL were not associated with any measures of immune cell activation or with any
antitumor response. Therefore, these factors together appear to support the hypothesis
that the enhanced efficacy of SL-TNF-a and radiation may, at least in part, be due to
immunomodulation of innate effector cell populations.
Future studies further pursuing this and other mechanisms are needed to further
optimize this combination treatment of SL-TNF-a and radiation.

The use of

immunocompetent mice would further elucidate immune mechanisms, especially those of
specific immunity mediated by T lymphocytes (T helper and T cytotoxic cells) that are
often cited as being the most critical in defense against tumors. In addition to immune
population analyses, activation parameters should be pursued. For example, cytokine
profiles (IL-1, IL-12, IFN-y, etc.) of tumor homogenates and plasma may further
demonstrate immune activation. Furthermore, vascular changes may also be involved in
the antitumor effects of SL-TNF-a and radiation, although no obvious hemorrhagic
necrosis or blood vessel occlusions were noted during histological analysis in the present
study. As mention in Chapter One, TNF-a can alter the endothelium, which can further
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enhance the antitumor effects of radiation. Thus, changes in tumor vasculature or VEGF
concentrations can further elucidate possible mechanisms.
Collectively, the results of this research demonstrated, in support of the original
hypothesis, that 1) SL-TNF-cc as a neoadjuvant to radiation is a promising therapy against
LS174T human colon adenocarcinoma and that 2) SL-TNF-a is a potentially more
efficacious and less toxic alternative to free TNF-a. The data also indicated that in
addition to the direct cytotoxic effects of TNF-a and radiation, encapsulated TNF-a
upregulates innate effector cell number and activity; the upregulation was spatially and
temporally different from that of free TNF-a and appears to account for, at least in part.
for the more enhanced inhibition of tumor growth. Overall, this research showed that the
combination of SL-TNF-a plus radiation is effective in inhibiting tumor progression
without causing unwanted systemic side effects, and thus, warrants further study and
consideration as a potential therapy for the treatment of various tumors.

232

APPENDIX ONE

IV.

A.

ADDITIONAL MATERIAL AND METHODS

Animals and tumor cell lines

The male athymic mice (nu/nu) used in this research were of an outbred
background from a nucleus colony maintained at the National Cancer Institute, Frederick,
Maryland). For the present research, they were obtained as 6-week-old weanlings from
Harlan, Inc. (Indianapolis, Indiana).

All studies involving these animals received

approval from the Animal Care and Use Committee of Loma Linda University.

In

Chapter Three, phase 1, 90 mice were divided into 10 treatment groups as follows: A) No
tumor control (n=9), B) Tumor control (n=9), C) TNF-a alone (n=9), D) SL (n=9), E)
SL-TNF-cc (n=9), F) Radiation alone (n=9), G) TNF-a plus radiation (n=9), H) SL plus
radiation (n=9), I) SL-TNF-a plus radiation (n=9), J) TNF-a plus radiation with multiple
treatments (n=9), and K) SL-TNF-a plus radiation with multiple treatments (n=9). In
Chapter Three, phase 2, 115 mice were divided into the following groups: A) No tumor
control (n=13), B) Tumor control (n=15), C) TNF-a alone (n=9), D) SL (n=13), E) SLTNF-a (n=13), F) Radiation alone (n=18), G) TNF-a plus radiation (n=9), H) SL plus
radiation (n=ll), and I) SL-TNF-a plus radiation (n=14). The group divisions for the
study in Chapter Five can be found in the Materials and Methods section of Chapter Five.
The LS174T cell line (American Type Culture Collection, Rockville, MD) was
originally established from a moderately differentiated, Dukes' type B human colorectal
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adencocarcinoma (Tom et al., 1976).

This cell line has been shown to produce

carcinoembryonic antigen (CEA; 1,916 ng/106 cells in 10 days), mucin, interleukin-10
(IL-10), and IL-6.

B.

SL-TNF-cc, SL, and TNF-a

Encapsulated recombinant human TNF-a protein (rh-TNF-a; Boehringer,
Ingelheim, Germany) was prepared in the laboratory of T. L. M. ten Hagen, Ph.D. using
Stealth® liposomes kindly provided by Dr. P. K. Working (ALZA Corporation,
Mountain View, CA) as previous described (van der Veen et al., 1998). Briefly, the
following chemicals were obtained: partially hydrogenated egg phosphatidyl choline
(PHEPC; Lipoid, Ludwigshafen, Germany), cholesterol (Choi; Sigma, St. Louis, MO),
and distearoyl phosphatidylethanolamine (DSPE) derivatized at its amino position with a
1900 MW segment of polyethylene glycol (PEG) (PEG-DSPE; ALZA Corp). A mixture
of PHEPC (242.5 mg), cholesterol (64.5 mg) and PEG-DSPE (67.6 mg) in a molar ratio
of 1.85:1:0.15 suspended in chloroform/methanol was evaporated in a rotary evaporator.
The dried lipid film was resuspended with HEPES buffer (10 mM HEPES, 150 mM
NaCl), vortexed, and formed into 100 nm liposomes by sonication (10-15 min at
amplitude 9) using an ultrasonic disintegrator with a 3.5 mm diameter exponential
microprobe (Soniprep 150, Sanyo, Leicester, UK). Liposome size was confirmed by
dynamic light scattering (Malvern 4700, Malvern, PA). For SL-TNF-a, TNF-a was
encapsulated into these liposomes by adding 2.5 ml TNF-a into the HEPES buffer (400
pg/ml). Stock solutions of SL-TNF-a (60 pmol/ml at 25 mg rh-TNF-a/100 pmol SL)
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and SL-placebo (60 pmol/ml) were prepared and stored at 4°C until immediately before
use.

C.

Irradiation of tumors and cells using gamma (y) radiation

Exposure to y-radiation (photons) was performed using a 60Cobalt (60Co) source
from an AECL Eldorado Model gamma (y) irradiation machine (Atomic Energy of
Canada, Ltd., Commercial Products Division, Ottawa, Canada) located in the Animal
Care Facility in the Loma Linda University Medical Center. The Eldorado machine was
calibrated using a Capintec Model PR06-G cylindrical thimble ionization chamber,
traceable to the National Institute of Standards and Technology (NIST). To irradiate
tumor xenografts, a vertical beam projected to a 20 x 20 cm field size was used to expose
only the tumor and the underlying normal tissue of the right hind leg. Immediately prior
to irradiation, the mice were anesthetized by intraperitoneal injection of a xylazine (5.2
mg/kg) and ketamine (80 mg/kg) combination. All mice, including control mice with no
tumor, were anesthetized. The leg was immobilized in the radiation field using masking
tape while the body lay outside of edge of the field; the body was further shielded by a 3inch Lipowitz metal alloy block. To have electronic equilibrium throughout the entire
irradiated volume, the tumors were covered with a bolus (‘superflab’) of 0.5 cm
thickness.

To irradiate cells, a vertical beam projected to a 30 x 30 cm field size was

used to expose cells grown in either 96-well microtiter plates or medium-filled T-25
flasks. The containers were covered with a polystyrene sheet of 5 mm thickness for
electron equilibrium.
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D.

[3H]-thymidine incorporation assay

LS174T cells were harvested, washed, and resuspended in RPMI-1640 medium at
1 x 103 cells/ml. Aliquots (200 pi) of single celled suspensions were dispensed in 8
wells/treatment into flat-bottom wells of 96-well microtiter plates with 50 pL of SLTNF-cc (0.24 pmol/ml), SL (0.24 pmol/ml), TNF-a (0.06 pg/ml), or PBS. The cells were
irradiated (cobalt) at 1, 2, 3, 4, and/or 6 Gy 18-20 h after plating. Cells were harvested at
various times before and after irradiation.

At 4 h previous to each harvest, [3H]-

thymidine ([3H]-TdR; specific activity = 46 Ci/mmol; ICN Radiochemicals, Irvine, CA)
was added at 1 pCi/50 pl/well. The cells were harvested with 0.25% trypsin solution
using a Tomtec multiple sample harvester (Hamden, CT) onto a single filter paper
subdivided into 96 sections. Each filter paper was sealed in a sample plastic bag with 5
ml of beta scintillation fluid. The incorporation of radioactivity into cell DNA (counts
per minute; cpm) was then quantified in the Trilux 1450 MicroBeta liquid scintillation
counter (Wallac, Turku, Finland)

E.
counts,

Relative spleen weight values, spleen processing, splenic leukocyte
splenic

spontaneous

blastogenesis,

and

EPS-induced

splenocyte

proliferation
Spleens were weighed at the time of euthanasia and relative spleen weight (RSW)
values were calculated as follows: RSW = (spleen weight (g) x 104)

body weight (g).

The spleens were then processed into single-celled suspensions, washed, and centrifuged.
Erythrocytes in cell pellets were lysed by incubation in 2 ml ACK (ammonium-chloridepotassium) solution (1 mg/ml potassium bicarbonate, 8.3 mg/ml ammonium chloride, and
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0.04 EDTA) for 4 min at 4°C. The remaining viable leukocytes were washed, suspended
in 1 ml of medium, and counted using the Vet ABC-Diff Hematology Analyzer (HESKA
Corporation, Waukesha,WI).

The measurements included leukocytes counts (WBC),

lymphocyte, monocyte, and granulocyte counts and percentages. The counting principle
is based on an impedance variation generated when cells pass through a calibrated micro
aperture; the impedance varies proportionally to the cell volume. The measured cell
types respond differently to the diluent used in the HESKA analyzer to process these
cells; this differential response is manifested as variable changes in the cell volume
characteristic of a cell type. Since the entire spleen was processed, the total leukocyte
number per spleen was equivalent to the number of cells/ml. Single-celled suspensions
of splenic leukocytes were adjusted to 2 x 106 cells/ml in RPMI 1640 medium
supplemented

with

10%

heat-inactivated

FBS

(Hyclone),

antibiotics,

and

mercaptoethanol. Aliquots (100 pi) of each cell suspension were dispensed in triplicate
into

flat-bottom

wells

of 96-well

microtiter plates

either with or without

lipopolysaccharide (EPS; Sigma) from E. coli serotype 0111:134 at 0.02 pg/100 pl/well.
The mitogen was pretitrated for maximal response beforehand using a control splenocyte
cell suspension. The plates were incubated at 37°C in 5% CO2 for two days. During the
last 4 hr of incubation, [3H]-TdR was added at 1 pCi/50 pl/well.

The cells were

harvested using the Tomtec multiple sample harvester, and the uptake of radioactivity
(counts per minute; cpm) was quantified in the Wallac beta scintillation counter and
expressed as a stimulation index (SI) as follows: SI = (cpm with EPS - cpm without EPS)
4-

cpm without EPS. To assay spontaneous blastogenesis, 50 pi aliquots of splenocyte

suspensions were diluted with 150 pi of complete RPMI-1640 culture medium and 1 pCi
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[3H]-TdR in 50 |il of medium was immediately added.

Each mouse was tested in

triplicate in 96-well microculture plates. The cells were incubated for 3 hr at 37°C in 5%
CO2, and the uptake of radioactivity was quantitated as described above. The leukocyte
counts/ml and the volume tested were used to convert the cpm into cpm/106 leukocytes.

F.

Flow cytometry analysis of lymphocyte populations in blood and spleen

The “Mouse Lyse/No Wash Staining Protocol” developed by Pharmingen was
used to stain blood and spleen samples from the mice. Twenty pi of each of the custom
antibody combinations (described below) were aliquoted into separate tubes. For each
mouse, 50 pi of blood or 50 pi of filtered spleen homogenate was added to each tube and
incubated for 20 minutes in the dark at room temperature.

Aliquots (450 pi) of

prewarmed lysing buffer were added to each tube and incubated in a 37°C water bath for
20 minutes. Following incubation, the tubes were placed on ice until data acquisition.
Lymphocyte populations in blood and spleen were quantified using a
FACSCaliburTM 4-channel, dual laser flow cytometer (Becton Dickinson, Inc.,
Rutherford, NJ).

Subpopulations of lymphocytes were defined using side scatter for

cytoplasmic complexity (SSC-cell granularity) versus CD45 (leukocyte common antigen)
and the appropriate antibodies labeled with different fluorochromes.

Approximately

10,000 lymphocyte events/tube were acquired using the threshold trigger on FL3
FACSComp setting within 6 hours of staining. The CD3+ T, CD4+ T helper (Th), CD8+
T cytotoxic (Tc), CD19+ B, pan-NK+ natural killer (NK) cells, and lymphocytes
expressing CD25 and CD71 activation markers were identified using 4-color, 2-tube or
4-color, 4-tube mixtures of fluorescence-labeled monoclonal antibodies (MAb) against
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the proper cell markers. The MAb mixtures were specially designed by Pharmingen (San
Diego, CA) in collaboration with Becton Dickinson for use by investigators in the
Radiobiology Program at Loma Linda University.

The MAb were labeled with

fluorescein isothiocyanate (FITC), R-phycoerythrin (PE), allophycocyanin (APC), or
peridinin chlorophyll protein (PerCP). These custom antibody conjugates used were the
following:
CD3*FTTC/CD8*PE/CD45*PerCP/CD4*APC
CD3*FITC/Pan-NK*PE/CD45PerCP/B220*APC
or
CD3*FITC/CD8*PE/CD45*PerCP/CD4*APC
CD3*FITC/Pan-NK*PE/CD45PerCP/B220*APC
CD25*FITC/CD71*PE/CD45*PerCP/CD3*APC
CD71*FITC/Pan-NK*PE/CD45*PerCP/B220*APC
By using multiple antibodies simultaneously, both single-antibody histogram analysis and
multiparameter analysis were possible.

Analysis was performed using CellQuest TM

software version 3.1 (Becton Dickinson). Purity calculations of the gated lymphocytes of
each acquisition, which were based on the sum of the percentages of each measured
subpopulation, were used to convert the raw percentage of each subpopulation to
normalized percentages. To obtain the absolute number of cells for each lymphocyte
population, the following formula was used: number of cells in population/ml = number
of leukocytes/ml x percentage of the population.
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G.

Statistical analysis

The data were assessed in all studies using one-way and/or two-way analysis of
variance (ANOVA) to determine if significant differences existed in the measured
parameters among multiple (greater than 2) treatment groups. One-way ANOVA was
used to compare differences among multiple treatment groups; two-way ANOVA was
used to compare difference among multiple treatment groups and among multiple time
points. These analyses were followed by a pairwise comparison between two groups
among the multiple treatment groups and the multiple time groups using the Tukey's
HSD (honestly significant differences) Test. A p value of <0.05 was taken as indicating
significant differences among groups. These analyses were performed with SigmaStat
Statistical Software version 2.03 (SPSS Inc., San Rafael, CA).
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APPENDIX TWO

X. ADDITIONAL TABLES

TABLE 1. Blood parameters not included in Chapter Five (published format).

Groups

18 h

6h

36 h

96 h

MCV
Tumor control

52.6 ± 0.8a

53.7 ±0.6

51.4 ± 0.5

53.3 ±0.6

TNF-a

52.4 ±0.6

53.5 ±0.2

52.1 ±0.5

51.3 ±0.7

SL

51.0 ± 0.7

52.6 ±0.5

51.6 ±0.6

52.3 ±0.4

SL-TNF-a

52.9 ± 1.0

51.9 ±0.4

52.4 ±0.5

53.1 ±0.3

MCH
Tumor control

17.0 ±0.3

17.4 ±0.1

16.2 ±0.2

17.2 ±0.2

TNF-a

17.0 ± 0.1

16.8 ±0.2

16.3 ±0.1

16.6 ±0.3

SL

16.5 ±0.2

16.6 ± 0.1

16.2 ±0.2

16.7 ±0.1

SL-TNF-a

17.1 ±0.3

16.4 ±0.2

16.5 ±0.1

17.0 ± 0.1

MCHC
Tumor control

32.4 ±0.1

32.1 ±0.1

31.4 ± 0.1

32.3 ±0.2

TNF-a

32.5 ±0.2

31.9 ± 0.1

31.3 ±0.2

32.4 ±0.1

SL

32.3 ±0.2

31.6 ±0.2

31.4 ± 0.1

32.0 ±0.2

SL-TNF-a

32.2 ±0.2

31.7 ± 0.1

31.3 ±0.1

32.0 ±0.3

aMean ± SEM
MCV: mean corpuscular volume (fl); MCH: mean corpuscular hemoglobin (pg); MCHC: mean corpuscular
hemoglobin concentration (g/dl)
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XI.

Figure 1.

ADDITIONAL FIGURES

Lymphocyte population percentages in the peripheral blood not included in

Chapter Three (published format). Each bar represents the mean ± SEM for 8 - 18 mice. Groups:
(A) No tumor control, (B) Tumor control, (C) TNF-a, (D) SL, (E) SL-TNF-a, (F) Radiation, (G)
TNF-oc plus Radiation, (H) SL plus Radiation, (I) SL-TNF-a plus Radiation.
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I

Figure 2.

Relative spleen weight and lymphocyte population percentages in the spleen not

included in Chapter Three (published format). Each bar represents the mean ± SEM for 8 - 18
mice. Groups: (A) No tumor control, (B) Tumor control, (C) TNF-a, (D) SL, (E) SL-TNF-a, (F)
Radiation, (G) TNF-a plus Radiation, (H) SL plus Radiation, (I) SL-TNF-a plus Radiation. 1:
significantly lower than no tumor control (p < 0.01), 2: significantly greater than no tumor control
{p < 0.01), 3: significantly greater than no tumor control, tumor control, radiation alone, and SL
plus radiation {p < 0.04).
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